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Intrauterine development influences the susceptibility to cardiovascular disease in adulthood, 
although the underlying molecular mechanisms are vastly unknown. Our group has 
previously demonstrated that the murine prenatal heart has a substantial regenerative 
capacity in response to tissue mosaicism for mitochondrial dysfunction caused by heart-
specific inactivation of the X-linked holocytochrome c synthase (Hccs) gene. In heterozygous 
heart conditional Hccs knockout (cHccs+/-) embryos, hyperproliferation of healthy 
cardiomyocytes compensates for the effective loss of 50 % cardiac cells, ensuring formation 
of a normally contracting heart at birth. However, it was assumed that embryonic heart 
regeneration alters peri- and postnatal cardiac growth. Indeed, neonatal cHccs+/- hearts are 
hypoplastic and contain a reduced number of cardiomyocytes. Thereby, cHccs+/- mice 
resemble many findings of classical intrauterine growth restriction (IUGR) models, which also 
demonstrate hypoplastic hearts and a reduced complement of cardiomyocytes at birth. 
Interestingly, in adult cHccs+/- hearts, compensatory increase in cell size (hypertrophy) 
normalizes morphology and organ size.  
The PhD project presented here aims at identifying pre- and postnatal adaptive growth 
mechanisms utilized by the hypoplastic cHccs+/- heart to restore organ size and allow normal 
heart function throughout lifetime. Unbiased functional annotation of genes differentially 
expressed in neonatal cHccs+/- hearts (identified in a genome wide RNA microarray screen) 
revealed numerous gene clusters involved in amino acid metabolism and protein 
homeostasis. The mechanistic target of rapamycin (mTOR) pathway is a master regulator of 
postnatal cardiac metabolism and growth that is sensitive to amino acid availability. We 
hypothesized that both normal amino acid homeostasis as well as mTOR pathway activation 
are crucial to sustain regeneration and compensatory growth of cHccs+/- hearts to build a 
regularly sized organ and allow normal postnatal function.  
Indeed, we revealed increased mTOR pathway activity in neonatal cHccs+/- hearts compared 
to littermate controls. To elucidate the role of the mTOR pathway for cHccs+/- heart 
development, growth and function, we inhibited mTOR complex 1 (mTORC1) in fetal and 
neonatal mice by rapamycin treatment of pregnant dams. Rapamycin treated neonates were 
characterized by overall growth restriction (reduction of whole body size and organ weights) 
and developmental delay, where cardiac development was especially affected with most 
severe consequences in cHccs+/- hearts (reduction of heart size, weight and heart weight to 
body weight ratio, severe thinning and noncompaction of the ventricular myocardium as well 
as immature myocardial morphology). While proliferation rates in neonatal rapamycin treated 
hearts were unaffected, the reduced neonatal heart size was attributed to decreased 
cardiomyocyte size and increased apoptosis compared to vehicle treated neonates, both 
were again more pronounced in rapamycin cHccs+/- hearts than in rapamycin Hccs+/+ hearts. 
SUMMARY 
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This indicates not only the importance of the mTOR pathway for cardiac development in 
general, but furthermore suggests that its enhanced activation is of particular importance for 
the developmentally impaired cHccs+/- heart. Surprisingly, prenatal mTORC1 inhibition only 
marginally affects heart function in newborn mice as determined by echocardiography. 
Moreover, reduced neonatal body and heart size was mostly normalized during postnatal life 
in both genotypes until the age of 11 weeks. Postnatal normalization of heart size was 
achieved by increased cardiomyocyte size, while extracellular matrix deposition was not 
affected. Furthermore, no indications for pathological conditions or myocardial tissue 
remodeling were observed in adult hearts after prenatal mTORC1 inhibition and cardiac 
function in adulthood was normal. In conclusion, we propose that prenatal mTORC1 
inhibition by rapamycin treatment of pregnant dams represents a new model of IUGR in the 
mouse, which allows the investigation of developmental programming mechanisms 
particularly in the fetal and neonatal phase of development. 
Given the induction of genes involved in amino acid metabolism in neonatal cHccs+/- hearts, 
we studied the effect of pre- and postnatal amino acid restriction on cardiac development, 
growth and function by feeding dams a low protein diet (LPD) throughout pregnancy and 
keeping the offspring on LPD until adulthood. Even though we did not find major effects of 
prenatal amino acid restriction on body and heart weight of neonatal Hccs+/+ and cHccs+/- 
mice, we observed increased cardiomyocyte size at birth in both LPD genotypes compared 
to their corresponding standard protein diet (SPD) controls. To investigate the underlying 
mechanisms that allow normal heart size despite increased cardiomyocyte size, we focused 
on proliferation rates. Importantly, proliferation in neonatal hearts was found to be unaffected 
by prenatal LPD exposure. Hence, we speculated that intrauterine LPD treatment might 
reduce proliferation rates in prenatal hearts, potentially resulting in a reduction of the 
cardiomyocyte number at birth. However, proliferation was unaffected in 13.5 days post 
coitum (dpc) LPD embryonic hearts as well. Still, proliferation rates in fetal LPD hearts 
remain to be investigated. In adulthood, heart size and function of unstressed LPD animals 
were normal. Even though amino acid restriction did not affect postnatal heart growth on the 
organ level, cardiomyocyte size in LPD adults was surprisingly reduced compared to adult 
SPD mice, whereas extracellular matrix deposition was normal. These data point toward 
other cardiac cell types that might compensate for the decreased cardiomyocyte size in 
adulthood resulting in normal heart size of adult LPD animals. Taken together, the embryonic 
murine heart appears to be surprisingly resistant to intrauterine amino acid restriction. These 
findings suggest that the late fetal period might be the more vulnerable phase during 
development and is especially sensitive for maternal malnutrition, which might have major 





Die Entwicklung eines Embryos und Fetus im Uterus beeinflusst die Anfälligkeit für 
kardiovaskuläre Erkrankungen im weiteren Verlauf des Lebens entscheidend. Die 
zugrundeliegenden molekularen und zellulären Mechanismen sind jedoch weitestgehend 
unbekannt. Das pränatale Mausherz weist eine beachtliche Regenerationsfähigkeit auf. So 
resultiert die Herz-spezifische Inaktivierung des X-chromosomalen „holocytochrome c 
synthase“ (Hccs) Gens in einem Zellmosaik für mitochondriale Dysfunktion. In Embryonen, 
welche heterozygot für den kardialen Hccs Knockout (cHccs+/-) sind, kompensieren die 
gesunden Kardiomyozyten den Verlust der 50 % dysfunktionalen Hccs-defizienten Zellen 
durch vermehrte Proliferation. Dadurch wird bis zur Geburt ein funktionsfähiges Herz 
gebildet. Möglicherweise beeinflusst diese embryonale Herzregeneration jedoch das peri- 
und postnatale Herzwachstum. Tatsächlich sind neugeborene cHccs+/- Herzen hypoplastisch 
und beinhalten eine reduzierte Kardiomyozytenzahl. Damit ähnelt das cHccs+/- Modell 
klassischen Tiermodellen für intrauterine Wachstumseinschränkung („intrauterine growth 
restriction“, IUGR), welche bei der Geburt ebenfalls hypoplastische Herzen mit einer 
verminderten Anzahl an Kardiomyozyten haben. Interessanterweise konnte in Herzen 
ausgewachsener cHccs+/- Mäuse gezeigt werden, dass ein verstärktes Größenwachstum der 
Kardiomyozyten zur Normalisierung der Herzgröße führt.  
Die vorliegende Doktorarbeit zielt auf die Identifikation prä- und postnataler adaptiver 
Wachstumsmechanismen ab, welche dem hypoplastische cHccs+/- Herz die Anpassung der 
Organgröße und die Aufrechterhaltung einer normalen Herzfunktion im Verlauf des Lebens 
ermöglichen. Funktionelle Annotationsanalysen differenziell exprimierter Gene in 
neugeborenen cHccs+/- Herzen identifizierten viele Gencluster, welche im 
Aminosäuremetabolismus und in der Proteinhomeostase eine Rolle spielen. Die 
„mechanistic target of rapamycin“ (mTOR) Signalkaskade ist ein zentraler Regulator des 
postnatalen kardialen Metabolismus und Wachstums und ist außerdem sensitiv gegenüber 
der Aminosäureverfügbarkeit. Wir vermuteten, dass sowohl eine ausgeglichene 
Aminosäurehomöostase als auch die Aktivität der mTOR Signalkaskade eine entscheidende 
Rolle bei der pränatalen Regeneration und dem postnatalen kompensatorischen Wachstum 
der cHccs+/- Herzen spielen und sind somit am Aufbau der regulären Organgröße und der 
Aufrechterhaltung der normalen postnatalen Herzfunktion beteiligt sind. 
Tatsächlich haben wir eine erhöhte Aktivität der mTOR Signalkaskade in neugeborenen 
cHccs+/- Herzen im Vergleich zu Wurfkontrollen festgestellt. Um die Rolle der mTOR 
Signalkaskade hinsichtlich Entwicklung, Wachstum und Funktion der cHccs+/- Herzen zu 
analysieren, haben wir den mTOR Komplex 1 (mTORC1) in fetalen und neugeborenen 
Mäusen mittels einer Rapamycin-Behandlung in trächtigen Weibchen inhibiert. Rapamycin-
behandelte Neugeborene zeichneten sich durch ein vermindertes Gesamtwachstum sowie 
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einer Entwicklungsverzögerung aus. Dabei war die kardiale Entwicklung besonders 
betroffen, was sich mit größter Deutlichkeit in den cHccs+/- Herzen zeigte (z.B. Reduktion von 
Herzgröße, -gewicht, Verhältnis von Herzgewicht zu Körpergewicht sowie deutliche 
Verdünnung und mangelnde Kompaktierung des ventrikulären Myokards). Proliferationsraten 
in Herzen Rapamycin-behandelten Neugeborenen waren nicht verändert. Jedoch konnte die 
verminderte Herzgröße auf eine verringerte Kardiomyozytengröße sowie auf eine erhöhte 
Apoptoserate (verglichen mit Vehikel-behandelten Neugeborenen) zurückgeführt werden. 
Beide zellulären Veränderungen waren erneut besonders deutlich in den Rapamycin-
behandelten cHccs+/- Herzen ausgeprägt. Diese Beobachtungen heben einerseits die 
Bedeutung der mTOR Signalkaskade für das grundlegende perinatale kardiale Wachstum 
hervor und zeigen andererseits, dass eine erhöhte Aktivität der mTOR Signalkaskade in 
cHccs+/- Herzen nach gestörter pränataler Entwicklung von besonderer Bedeutung ist. 
Überraschenderweise führt die pränatale mTORC1 Inhibierung nur zu geringfügigen 
Veränderungen der Herzfunktion neugeborener Mäuse. Des Weiteren normalisierte sich das 
reduzierte Körper- und Herzgewicht der neugeborenen Rapamycin-behandelten Mäuse 
weitestgehend im weiteren Verlauf des Lebens bis zum Alter von 11 Wochen. Die postnatale 
Normalisierung der Herzgröße wird durch eine erhöhte Kardiomyozytengröße gewährleistet. 
Vermehrte Ablagerungen extrazellulärer Matrix oder pathologische Fibrose waren dabei nicht 
zu beobachten. Anhaltspunkte für pathologische Zustände oder myokardialen 
Gewebeumbau in 11 Wochen alten Mausherzen nach pränataler Rapamycin-Behandlung 
wurden ebenfalls nicht gefunden. Auch die Herzfunktion war normal. Zusammenfassend 
schlagen wir die pränatale mTORC1-Inhibierung durch Rapamycin-Behandlung trächtiger 
Weibchen als ein neues IUGR Modell vor, welches Untersuchungen von Programmierungs-
Mechanismen vor allem in der fötalen und perinatalen Entwicklung erlaubt.  
Angesichts der Induktion von Aminosäuremetabolismus-relevanten Genen in neonatalen 
cHccs+/- Herzen, untersuchten wir die Auswirkungen prä- und postnataler 
Aminosäurerestriktion auf Herzentwicklung, -wachstum und -funktion. Hierfür wurde Mäusen 
während der gesamten Schwangerschaft eine Niedrigproteindiät („low protein diet“, LPD) 
gefüttert. Die Nachkommen wurden anschließend fortführend auf LPD gehalten. Zwar fanden 
wir keine weitreichenden Veränderungen hinsichtlich Körper- und Herzgröße neugeborener 
Hccs+/+ und cHccs+/- Mäuse, jedoch konnten wir eine deutlich erhöhte Kardiomyozytengröße 
in beiden LPD Genotypen verglichen mit den jeweiligen Standardproteindiät (SPD) 
Kontrollgruppen bei der Geburt feststellen. Um zu untersuchen, wodurch die Herzgröße trotz 
erhöhter Kardiomyozytengröße konstant gehalten wird, fokussierten wir uns auf 
Proliferationsraten. Kardiale Proliferationsraten in neugeborenen LPD Mäusen waren 
unverändert verglichen mit neugeborenen SPD Mäusen. Demnach könnte eine pränatale 
Aminosäurerestriktion jedoch Auswirkungen auf die Proliferationsraten in pränatalen Herzen 
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haben und somit eventuell zu einer verringerten Zellzahl in neugeborenen Herzen führen. 
Allerdings waren die Proliferationsraten in 13.5 dpc embryonalen Herzen ebenfalls nicht 
durch Aminosäurerestriktion verändert. Analysen der Proliferationsraten in fetalen LPD 
Herzen wurden bisher jedoch nicht durchgeführt. Herzgröße und -funktion in 11 Wochen 
alten ungestressten LPD Mäusen waren normal obwohl die Kardiomyozytengröße in adulten 
LPD Herzen verringert war. Diese Daten lassen daher vermuten, dass andere kardiale 
Zelltypen die verringerte Kardiomyozytengröße kompensieren, was in einem normalen 
Herzgewicht in 11 Wochen alten LPD Tieren resultiert. Zusammenfassend ist festzuhalten, 
dass embryonale Mausherzen erstaunlich resistent gegenüber intrauteriner 
Aminosäurerestriktion sind. Jedoch scheint die späte Fetalphase die entscheidende und am 
meisten verwundbare Phase während der Entwicklung im Uterus zu sein, welche daher 
möglicherweise besonders empfindlich für maternale Mangelernährung ist. Perspektivisch 
könnte dies bedeutende Auswirkungen im Hinblick auf IUGR und der Prävention von 




3.1 The heart of the matter 
The mature mammalian heart consists of four valves and four chambers (two cranial atria 
and two caudal ventricles) with the wall of each chamber built up of three tissue layers: 
endocardium, myocardium and epicardium (Figure 1). As a muscular organ, it constantly 
pumps blood throughout the blood vessels to all parts of the body by repeated, rhythmic 
contractions. The human heart beats approximately 60-80 times per minute, which sums up 
to over 30 billion beats per lifetime with a total volume of 200 million liter blood that is 
pumped through the body’s blood vessels. During each cardiac cycle, the right atrium (RA) 
relaxes and receives deoxygenated blood from the body periphery via the vena cava. In 
diastole, the relaxed right ventricle (RV) receives blood through the tricuspid valve from the 
contracting RA. Subsequent contraction of the RV during systole passes the blood through 
the pulmonary valve into the pulmonary arteries to the lungs, where carbon dioxide is 
exchanged for oxygen. Oxygenated blood returns from the lungs through the pulmonary 
veins into the relaxed left atrium (LA). The latter then contracts and the blood is pushed 
through the mitral valve into the relaxed left ventricle (LV). Subsequent contraction of the LV 
during systole ejects the oxygenated blood out of the heart through the aortic valve into the 
aorta from where it is distributed to the systemic circulation (Figure 1). 
 
Figure 1. Schematic drawing of the mammalian heart. 
The mature mammalian heart consists of four chambers (left (LV) and right (RV) ventricle, left (LA) and right (RA) atrium) and 
four valves (pulmonary, tricuspid, mitral and aortic valve). The wall of each chamber is built up of three tissue 
layers: endocardium, myocardium and epicardium. The compass indicates the orientation of the heart in the body (Ca: caudal, 
Cr: cranial, L: left, R: right). Figure modified from Lin et al. 2012
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. 
According to the World Health Organization (WHO), cardiovascular diseases (CVD) are the 
most common cause of death worldwide with 17.5 million people killed in 2012. The numbers 
are continuously increasing with dramatic costs for health care systems (according to the 




2008). Importantly, causes of CVD can be found in both embryonic development and 
adulthood. While classical lifestyle-related risk factors, for instance hypertension, smoking, 
obesity or diabetes, are widely acknowledged to cause CVD, developmental origins of CVD 
are far less established and are not necessarily part of the public awareness. Thus, 
investigation and elucidation of mechanisms underlying the latter remain absolutely 
imperative to allow better disease prevention. 
3.2 Developmental programming of adulthood disease 
3.2.1 The developmental programming concept (“thrifty phenotype” hypothesis) 
Mammalian development in utero is a complex and dynamic process. It depends on the 
interaction of the mother with the embryo or fetus, respectively, to sustain optimal growth and 
survival throughout pregnancy. The supply of the growing embryo and fetus with nutrients, 
oxygen and endocrine signals impacts not only the growth of the unborn itself but also the 
health of the offspring in adulthood (Figure 2). In this context, low birth weight in newborns 
was suggested to be inversely related to the susceptibility for CVD, cardiovascular mortality 
and insulin resistance in adulthood2-6. Based on these initial observations, Hales and Barker 
proposed the “thrifty phenotype” hypothesis, which states that fetuses exposed to 
unfavorable intrauterine growth conditions induce various permanent physiological cellular, 
molecular and metabolic adaptations in anticipation of similar suboptimal conditions in 
postnatal life7 (Figure 2). This programming might slow down embryonic and fetal growth, 
ultimately resulting in lower birth weight7. In case of nutritionally rich postnatal conditions and 
resources, as provided in the Western culture, the adaptive changes could become 
maladaptive and the trade-off for overcoming the challenge during intrauterine development 
might be an increased susceptibility to suffer from chronic diseases in later life7. Supporting 
evidence for the developmental programming concept comes from human epidemiology. 
Studies with monozygotic twins revealed that the twin with Type 2 diabetes mellitus in 
adulthood had a significantly lower birth weight compared to its euglycaemic co-twin8. 
Periods of famine also provide important insights regarding the effects of global nutrient 
restriction during pregnancy. The Second World War Dutch famine was provoked by a Nazi 
blockade of the western part of Holland from 1944 to 1945. Caloric intake was severely 
reduced to a daily dose of 450-750 kcal. Individuals born from pregnancies during the famine 
suffered from maternal undernutrition, had lower birth weights and displayed increased 




Figure 2. The “thrifty phenotype” hypothesis.  
Adverse environmental cues from the mother (yellow) cause unfavorable intrauterine growth conditions for the developing 
embryo and fetus (blue). Subsequently, permanent physiological adaptations in the unborn are induced, a process known as 
developmental programming. This programming in combination with an unhealthy lifestyle later in life (green) systemically 
affects a variety of different organ systems (purple) and consequently predisposes the entire organism for chronic diseases in 
adulthood (red). Figure modified from Fowden et al.
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 and Langley-Evans and McMullen
13
. (CHD: coronary heart disease, 
CVD: cardiovascular disease, CVS: cardiovascular system) 
Importantly, intrauterine growth restriction (IUGR) is not the only determinant of long-term 
health. Various lifestyle-related risk factors (e.g. drug abuse, alcohol and nicotine 
consumption) as well as accelerated postnatal growth (also referred to as “catch-up growth”, 
e.g. due to obesity) additionally promote the manifestation of adulthood disease following 
IUGR and developmental programming14-17 (Figure 2). For example, the Dutch famine 
studies demonstrated that individuals with the worst glucose tolerance were those who had a 
low birth weight and became obese as adults9. Thus, suboptimal intrauterine conditions 
cause a predisposition for adulthood diseases that is manifested if additional stress occurs 
later in life (Figure 2). This combination of developmental programming and unhealthy 
lifestyle is a major risk factor of the world wide epidemic of the most common chronic 
adulthood diseases, such as stroke, hypertension, coronary heart disease, Type 2 diabetes 
mellitus, hyperglycemia or metabolic syndrome18,19 (Figure 2). Furthermore, developmental 




and middle-income countries, where the combination of poor nutrition in utero and 
overnutrition in later life is common20.  
Unfortunately, due to the long time span between the impairment of development in utero 
and the observable consequences later in life, very little mechanistic knowledge can be 
retrieved from these few human epidemiology studies. However, there is accumulating 
experimental data from a variety of animal models, which try to shed light on this 
problem (see Chapter 3.2.2). 
3.2.2 Animal models of intrauterine growth restriction and implications for the heart 
Intrauterine growth restriction (IUGR) is the most commonly used model in various animal 
species to identify basic molecular and cellular mechanisms of developmental programming. 
To date, consequences of IUGR on cardiac development and growth are best described in 
studies manipulating maternal nutrition during gestation. Fetal nutrient supply is one of the 
most important environmental determinants affecting pregnancy outcome, where amino acids 
are assigned a key role21. The original rodent model of maternal protein and thus amino acid 
restriction involves feeding pregnant rats a isochaloric low protein diet (LPD) (8-10 % protein 
versus 20-22 % protein in standard protein diet (SPD))22. Body (BW) and heart weight (HW) of 
LPD newborns are significantly lower compared to pups from dams on SPD23. Although HW to 
BW (HW/BW) ratio is not different between the diet groups, hearts of LPD newborn rats have 
significantly less cardiomyocytes23. Consistently, a suppressed replicative potential of neonatal 
cardiomyocytes correlates with prenatal LPD24. Notably, changes in HW and cardiomyocyte 
number in LPD neonatal rats often normalize within the first few weeks of life if the diet is 
changed to SPD after birth, indicating postnatal compensatory growth25. Interestingly, prenatal 
amino acid restriction provokes significant changes in heart morphology and function later in 
life, as obvious by increased deposition of extracellular matrix (ECM)26, cardiac hypertrophy27 
and increased stiffening28 of the LV in young adults under baseline conditions. Consistently, 
spontaneous cardiac dysfunction27, impaired recovery after ischemia-reperfusion injury28-30, 
and altered cellular stress response31 were observed in adult rat hearts upon intrauterine 
amino acid restriction, suggesting significant consequences of LPD-induced IUGR for the 
health of the cardiovascular system in adulthood. 
In humans, placental insufficiency (e.g. due to abnormalities in placental development or 
maternal nicotine abuse) is one of the most common causes of IUGR in Western societies and 
results in low birth weight offspring that are predisposed to adulthood disease32. Placental 
insufficiency, induced by uterine artery ligation in pregnant rats, resembles many observations 
seen after LPD, such as HW reduction and decreased cardiomyocyte number in neonates33. In 
line with the LPD studies, these impairments can be restored if postnatal nutrition is 
normalized33. Although the underlying cellular mechanisms (i.e. proliferative or hypertrophic 
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growth) are poorly understood, these findings also indicate postnatal restoration of cardiac 
organ size after IUGR. 
In addition, IUGR can result from maternal chronic hypoxia. Experimental studies in pregnant 
rats exposed to low oxygen conditions (10.5 % low oxygen compared to 21 % normal oxygen) 
for a defined period of time during gestation demonstrated increased HW/BW ratios in 
neonates and in fetuses prior to birth34,35. Furthermore, apoptosis rates in fetal hearts are 
increased and cardiomyocytes are prematurely terminally differentiated and hypertrophic34. In 
mice, maternal hypoxia during pregnancy causes ventricular dilation, myocardial 
hypoplasia (thinner ventricular myocardium) as well as heart failure in mid-gestation 
embryos36. Importantly, prenatal hypoxia leads to LV hypertrophy and increased 
cardiomyocyte size in adult rat hearts35,37. Furthermore, intrauterine hypoxia has significant 
adverse consequences for cardioprotection in the adult rat myocardium, resulting in 
pathological cardiac remodeling28, cardiac fibrosis28 and LV diastolic dysfunction35 under 
baseline conditions as well as increased susceptibility to ischemia-reperfusion injury28,38. 
Notably, maternal nutritional intake is reduced by hypoxia28, suggesting that there might be an 
overlap in the consequences observed after IUGR induced by maternal hypoxia or maternal 
undernutrition.  
All these IUGR models agree that perturbations of intrauterine environment affect 
cardiomyocyte morphology and number as well as heart size at birth. Moreover, even though 
the results are not always consistent (perhaps reflecting differences in methodology, the 
animal species or strains), most of these studies demonstrate that postnatal restoration of 
cardiac organ size after IUGR occurs and, importantly, is associated with adverse 
consequences for heart morphology and function later in life. In human studies (see Chapter 
3.2.1), accelerated postnatal growth was also correlated with an increased risk for CVD in 
adulthood14-17. These observations strongly support the concept of developmental 
programming. However, studies identifying precise molecular mechanisms and targets are 
rare. The most widely discussed mechanism how such programming might happen are 
epigenetic modifications of certain gene promoters resulting in aberrant gene expression39. 
Even though the epigenetic code is heritable, it is thought not to be fixed throughout the entire 
lifetime. Instead, it is known to be vulnerable to alterations during several life stages: 
embryogenesis, fetal and neonatal development, puberty as well as old age40,41. During 
gestation, the developing embryo and fetus is subject to both demethylation and 
remethylation42. Thus, the process of methylation is a good candidate for disturbances by 
environmental interference and hence provides a potential mechanism for developmental 
programming. Even if such changes have rarely been experimentally proven yet, epigenetic 
modifications of renin-angiotensin system (RAS) components have been suggested to be 




angiotensin receptor gene in the adrenal gland was upregulated by the first week of life, which 
was accompanied by significant undermethylation of the proximal promoter of the AT1b gene
43. 
Importantly, these changes were suggested to provoke adulthood hypertension in the LPD rat 
model43. However, the precise molecular mechanisms that underlie such an alteration in 
methylation pattern as a result of developmental programming remain to be determined. 
Consequently, the actual programming mechanisms that enhance disease susceptibility in 
adulthood after impaired intrauterine development remain mostly obscure. Due to the short life 
span and reproduction time of most animal models, long-term consequences of developmental 
programming, which would be more relevant for human subjects, are difficult to analyze. 
Besides, because IUGR affects the entire organism, dissecting developmental programming 
mechanisms in one particular organ and differentiating between primary and secondary 
causes and effects imposed by systemic alterations remains difficult. Nevertheless, only if 
these challenges are successfully solved and basic processes of developmental programming 
in the heart are uncovered, focus can be directed toward therapeutic or preventive strategies 
for adulthood CVD induced during prenatal development.  
3.3 Growth and organ size control of the mammalian heart 
IUGR affects hearts size and cardiomyocyte number and thereby impacts on postnatal 
cardiovascular health. But how does the heart grow after all? Between the early heart tube 
stage and adulthood, the murine heart increases more than 300-fold in mass44. While fetal 
cardiac growth mainly occurs through cardiomyocyte proliferation, postnatal heart growth 
primarily involves increased cardiomyocyte size. Importantly, both the early patterning events 
of the embryonic heart and growth as well as maturation of the various cardiac structures 
during embryonic, fetal and postnatal life are essential for survival of the entire organism. 
3.3.1 Prenatal cardiac development and growth 
Mammalian heart development from a simple tube-like vessel into a mature complex four-
chambered organ has been examined extensively over the past decades, whit the mouse 
being the best studied model45-47. In the murine embryo, at about 8 days post coitum (dpc), a 
primitive linear heart tube composed of a myocardial and endocardial cell layer has formed, 
which shortly after begins to contract. Between 8.5 dpc and 10.5 dpc, the heart tube 
undergoes rightward looping to align the atria as well as inflow and outflow tract cranial to the 
ventricles. Furthermore, the future ventricles become distinct and balloon outwards. 
Meanwhile, a third tissue layer is added to the outer surface of the heart, called epicardium. 
At the same time, myocardial cells of the ventricular chambers proliferate, differentiate and 
protrude into the lumen to develop trabeculation of endocardium-covered myocardium. The 
trabeculae formed at the inner curvature of the ventricular chambers are especially important 
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for proper and powerful cardiac contraction. Moreover, the inner surface area increases and 
the nutritional requirements of the growing myocardium can be met from the luminal blood 
even in the absence of a mature coronary circulatory system. To fulfill these requirements in 
the early phases of cardiac development, the trabeculated layer is much thicker than the 
outer layer of compact myocardium (Figure 3A). Importantly, between trabeculated and 
compact layer a gradient regarding cardiomyocyte differentiation as well as proliferation rate 
exists. Cardiomyocytes within the trabeculated layer are further differentiated and appear 
elongated with mature sarcomere organization but proliferate only slowly48-50. In contrast, 
cells in the outer compact myocardium appear round and small with less mature sarcomere 
structures but high proliferative capacity48-50. Thus, proliferative growth of the embryonic 
myocardium is mainly accomplished by cell apposition from the periphery. At 10.5 dpc, 
looping is completed and the heart has acquired well-defined chambers, all now composed 
of an endothelial, myocardial and epicardial layer (Figure 3A). Since inflow and outflow 
tract (OFT) are now in close proximity and the chambers (common atrium and common 
ventricle) are specified and functional, cardiac septation can begin from 11.0 dpc onwards. 
The atrial and ventricular chambers are divided into two atria and two ventricles, forming a 
pre-stage four-chamber heart (Figure 3B). Meanwhile, mitral and tricuspid orifices are formed 
and the OFT divides into the left and the right ventricular outlets. By these septation events, 
systemic and pulmonary circulations become separate. At 13.5 dpc LV and RV are almost 
completely separated by the interventricular septum (IVS) (Figure 3B).  
 
Figure 3. Morphogenesis of the mouse heart during the second half of gestation. 
A) Ventral view of an H&E-stained longitudinal heart section at 10.5 dpc. At this stage, looping is complete and one common 
ventricle (CV) and one common atrium (CA) are obvious. The wall of each chamber is made up of all three tissue layers: 
endocardium (EnC), epicardium (EpC) and myocardium. Note that the trabeculated myocardial layer (TrM) is much thicker than 
the outer compact myocardium (CoM) (scale bar = 300 µm). B) Ventral view of an H&E-stained longitudinal heart section at 
13.5 dpc reveals almost complete septation (scale bar = 300 µm). C) Ventral view of a schematic longitudinal heart section at 
14.5 dpc. The pulmonary trunk (PT) and the aorta (Ao) connect to the chambers and ensure the separation of pulmonary and 
systemic circulation. (AA: aortic arch, AVCu: atrioventricular cushions, H&E: hematoxylin and eosin, IVC: inferior vena cava, 
IVS: interventricular septum, LA: left atrium, LV: left ventricle, OFT: outflow tract, PV: pulmonary vein, RA right atrium, RV: right 
ventricle, SVC: superior vena cava, Tr: trabeculae, TW: thoracic wall).) 
After septation is completed at 14.5 dpc (Figure 3C), the ventricular myocardium undergoes 




myocardial layer accompanied by compaction of the trabeculae. At the same time, the 
coronary system is established to meet the increasing nutritional requirements of the mature 
myocardium. The last step of heart development is the formation of the valve leaflets based 
on sculpting of the endocardial cushions (OFT cushions and atrioventricular 
cushions (AVCu)), a process that continues until birth. On the way to a mature adult heart, 
the proportion of the compact myocardium increases even more (especially in the LV), while 
trabeculation only remains as a thin layer of honeycomb-like relief on the luminal surface of 
both ventricles. 
In fact, growth of the heart is tightly regulated so that the heart reaches a predetermined final 
size in adulthood. Thus, impairments of growth regulatory pathways potentially result in 
congenital heart malformations, the leading form of major birth defects in humans. For 
instance, failure of the process of myocardial compaction can lead to a disease termed left 
ventricular noncompaction (LVNC). LVNC is characterized by prominent and excessive 
trabeculation with deep recesses in the ventricular wall and subsequent thinning of the 
compact myocardium51. This can cause heart failure, stroke, arrhythmias and sudden cardiac 
death in adulthood52. Even though LVNC was shown to be caused by mutations in genes 
encoding sarcomeric53, cytoskeletal54, nuclear-membrane55 and chaperone proteins56, the 
precise underlying molecular and cellular mechanisms are unknown. In addition, research 
suggests that LVNC is caused by proliferation defects during heart development57. In this 
context, the Hippo kinase cascade is an important regulator of cardiac organ growth58. In 
mice, fetal cardiomyocyte-restricted inactivation of the yes-associated protein 1 (Yap1) 
gene (YAP1 is normally inhibited by Hippo kinase activity) causes decreased cardiomyocyte 
proliferation leading to myocardial hypoplasia and embryonic lethality after 16.5 dpc59. In 
contrast, fetal activation of Yap1 stimulates cardiomyocyte proliferation particularly within the 
trabeculated myocardium, which normally exhibit low cell cycle activity59. This causes 
marked expansion of the trabeculated myocardium, resulting in chamber obliteration and 
fetal death after 15.5 dpc59. Furthermore, cardiac-specific inactivation of the mitochondrial 
apoptosis inhibitor Survivin results in decreased proliferation of cardiomyocytes within the 
compact myocardium during murine development60. Consequently, cardiac Survivin 
knockout (KO) mice have less cardiomyocytes at birth, resulting in smaller hearts60. These 
mice die prematurely after 8 month due to progressive heart failure associated with 
pathological hypertrophy and fibrosis60. The Survivin model resembles many phenotypic 
abnormalities found in animal models of IUGR, such as reduced heart size and 
cardiomyocyte number at birth and development of heart disease in adulthood (see Chapter 
3.2.2). However, its potential to serve as model for the investigation of developmental 
programming mechanisms specifically within the heart is limited. In contrast to the concept of 
developmental programming, the genetic alteration persists throughout the entire postnatal 
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life and is not released after birth, as normally the case for unfavourable intrauterine growth 
conditions. In summary, even though few animal models for impaired prenatal heart 
development exist, they have limited potential to study molecular and cellular mechanisms of 
cardiac developmental programming; either because they die in utero or, if they survive until 
adulthood and indeed develop postnatal heart disease, because the insult is not restricted to 
prenatal development. 
3.3.2 Growth mechanisms and metabolic changes in the perinatal mammalian heart  
Cardiomyocytes in the pre- and postnatal mammalian heart demonstrate significant 
differences regarding their growth patterns. Embryonic and fetal cardiac cells are highly 
proliferative61,62. Thus, prenatal increase in cardiac mass is primarily achieved by proliferation 
of mononucleated contractile cardiomyocytes and non-cardiomyocytes, leading to an 
increase in cell number (hyperplasia)61,62. This proliferative potential, however, decreases in 
late gestation and soon after birth cardiomyocytes lose their capability of dividing63. 
Consequently, a rapid switch from hyperplastic to hypertrophic (increase in size) 
cardiomyocyte growth occurs64. In rodents, this transition occurs within the first postnatal 
week65; whereas it takes place almost immediately after birth in larger mammals64,66. At a 
morphological level, the switch from pre- to postnatal growth patterns coincides with terminal 
differentiation of cardiomyocytes, characterized by a marked increase in myofibril density, 
appearance of mature intercellular junctional complexes (intercalated discs) and 
binucleation65,67,68. In rodents, the latter is achieved since cardiomyocytes undergo a final 
round of deoxyribonucleic acid (DNA) synthesis and nuclear mitosis (karyokinesis) without 
cell division (cytokinesis)69. In humans, karyokinesis is rare so that adult human 
cardiomyocytes are polyploid but not necessarily multinucleated. After terminal 
differentiation, cardiomyocytes withdraw from the cell cycle without permitting further cell 
division. For a long time it was widely believed that from now on cytokinesis is blocked and 
continuous increase in heart muscle mass and thus organ size is accomplished exclusively 
by the enlargement of individual pre-existing cardiac cells in the absence of cell division68-71. 
However, this strict paradigm of terminal differentiation is currently under debate. In mice, a 
brief but intense proliferative burst of predominantly binucleated cardiomyocytes during 
preadolescence was revealed72. Anyway, cardiomyocyte hypertrophy is the predominant 
postnatal growth mechanism. Especially from the neonatal period until early adulthood it 
facilitates the rapid increase of heart size to accommodate the increasing demands of the 
fast growing animal73.  
Even though the molecular and cellular mechanisms, which regulate cardiomyocyte cell 
cycle exit, binucleation and terminal differentiation accompanying the switch from 
proliferative to hypertrophic cardiac growth are not well understood, changes in the 




activating genes, such as cyclin-dependent kinases (Cdk) (e.g. Cdk 2, 4 and 6) and 
cyclins (Ccn) (e.g. Ccnd1, Ccnd2, Ccnd3, Ccna, Ccnb and Ccne) are highly expressed in the 
prenatal heart but demonstrate decreased expression in neonates and are almost 
undetectable in adult hearts70,74-79. In contrast, genes coding for cyclin-dependent kinase 
inhibitors (Cdkn) (e.g. Cdkn1a and Cdkn1b) display a higher expression in adult hearts than 
in prenatal stages80,81. Importantly, in the context of elucidating underlying mechanisms 
responsible for the switch from proliferative to hypertrophic cardiac growth, transition to the 
oxygen-rich postnatal environment, accompanied by the switch to an oxidative metabolism, 
was recently identified as an essential factor that facilitates postnatal cardiomyocyte cell 
cycle exit82. The transition from hyperplastic to hypertrophic growth is furthermore 
accompanied by major changes in cardiac metabolism. In utero and in early neonates the 
mammalian heart performs mainly glycolysis, using carbohydrates, such as lactate and 
glucose, as primary substrates for adenosine triphosphate (ATP) production83-87. In contrast, 
the rates of mitochondrial glucose and fatty acid oxidation in the fetal heart are low due to 
low oxygen concentrations88,89. However, the rate of both processes, glucose and fatty acid 
oxidation, increases immediately after birth, while glycolytic rates decrease90,91. Consistently, 
in the adult heart, fatty acids are the preferred energy substrates and most of the required 
ATP comes from mitochondrial oxidative phosphorylation as well as glucose oxidation92. The 
perinatal metabolic transition is associated with changes in the activity of key enzymes 
involved in the regulation of fatty acid as well as glucose metabolism. Increased 5´-
adenosine monophosphate-activated protein kinase (AMPK) activity results in inhibition of 
acetyl-Coenzyme A carboxylase (ACC) and consequently in a drop in cardiac malonyl 
Coenzyme A levels93-96. These metabolic changes are considered to be the key event 
responsible for the increase in myocardial fatty acid oxidation rates in the postnatal heart96,97. 
Taken together, the determination of final cardiac organ size is a highly coordinated and 
complex process relying on a precise regulation of cell number established during embryonic 
and fetal development as well as cell size achieved by postnatal cardiac hypertrophic growth. 
In this context, metabolic changes accompanying the transition from prenatal to postnatal 
cardiac growth play an important role. 
3.3.3 Postnatal cardiac growth: Pathological and physiological cardiac hypertrophy 
Physiological cardiac hypertrophy not only drives the normal growth of the heart from birth to 
early adulthood but also the growth of the maternal heart during pregnancy98. It furthermore 
occurs as response to physiological stimuli, such as isotonic exercise (running, walking, 
cycling, swimming) as well as isometric/static exercise (wrestling, weight lifting)99. In contrast, 
pathological cardiac hypertrophy serves the heart to overcome pathological conditions and 
maintain cardiac function100,101. It develops in response to pressure overload (e.g. due to 
hypertension or aortic stenosis) or volume overload (e.g. due to aortic regurgitation or 
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arteriovenous fistulas or shunts) as well as in response to valve disease, myocardial 
infarction, ischemia and genetic mutations100,101. Dependent on the initiating stimulus, 
both (pathological and physiological hypertrophy) can be subclassified as concentric (hearts 
with thick walls and relatively small cavities) and eccentric (hearts with large dilated cavities 
and relatively thin walls), respectively102,103. While isotonic exercise103 and volume overload102 
cause eccentric hypertrophy; isometric exercise103 and pressure overload102 provoke 
concentric hypertrophy. Even though physiological and pathological hypertrophic cardiac 
growth both result in an increase in cell mass due to increased cardiomyocyte size, they 
induce distinct histological and molecular changes104-108. The enlargement of cardiomyocytes 
and the formation of new sarcomeres during pathological hypertrophy initially allows 
compensatory growth, ensuring normalization of wall stress and permitting normal 
cardiovascular function at rest100. However, if the pathological insult persists, cardiac 
fibroblasts and ECM proteins accumulate disproportionately and excessively109. This causes 
cardiac fibrosis and mechanical stiffness of the ventricular wall, which contributes to diastolic 
dysfunction (i.e. insufficient filling of the ventricles upon relaxation) and can progress to 
systolic dysfunction (i.e. reduced contractility and insufficient output)109. Cardiac function in 
the pathologically hypertrophied heart may eventually decompensate, leading to LV dilation, 
potentially resulting in heart failure, arrhythmia and sudden death110. Furthermore, 
pathological cardiac hypertrophy is often associated with upregulation of fetal genes, 
including natriuretic peptide type A (Nppa), natriuretic peptide type B (Nppb) and genes for 
fetal isoforms of contractile proteins, such as skeletal α-actin and β-myosin heavy 
chain (Myh7)111-114. In contrast, increase of interstitial fibrosis and upregulation of the fetal 
gene program are not associated with physiological hypertrophy, and decompensation into 
dilated cardiomyopathy or heart failure does not occur103,115. Finally and most importantly, 
physiological hypertrophy is reversible, while pathological hypertrophy, especially after 
establishment of fibrosis and tissue remodeling, is irreversible116. Interestingly, the 
mechanistic target of rapamycin (mTOR) pathway was shown to be of particular importance 
in the regulation of cardiomyocyte size and hypertrophic growth in adult murine hearts; both 
under physiological as well as pathological conditions117 (see Chapter 3.3.4). 
3.3.4 The mechanistic target of rapamycin pathway and its role in cardiac growth 
Even though progress has been made in elucidating the structural and molecular 
characteristics of cardiac hypertrophy, our understanding of the precise molecular signaling 
pathways defining “physiological” versus “pathological” postnatal cardiac growth is 
incomplete. In this context, the mechanistic target of rapamycin (mTOR) pathway has been 
implicated in controlling cardiac organ size and regulating both types of hypertrophy within 
the heart (reviewed by Csibi and Blenis58) (see Chapter 3.3.4.2). It is not only a master 




of cell nutrition and energy status118. The MTOR protein itself is an evolutionary conserved 
289 kDa serine-threonine kinase that belongs to the phosphoinositide 3-kinase (PI3K)-
related kinase family. It forms the catalytic subunit of two distinct multiprotein complexes, 
mTOR complex 1 (mTORC1) and 2 (mTORC2), which differ in their functions and complex 
components (Table 1, Figure 4 and see 3.3.4.1, Figure 5)118. Importantly, mTOR pathway 
activity depends on sufficient amino acid availability119. Given that the mTOR signaling 
cascade plays a major role in the regulation of heart growth (see Chapter 3.3.4.2), it might 
even be involved in IUGR-induced cardiac hypoplasia (e.g. reduced heart size after prenatal 
amino acid restriction).  
Table 1. Protein components of the two mTOR complexes and their known functions 
mTORC1 mTORC2 
MTOR serine/threonine kinase MTOR serine/threonine kinase 
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Listed are complex components of mTORC1 and mTORC2. Italic components are specific for mTORC1 or mTORC2, 
respectively. Bold components are core components essential for complex function. Table adapted from Laplante and 
Sabatini
135
. (DEPTOR: DEP domain containing mTOR-interacting protein, MLST8: mammalian lethal with sec-13 protein 8, 
MSIN1: mammalian stress-activated map kinase-interacting protein, MTOR: mechanistic target of rapamycin, 
mTORC1/2: mTOR complex 1/2, RAPTOR: regulatory-associated protein of mTOR, RICTOR: rapamycin-insensitive companion 
of mTOR, PRAS40: proline-rich Akt substrate 40 kDa, PROTOR1/2: protein observed with rictor 1 and 2, SGK1: serum- and 
glucocorticoid-induced protein kinase 1) 
 
Figure 4. mTORC1 and mTORC2 have distinct cellular functions. 
The mechanistic target of rapamycin (mTOR) kinase functions as the catalytic subunit of two different multiprotein complexes 
termed mTOR complex 1 (mTORC1) and 2 (mTORC2). mTORC1 integrates various upstream signals such as amino acids, 
stress, oxygen, energy and growth factors. It regulates multiple anabolic and catabolic processes, respectively, and promotes 
cell cycle progression. In contrast, mTORC2 responds to growth factors and is subsequently involved in the control of cell 
survival, metabolism, cell cycle progression and cytoskeletal organization. While mTORC1 is inhibited by rapamycin, mTORC2 





3.3.4.1 Regulation and function of the mTOR pathway with emphasis on mTORC1 
mTORC1 is activated by three major upstream signals: growth factors, high cellular energy 
status and nutrients (amino acids)135. Growth factors stimulate mTORC1 through the PI3K-
phosphoinositide-dependent kinase 1 (PDK1)-AKT pathway (Figure 5a). AKT phosphorylates 
and thus inactivates the mTORC1 inhibitor complex tuberous sclerosis ½ (TSC1/2) at 
serine 939 and threonine 1462136-140. On the other hand, growth factor activated AKT 
phosphorylates the non-essential mTORC1 inhibitory component proline-rich Akt substrate 
40 kDa (PRAS40), which in turn dissociates from regulatory-associated protein of 
mTOR (RAPTOR), resulting in mTORC1 activation123-126. Moreover, phosphorylation of AKT 
at serine 473 links upstream mTORC2 activity to mTORC1141. The energy status of the cell is 
signaled to mTORC1 through AMPK, which is a master sensor of intracellular ATP 
levels (Figure 5b)142,143. In response to energy starvation (low ATP/adenosine 
diphosphate (ADP) or ATP/adenosine monophosphate (AMP) ratio), AMPK is activated and 
phosphorylates TSC2 on at least two residues (threonine 1271 and serine 1387) as well as 
RAPTOR at serine 792144,145. Consequently, mTORC1 becomes inactivated. Even in the 
presence of additional upstream stimuli (e.g. growth factors), amino acids must be available 
to activate mTORC1 (Figure 5c)119,146. Although it has long been known that amino acids 
signal independently of TSC1/2147, the precise molecular mechanisms by which intracellular 
amino acids activate mTORC1 are currently under debate. Several modes of actions have 
recently been proposed, as reviewed in Jewell et al., 2013148 and Shimobayashi and 
Hall, 2014149. In this context, it was shown that in the presence of amino acids, mTORC1 
translocates from a poorly characterized cytoplasmic location to the lysosomal surface to get 
in proximity to its main activator RHEB 150-156. Moreover, mTORC1 is a physiological target of 
rapamycin, also named sirolimus, a macrolipid produced in Streptomyces hygroscopius that 
is known to inactivate mTORC1 (Figure 5d)157-159. Rapamycin works through a gain-of-
function mechanism in which it binds to the intracellular FKBP12 protein, which in turn binds 
to and inhibits the kinase activity of mTORC1158,159.  
Downstream, mTORC1 promotes cell growth and proliferation by activating various anabolic 
processes (e.g. protein and lipid biosynthesis (Figure 5e), mitochondrial metabolism and 
biogenesis (Figure 5f)) and by limiting catabolic processes such as autophagy (Figure 5g)160. 
Among those downstream effects of mTORC1, protein biosynthesis is by far the best 
characterized process (Figure 5h). mTORC1 directly phosphorylates two important 
translational regulators: eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) 
and S6 kinase 1 (S6K1)161. Phosphorylation of 4E-BP1 prevents it from binding to and 
thereby interfering with the cap-binding protein eukaryotic translation initiation 
factor 4E (EIF4E). Instead, after 4E-BP1 dissociation, EIF4E forms a complex that is required 




through a number of effectors (e.g. eukaryotic translation initiation factor 4E (EIF4B) and S6 
ribosomal protein (S6)), to increased messenger ribonucleic acid (mRNA) biogenesis, 
translational initiation and elongation161. In the context of positive regulation of anabolic 
processes, mTORC1 furthermore controls cellular metabolism and ATP production (Figure 
5f). It does so by increasing the glycolytic flux by activating transcription and translation of 
hypoxia inducible factor 1, alpha subunit (HIF1α), a positive regulator of many glycolytic 
genes163,164. Moreover, mTORC1 is involved in mitochondrial biogenesis and oxidative 
metabolism by increasing the mitochondrial DNA content, mitochondrial membrane potential 
and mitochondrial oxygen consumption165. 
Inhibition of catabolic processes by mTORC1 occurs via inhibition of autophagy (Figure 5g), 
the central cellular degradation process important for protein turn-over, recycling of damaged 
organelles and consequently organismal and cellular adaptation to nutrient 
starvation (reviewed by Baehrecke166 and Mizushima and Komatsu167). In mammals, 
mTORC1 directly phosphorylates and thereby suppresses a protein complex consisting of 
unc-51-like kinase 1 (ULK1), mammalian autophagy-related gene 13 (ATG13) and focal 
adhesion kinase family-interacting protein of 200 kDa (FIP200), which is required to initiate 
autophagy168-171. Besides, mTORC1 impacts autophagy by additional mechanisms, for 
instance by regulation of the autophagy suppressor death-associated protein 1 (DAP1)172. 
Furthermore, mTORC1 inhibits the biogenesis of lysosomes, which are important cellular 




Figure 5. Simplified schematic drawing of the mTOR signaling network in mammalian cells. 
Figure shows major upstream and downstream cascades of mTOR signaling. Critical inputs regulating mTORC1activity include 
a) growth factors such as insulin and insulin-like growth factors (IGFs), b) energy signals that act through adenosine 
monophosphate-activated protein kinase (AMPK), c) nutrient signals that are generated by amino acids and d) inhibition 
through rapamycin. When active, mTORC1 promotes e) lipogenesis, f) cellular energy metabolism, g) autophagy inhibition and 
h) mRNA translation and protein synthesis. In contrast, mTORC2 is activated by a) growth factors and regulates i) cytoskalatal 
organization and j) cell survival and metabolism. Note that not all complex components of mTORC1 and mTORC2 are shown. 
Only selected phosphorylation sites and cascade components are depicted. Arrows represent activation, whereas bars 
represent inhibition. Dashed lines indicate connections that have not been fully elucidated yet. (4E-BP1: eukaryotic translation 
initiation factor 4E binding protein 1, AKT: serine/threonine protein kinase Akt, AMP: adenosine monophosphate, 
AMPK: adenosine monophosphate-activated protein kinase, ATP: adenosine trihosphate, ATG13: autophagy-related gene 13, 
DAPI: death-associated protein 1, EIF4B: eukaryotic translation initiation factor 4B, EIF4E: eukaryotic translation initiation factor 
4E, FIP200: focal adhesion kinase family-interacting protein of 200 kDa, HIF1α: hypoxia inducible factor 1, alpha subunit, 
IRS1: insulin receptor substrate 1, LKB1: serine/threonine kinase LKB1, MLST8: mammalian lethal with sec-13 protein 8, 
MSIN1: mammalian stress-activated map kinase-interacting protein, MTOR: mechanistic target of rapamycin, 
mTORC1/2: mTOR complex 1/2, PDK1: phosphoinositide-dependent kinase 1, PIK3: phosphatidylinositol 3-kinase, 
PRAS40: proline-rich Akt substrate 40 kDa, RAPTOR: regulatory-associated protein of TOR, RHEB: Ras homolog enriched in 
brain, RICTOR: rapamycin-insensitive companion of mTOR, S6: ribosomal protein S6, S6K1: S6 kinase 1, Ser: serine, 
SGK1: serum- and glucocorticoid-induced protein kinase 1, Thr: threonine, TSC1/2: tuberous sclerosis 1/2, Tyr: tyrosine, 




3.3.4.2 The role of the mTOR pathway in the mammalian heart 
A growing number of publications within the last couple of years revealed that the mTOR 
pathway is of particular importance in the heart and acts as a key regulator of postnatal 
cardiac metabolism and growth176. While conventional Mtor, Rictor, Raptor and Rheb KO 
mice die early during embryonic development122,177-181, tamoxifen-inducible cardiac-specific 
Mtor and Raptor deletion in adult mice both lead to cardiac dysfunction and heart failure, with 
chamber dilation and wall thinning182,183. This goes in line with massive apoptosis, fibrosis, 
induction of autophagy, mitochondrial abnormalities and dysfunction, sarcomere disarray and 
death within less than eight weeks after tamoxifen-induced gene deletion under baseline 
conditions182,183.  
Furthermore, the mTOR signaling cascade was shown to play a key role in the development 
of both types of postnatal cardiac hypertrophy (physiological and pathological, see Chapter 
3.3.3), either relying on increased protein turnover required for cardiomyocyte growth176. In 
this context, mTOR pathway activity has been demonstrated to be increased in the 
physiologically hypertrophied heart after prolonged exercise117. In contrast, pressure 
overload upon transverse aortic constriction (TAC) was associated with decreased mTOR 
pathway activity117. Additionally, pharmacological inhibition of mTORC1 by rapamycin in 
adulthood inhibits pathological cardiac hypertrophy in response to pressure overload and 
reduces heart size184,185. Rapamycin administration also blunts both established 
compensated and decompensated cardiac hypertrophy induced by TAC186. Interestingly, 
neither constitutively active nor wildtype (WT) Mtor overexpression induced significant 
increase in cardiac mass in mice187,188. In contrast, adult mice with inducible cardiac-specific 
Mtor or Raptor deletion do not develop compensatory cardiac hypertrophy after TAC-induced 
pressure overload, but rapidly demonstrate signs of ventricular dilation and cardiac 
dysfunction already 1 to 2 weeks after the TAC procedure182,183. In conclusion, changes in 
opposite directions of the myocardial mTOR pathway appear to distinguish between 
physiological and pathological hypertrophies. 
Even though there is a constantly growing body of evidence emphasizing the role of the 
mTOR signaling cascade in the healthy as well as challenged adult heart, studies on its role 
during prenatal cardiac development as well as in the perinatal period are scarce. Recently, 
Tamai et al. showed that mice with a cardiac-specific deficiency for Rheb (cRheb-KO), the 
most important upstream regulator of mTORC1, die from postnatal day 8 to 10189. 
Surprisingly, analysis in 3 and 5 day old cRheb-KO mice revealed no differences regarding 
heart size and function compared to controls189. However, at day 8, cRheb-KO mice 
presented signs of dilated cardiomyopathy, such as significantly lower HW/BW ratios and 
reduced cardiomyocyte cross sectional area (CSA) as well as cardiac dysfunction compared 
to controls189. Why this phenotypic abnormalities become obvious only from postnatal day 8 
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onwards remains elusive. In conclusion, Tamai et al. suggested that RHEB-dependent 
mTORC1 activation is not required for embryonic as well as neonatal heart development 
immediately after birth189. However, RHEB becomes essential for postnatal cardiomyocyte 
hypertrophic growth and normal heart development after the early postnatal period189. 
Importantly, as stated by the authors, a suggested RHEB-independent mTORC1 signaling 
pathway in the neonatal period until day 8 remains unknown and requires further 
investigation. 
Another study focusing on components of the mTOR signaling pathway within the heart 
examined the role of the mTORC1 upstream kinase AKT in the regulation of organ size190. 
Shioi et al. generated and characterized transgenic mice expressing constitutively active 
Akt (cactAkt) and kinase-deficient Akt (ckidAkt) specifically within the heart190. They observed 
a significant increase in cardiomyocyte size and HW in 3 to 4 month old adult cactAkt mice 
compared to non-transgenic controls. This coincided with increased S6K1 activity, as 
determined by immune complex kinase assays190. Interestingly, the cardiomyocyte and heart 
overgrowth could be attenuated by rapamycin treatment190. These observations suggest that 
MTOR or effectors of MTOR mediate cactAkt-induced heart growth190. However, 
cardiomyocyte and heart size in adult ckidAkt mice were not different compared to non-
transgenic controls, even though ckidAkt mice effectively attenuated PI3K-induced 
overgrowth of the heart190. Unfortunately, mTOR pathway activity was not analyzed in 
ckidAkt mice at any developmental stage190, leaving open questions regarding the role of 
MTOR in the prenatal, perinatal and neonatal heart.  
To the best of our knowledge, there is only one published study that characterized mice 
harboring a heart conditional KO of one of the mTORC1 core components (namely Mtor 
itself) during prenatal development191. This heart-specific, embryonic Mtor-KO mouse 
model (cMtor-KO) suggests an essential role of mTOR signaling during heart 
development191. Hearts of embryonic cMtor-KO mice demonstrated increased apoptosis 
rates, reduced cardiomyocyte proliferation, decreased heart size and cardiac dysfunction 
compared to controls191. Thus, cMtor-KO mice are embryonically lethal and died from 
13.5 dpc onwards191. However, since no complete cardiac Mtor inactivation was achieved191, 
substantial parts of the data are not conclusive and show a high variability between the 
animals analyzed, such that the true significance of this study awaits further confirmation. 
Taken together, the studies discussed above underscore the complexity associated with 
mTOR signaling in the heart, such that pharmacologic inhibition with rapamycin can blunt 
physiological hypertrophy, but deletion of Mtor or other pathway regulators induces cardiac 
dilatation and pathology. Thus, many aspects of the pathophysiology of mTOR signaling are 
still unclear and further studies are required to complete the entire picture of mTOR pathway 




perinatal heart development also remains obscure. Moreover, the involvement of mTOR 
signaling in IUGR and developmental programming has not been addressed to date.  
3.4 The heart conditional holocytochrome c synthase
 
KO mouse model: A 
novel model for impaired intrauterine cardiac development 
According to the concept of developmental programming, the entire organism undergoes 
adaptations in response to IUGR, as demonstrated by the variety of organs affected (see 
Chapter 3.2). Consequently, dissecting the precise cause and effect of molecular changes in 
one particular organ is still an ongoing challenge. To this end, apart from the traditional models 
for developmental programming and IUGR, studies on organ-specific embryonic and fetal 
growth disturbances might prove useful. In this context, our group has generated a new 
mouse model for impaired prenatal cardiac development192.  
The model is based on heart-specific inactivation of the highly conserved holocytochrome c 
synthase (Hccs) gene192. The Hccs gene product is a mitochondrial heme lyase that is 
responsible for the activation of two related electron transporters, which are crucial 
components of the electron transport chain (ETC): cytochrome (CYT) c and c1193,194. In 
mammals, the ETC can be found in the inner mitochondrial membrane where it serves as the 
site of oxidative phosphorylation through the ATP synthase complex195. Coordinated 
transport of electrons and protons along a series of carrier molecules leads to the production 
of energy in form of ATP. This makes mitochondria the most important energy producers in 
animal cells196. Hence, in cardiomyocytes, mitochondria are present in large amount to cover 
the high energy demand for constant contraction. The HCCS enzyme is located within the 
mitochondrial intermembrane space and catalyzes the transfer of a prosthetic heme moiety 
to the precursor apo-CYT c and c1, which in turn become functionally active holo-
cytochromes197,198. Active CYT c1 integrates into complex III of the ETC and delivers 
electrons from ubiquinol to CYT c, which in turn shuttles the electrons between complex III 
and complex IV195,196,199.  
In mice and humans, the Hccs gene is located on the X chromosome. Consequently, its 
allelic expression is subjected to X chromosome inactivation, a highly conserved process that 
occurs exclusively in mammals200. It leads to random transcriptional silencing of one of the 
two X chromosomes in all female somatic cells during early embryonic development. Thus, 
differences in dosage of X-linked genes between the sexes are compensated. The silencing 
pattern is maintained through successive cell divisions in the arising daughter cells such that 
females can be considered cellular mosaics, which determines the phenotypic outcome in 
females heterozygous for X-linked mutations201. 
In the heart conditional Hccs KO model, parts of the Hccs gene are specifically knocked out in 
cardiomyocytes from 7.5 dpc onwards applying Cre/locus of X-over P1 (loxP) 
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recombination192 (see Chapter 5.1.2.1). In affected cells, the HCCS enzyme is inactive. 
Consequently, no active CYT c and c1 can be built, complex III assembly and the electron 
shuttle to complex IV within the ETC is disturbed and mitochondrial energy production does 
not function properly192. Subsequently, loss of HCCS enzymatic activity results in 
mitochondrial dysfunction, causing disturbed cardiomyocyte differentiation as well as reduced 
cell cycle activity192. 
Our breeding strategy allows the generation of healthy control males (Hccs+/Y) and 
females (Hccs+/+), as well as cardiac-specific hemizygous KO males (cHccs-/Y) and 
heterozygous KO females (cHccs+/-) (see Chapter 5.1.2.1, Figure 6). cHccs-/Y males exhibit 
dysfunction of the ETC in all cardiomyocytes and die at midgestation192. In contrast, in 
heterozygous cHccs+/- females, 50 % of cardiac cells have the defective X chromosome 
silenced and remain healthy, while 50 % of cardiomyocytes keep the defective X chromosome 
active and consequently demonstrate disturbed ETC function192. Thus, in cHccs+/- offspring, a 
cardiac mosaic for mitochondrial dysfunction develops at midgestation192. However, Hccs-
deficient cardiac cells are not actively eliminated and are still detectable in adult cHccs+/- 
hearts192 Interestingly, increased proliferation of the healthy cardiac cell population during the 
second half of gestation compensates for the functional loss of 50 % cardiac tissue192. 
Thereby, the contribution of Hccs-deficient cardiac cells to the cardiac tissue decreases from 
50 % at midgestation to 10 % at birth, which in turn implies that 90 % of the neonatal heart is 
built of the healthy cardiac cell population192. Importantly, in spite of the functional inactivation 
of roughly half of the cardiomyocytes at 7.5 dpc, cHccs+/- mice have a functional heart at birth 
and survive to adulthood, indicating an impressive regenerative potential of the embryonic 
mammalian heart192.  
However, formation of the heart from just 50 % of embryonic cardiomyocytes is not sufficient 
to generate a mature organ until birth. Despite normal function, hearts of neonatal cHccs+/- 
mice reveal a hypoplastic phenotype. They have a reduced HW/BW ratio, thinner LV walls, 
significant reduction in cardiomyocyte number by 25 % and LV noncompaction (e.g. thin 
myocardial compact layer accompanied by hypertrabeculation) (unpublished data). 
Surprisingly, the reduction in heart size as well as LV wall dimensions was no longer evident in 
adult cHccs+/- hearts, suggesting postnatal compensatory growth. While no alterations in 
cardiomyocyte proliferation rates were observed at any postnatal stage, cardiomyocyte 
hypertrophy was revealed to account for this catch-up growth of the hypoplastic 
myocardium (unpublished data). Important to note, cHccs+/- mice sustain lifelong normal 
cardiac function under baseline conditions192. Nevertheless, adult cHccs+/- mice demonstrate 
significant cellular and molecular alterations in response to cardiac stress and ageing. This 




adaptations cause different alterations in cHccs+/- hearts in response to stress compared to 
healthy Hccs+/+ hearts (unpublished data).  
Importantly, the heart conditional Hccs KO model resembles many observations found in 
classical IUGR models (see Chapter 3.2.2), such as reduced heart size at birth, altered 
stress response in adulthood and postnatal cardiac catch-up growth. According to the 
developmental programming concept (see Chapter 3.2.1), the latter contributes to increased 
disease susceptibility in adulthood rather than being beneficial15,16. However, in contrast to 
the well-established developmental programming models, no systemic insult is applied in 
cHccs+/- mice. Nevertheless, formation of the heart from a mosaic of healthy and defective 
cardiomyocytes can be considered as an insult affecting cardiac development and growth. 
Thereby, our model provides an organ specific developmental impairment and consequently 
might serve as a new model for impaired prenatal cardiac growth and developmental 
programming in the heart. 
3.5 Aims and Hypotheses 
Impaired embryonic and fetal growth has various effects on postnatal health in humans 
because unfavorable intrauterine growth conditions induce permanent physiological 
adaptations in the unborn organism, which are supposed to provoke increased disease 
susceptibility in adulthood2,3,7. Elucidation of key processes and factors essential for the pre- 
and even postnatal heart to cope with the molecular, cellular and organ-wide consequences 
of IUGR might reveal new strategies for the prevention of congenital and postnatal heart 
diseases. In this context, the heart conditional Hccs KO model resembles many observations 
identified in classical animal models for IUGR, such as smaller hearts, thinner left ventricular 
walls and reduced cardiomyocyte number at birth as well as postnatal cardiac catch-up 
growth and altered stress response in adulthood15,16,23,192. Thus, we propose that our model 
is suitable to study basic mechanisms of pre- and postnatal adaption of the myocardium in 
response to impaired intrauterine development and that it might help to identify molecular 
mechanisms of cardiac developmental programming. 
Results from previously performed genome-wide microarray analysis and preliminary data 
suggest that adaptations employed by embryonic and neonatal cHccs+/- hearts in response to 
disturbed cardiac development are predominantly involved in amino acid metabolism and 
protein homeostasis (unpublished data). Moreover, in the well-established LPD rat model, 
neonatal hearts were shown to be hypoplastic, as evident by a reduced HW and a significant 
reduction in the cardiomyocyte number23. Given that our neonatal cHccs+/- mice resemble 
those findings and considering that the mTOR signaling cascade is a master regulator of 
postnatal cardiac metabolism and growth that is sensitive to amino acid availability, we 
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hypothesize that amino acid availability as well as mTOR pathway activation are crucial to 
sustain regeneration and compensatory growth of cHccs+/- hearts. To test this hypothesis 
and to investigate the importance of amino acids and mTOR for development and growth of 
cHccs+/- hearts, this PhD project aims at interfering with these metabolic switches that were 
identified during impaired intrauterine cardiac development. We aspire to achieve this 
interference by prenatally inhibiting the mTOR pathway and by applying a dietary protein 
restriction model. To this end, pregnant dams will be treated with the pharmacological 
mTORC1 inhibitor rapamycin. In a second approach, a protein-restricted diet will be fed 
during pre- and postnatal development to limit the amino acid availability. We hypothesize 
that interfering with these key mechanisms will inhibit cardiac adaptation and reduce heart 
size, resulting in impaired cardiac function in adulthood and eventually causing postnatal 
heart disease. To test this, consequences of the two experimental strategies (mTOR 
inhibition and amino acid restriction) will be studied in the cHccs+/- model with regard to heart 
development and growth as well as long-term consequences and cardiac function in 
adulthood. Because organ size is mainly determined by the combination of cell number and 
size, main emphasis will be put on processes like apoptosis and proliferation as well as on 
cardiomyocyte size. 
Importantly, the consequences of both interventions (mTOR inhibition and amino acid 
restriction) are not only going to be analyzed with respect to the cHccs+/- model. Data about 
the general role of the mTOR pathway during heart development are limited and insufficient. 
Due to its crucial role in cardiac metabolism and growth, we hypothesize that prenatal 
impairment of the mTOR signaling cascade will also alter cardiac development in general, 
independent of the cHccs+/- model. In line, consequences of prenatal amino acid restriction in 
the mouse are vastly unknown and pre- and postnatal impairment of the amino acid 
availability might also have important implications for the murine heart. Thus, another 
important aim of this thesis is to elucidate the role of the amino acid availability and mTOR 
signaling during heart development. 
In summary, this PhD project aims to answer the following two central questions: 
1. What are the consequences of prenatal mTORC1 inhibition and pre- as well as 
postnatal amino acid restriction on heart development, growth and function in 
general? 
2. Are amino acid availability and mTOR pathway activation essential for embryonic 
regeneration and postnatal compensatory growth of cHccs+/- hearts? 
By answering these crucial questions and by using our cHccs+/- model as new tool to 
resemble IUGR in the heart, we aim at investigating mechanisms of cardiac growth and 





4.1 Laboratory equipment 
Table 2. Laboratory equipment 
Equipment Company 
Agarose electrophoresis unit HE99X max horizontal Hoefer, Holliston, USA 
Centrifuge 5402 with 18-place kit rotor F-45-18-11 Eppendorf, Hamburg, Germany 
Centrifuge 5425 with 24-place aerosol-tight fixed-angle 
rotor FA-45-24-11 
Eppendorf, Hamburg, Germany 
Centrifuge 5810R with swing-bucket rotor A-4-62 Eppendorf, Hamburg, Germany 
Confocal laser scanning microscope TSC SPE Leica Microsystems, Wetzlar, Germany 
Cryolys® Precellys® 24 cooling unit peqLab Biotechnology, Wilmingon, USA 
Film developing machine Curix 60 Agfa, Mortsel, Belgium 
Digital camera EOS 400D Canon, Tokyo, Japan 
Digital camera for microscope IC80 HD Leica Microsystems, Wetzlar, Germany 
Fluorescence microscope Biozero BZ-8100 Keyence, Osaka, Japan 
Gel documentation system GelDoc2000 Bio-Rad Laboratories, Hercules, USA 
Glass ware Schott, Mainz, Germany 
Homogenizer Precellys® 24  peqLab Biotechnology, Wilmingon, USA 
Hybridization oven OV1 Biometra, Göttingen, Germany 
Imaging system Odyssey® Fc LI-COR® Biosciences, Lincoln, USA 
Light microscope DM IL Leica Microsystems, Wetzlar, Germany 
Light microscope M205 C Leica Microsystems, Wetzlar, Germany 
Magnetic stirrer neoLab Migge, Heidelberg, Germany 
Microcentrifuge Galaxy mini VWR, Radnor, USA 
Microcentrifuge MiniStar silverline VWR, Radnor, USA 
Micropestle  Carl Roth, Karlsruhe, Germany 
Microtome RM 2155 Leica Microsystems, Wetzlar, Germany 
Microwave oven 0749730M Privileg, Stuttgart, Germany 
Mini-PROTEAN® combs (1.0 mm, 10 well and 15 well) Bio-Rad Laboratories, Hercules, USA 
Mini-PROTEAN® tetra handcast system Bio-Rad Laboratories, Hercules, USA 
Mini-PROTEAN® tetra cell Bio-Rad Laboratories, Hercules, USA 
Mini Trans-Blot® cell Bio-Rad Laboratories, Hercules, USA 
MiniTwist nutating mixer Select BioProducts, Edison, USA 
Orbital shaker 3017 GFL, Burgwedel, Germany 
Paraffin embedding center EC 350 Leica Microsystems, Wetzlar, Germany 
pH meter 766 Knick Eleketronische Messgeräte, Berlin, Germany 
Pipette filler Pipetus® Hirschmann Laborgeräte, Eberstadt, Germany 
Pipettes (2 µl, 10 µl, 20 µl, 100 µl, 200 µl, 1000 µl) Gilson, Middleton, USA 
PowerPac™ basic power supply Bio-Rad Laboratories, Hercules, USA 
Precision scale AB104 Mettler-Toledo, Greifensee, Switzerland 
Scale 440-47N Kern&Sohn, Balingen, Germany 
Sonifier® cell disruptor 450 Branson Ultrasonics, Danbury, USA 
Spacer plates with 1.0 mm integrated spacers  Bio-Rad Laboratories, Hercules, USA 
Spectrophotometer nanoDrop ND-1000 peqLab Biotechnology, Wilmingon, USA 
Spectrophotometer SmartSpec™ 3000 Bio-Rad Laboratories, Hercules, USA 
Staining boxes Rotilabo® Carl Roth, Karlsruhe, Germany 
Staining cuvettes Carl Roth, Karlsruhe, Germany 
Stain Tray™ Carl Roth, Karlsruhe, Germany 
Surgical instruments Fine Science Tools, Heidelberg, Germany 
Thermasonic® gel warmer Parker Laboratories, Fairfield, USA 
Thermocycler PTC-200  Bio-Rad Laboratories, Hercules, USA 
Thermocycler Tetrad® 2  Bio-Rad Laboratories, Hercules, USA 
Thermomixer® comfort Eppendorf, Hamburg, Germany 
Vevo® 2100 ultrasound system FUJIFILM VisualSonics, Toronto, Canada 
Vevo® compact dual anesthesia system  FUJIFILM VisualSonics, Toronto, Canada 
Vevo® imaging station FUJIFILM VisualSonics, Toronto, Canada 
Vevo® MicroScan™ transducer MS400 FUJIFILM VisualSonics, Toronto, Canada 
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Equipment Company                                                  continued 
Vevo® MicroScan™ transducer MS700 FUJIFILM VisualSonics, Toronto, Canada 
Vortex mixer VortexGenie® 2 Scientific Industries, Bohemia, USA 
ViiA™ 7 real-time PCR system Applied Biosystems, Foster City, USA  
Water bath HI1210 Leica Microsystems, Wetzlar, Germany 
X-ray cassettes  Dr. Goos-Suprema, Heidelberg, Germany 
 
4.2 Consumables 
Table 3. Consumables 
Consumable Company 
Ceramic beads (1.4 mm and 2.8 mm) peqLab Biotechnology, Wilmingon, USA 
CL-XPosure™ films Thermo Fischer Scientific, Waltham, USA 
Histology embedding cassettes Carl Roth, Karlsruhe, Germany 
Falcon tubes (15 ml and 50 ml) Greiner Bio-One, Kremsmünster, Austria 
Filter papers Macherey-Nagel, Düren, Germany 
Glass cover slips Gerhard Menzel, Braunschweig, Germany 
Homogenization tubes peqLab Biotechnology, Wilmingon, USA 
MicroAmp® optical 384-well reaction plates Applied Biosystems, Foster City, USA 
MicroAmp® optical adhesive films  Applied Biosystems, Foster City, USA 
Microtome blades R35 FEATHER Safety Razor, Osaka, Japan 
Nitrocellulose blotting membrane Amersham Hybond 
ECL (pore size 0.45 µm) 
GE Healthcare, Fairfield, USA 
PCR disposable strips of 8 tubes with caps BRAND, Wertheim, Germany 
Petri dishes Greiner Bio-One, Kremsmünster, Austria 
Pipette tips (2 µl, 10 µl, 20 µl, 100 µl, 200 µl, 1000 µl) Biozym Scientific, Hessisch Oldendorf, Germany 
Serological pipettes (2 ml, 5 ml, 10 ml, 25 ml) Sarstedt, Nümbrecht, Germany 
Spectrophotometer cuvettes BRAND, Wertheim, Germany 
Superfrost® plus microscope slides Gerhard Menzel, Braunschweig, Germany 
Surgical disposable scalpels B. Braun Melsungen, Melsungen, Germany 
Reaction tubes (1.5 ml and 2.0 ml) BRAND, Wertheim, Germany 
Reagent and centrifuge tubes (5 ml) Sarstedt, Nümbrecht, Germany 
Weighing dishes Greiner Bio-One, Kremsmünster, Austria 
Whatman® gel blotting paper GE Healthcare, Fairfield, Germany 
 
4.3 Chemicals and reagents 
Table 4. Chemicals and reagents 
Chemical/Reagent Company 
2-Mercaptoethanol Carl Roth, Karlsruhe, Germany 
2-Propanol Carl Roth, Karlsruhe, Germany 
Acetic acid Carl Roth, Karlsruhe, Germany 
Agarose Biozym Scientific, Hessisch Oldendorf, Germany 
Ammonium persulfate (APS) Carl Roth, Karlsruhe, Germany 
Bovine serum albumin (BSA) Carl Roth, Karlsruhe, Germany 
Bromophenol blue Carl Roth, Karlsruhe, Germany 
Chlorophorm Carl Roth, Karlsruhe, Germany 
Coumaric acid Sigma-Aldrich, St. Louis, USA 
Deoxyribonucleotides (dNTPs) Fermentas, Burlington, Canada 
Developer type E Christiansen und Linhardt, Planegg, Germany 
Dimethylacetamide (DMA) Sigma-Aldrich, St. Louis, USA 
Direct red 80 Sigma-Aldrich, St. Louis, USA 
Disodium hydrogen phosphate (Na2HPO4) Carl Roth, Karlsruhe, Germany 
DNA loading dye (6×) Fermentas, Burlington, Canada 
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Chemical/Reagent Company                                             continued 
Electrode gel 
GE Medical Systems Information Technologies, 
Freiburg, Germany 
Eosin G solution (0.5 %) Carl Roth, Karlsruhe, Germany 
Ethanol (EtOH)  Carl Roth, Karlsruhe, Germany 
Ethidium bromide (EtBr) Carl Roth, Karlsruhe, Germany 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, St. Louis, USA 
Eukitt® quick hardening mounting medium Sigma-Aldrich, St. Louis, USA 
Fixer type F Christiansen und Linhardt, Planegg, Germany 
Glycerol Carl Roth, Karlsruhe, Germany 
Glycine Serva, Heidelberg, Germany 
Hematoxylin solution according to Harris Carl Roth, Karlsruhe, Germany 
Heematoxylin solution according to Weigert Carl Roth, Karlsruhe, Germany 
Hydrochloride (HCl) (37 %) Carl Roth, Karlsruhe, Germany 
Hydrogen peroxide (H2O2) (30 %) Carl Roth, Karlsruhe, Germany 
Isoflurane (Forene®) Abbott Laboratories, North Chicago, USA 
Luminol Sigma-Aldrich, St. Louis, USA 
Methanol (MeOH) Carl Roth, Karlsruhe, Germany 
Monopotassium phosphate (KH2PO4) Carl Roth, Karlsruhe, Germany 
Nitrogen (N2) Linde, Munich, Germany 
Nonyl phenoxypolyethoxylethanol (NP-40) (Igepal®) Sigma-Aldrich, St. Louis, USA 
Normal goat serum (NGS) 
Jackson ImmunoResearch Laboratories, West 
Grove, USA 
Paraffin (Paraplast®) Carl Roth, Karlsruhe, Germany 
Paraformaldehyde (PFA) Carl Roth, Karlsruhe, Germany 
Picric acid solution (1.3 % in H2O (saturated)) Sigma-Aldrich, St. Louis, USA 
Polyethylene glycol 300 (PEG300) Sigma-Aldrich, St. Louis, USA 
Potassium chloride (KCl) Carl Roth, Karlsruhe, Germany 
Powdered milk Carl Roth, Karlsruhe, Germany 
Rapamycin Cayman chemical, Ann Arbor, USA 
RNA loading dye (2×) Fermentas, Burlington, Canada 
RNase AWAY® Thermo Fisher Scientific, Waltham, USA 
Rotiphorese® gel 30 (acrylamide/bisacrylamide 37.5:1) Carl Roth, Karlsruhe, Germany 
Sodium chloride (NaCl) Carl Roth, Karlsruhe, Germany 
Sodium chloride (NaCl) solution (0.9 %) B. Braun Melsungen, Melsungen, Germany 
Sodium citrate Carl Roth, Karlsruhe, Germany 
Sodium deoxycholate Sigma-Aldrich, St. Louis, USA 
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe, Germany 
Sodium hydroxide (NaOH) Carl Roth, Karlsruhe, Germany 
Taurine Carl Roth, Karlsruhe, Germany 
Tetramethylethylenediamine (TEMED) Carl Roth, Karlsruhe, Germany 
Toluol Carl Roth, Karlsruhe, Germany 
Tris-hydrochloride Carl Roth, Karlsruhe, Germany 
Tris(hydroxymethyl)aminomethane (Tris) Carl Roth, Karlsruhe, Germany 
Triton® X 100 Carl Roth, Karlsruhe, Germany 
TRIzol® reagent Invitrogen, Carlsbad, USA 
Tween® 20 Carl Roth, Karlsruhe, Germany 
Tween® 80 Sigma-Aldrich, St. Louis, USA 
Ultrasound transmission gel Aquasonic® 100 Parker Laboratories, Fairfield, USA 
Xylol Carl Roth, Karlsruhe, Germany 
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4.4 Size standards 
Table 5. Size standards 
Size standard Company 
Generuler™ 100 bp DNA ladder  Fermentas, Burlington, Canada 
HiMark™ prestained high molecular weight protein 
standard 
Invitrogen, Carlsbad, USA 
PageRuler™ prestained protein ladder Fermentas, Burlington, Canada 
RiboRuler™ low range RNA ladder Fermentas, Burlington, Canada 
 
4.5 Enzymes and enzyme kits 
Table 6. Enzymes and enzyme kits 
Enzyme (kit) 
Further required kit 
components 
Company 
M-MuLV reverse transcriptase (200 U/µl) 
10× reverse transcriptase 
reaction buffer 
New England Biolabs, Beverly, USA  
 
Power SYBR®Green PCR master mix n/a Applied Biosystems, Foster City, USA 
Proteinase K (30 U/mg) (lyophilized)  n/a Carl Roth, Karlsruhe, Germany 
Taq DNA polymerase (5 U/µl)  10× PCR buffer Qiagen, Hilden, Germany 
RNase-free DNase set (lyophilized) 
(1500 Kunitz units) 
RNase-free water 
RDD buffer 
Qiagen, Hilden, Germany 
(n/a: not applicable) 
4.6 Inhibitors 
Table 7. Inhibitors 
Inhibitor Company 
COmplete mini EDTA-free protease inhibitor cocktail tablets Roche Diagnostics, Mannheim, Germany 
PhosSTOP phosphatase inhibitor cocktail tablets Roche Diagnostics, Mannheim, Germany 
RiboLock® ribonuclease inhibitor (40 U/µl) Fermentas, Burlington, Canada 
 
4.7 Buffers and solutions 
Table 8. Formulation of buffers and solutions 
Buffer/Solution Formulation 
Acidified water 1 % (v/v) acetic acid in ddH2O 
Antibody solution 0.1 % (v/v) Triton® X 100, 0.05 % (v/v) Tween® 20, 1 % (w/v) BSA in 1× TBS 
10 % APS 10 % (w/v) APS in ddH2O 
Blocking solution 5 % (v/v) NGS in antibody solution  
ECL solution A 0.4 mM coumaric acid, 2.5 mM luminol in 1× ECL stock solution 
ECL solution B 0.018 % (v/v) H2O2 (30 %) in 1× ECL stock solution 
1× ECL stock solution 100 mM Tris-HCl in ddH2O (pH 8.8) 
70 %, 80 %, 90 %, 96 %, 
99 % EtOH 
x % (v/v) EtOH in ddH2O 
1× Lysis buffer 
100 mM Tris-HCl, 200 mM NaCl, 5 mM EDTA, 0.2 % (w/v) SDS in ddH2O 
(pH 8.5), before use add 0.02 % (w/v) proteinase K  
5 % milk in 1× TBS-T 5 % (w/v) milk in 1× TBS-T 
10 N NaOH 10 N NaOH in ddH2O 
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Buffer/Solution Formulation                                                                                           continued 
1× PBS 
1.8 mM KH2PO4 in 8.1 mM Na2HPO4, 140 mM NaCl, 2.9 mM KCl in ddH2O 
(pH 7.4) 
4 % PFA solution 4 % (w/v) PFA in 1× PBS 
Proteinase K solution 0.02 % (w/v) proteinase K in 1× TBS 
1× RIPA buffer 
0.1% (w/v) SDS, 1 % (v/v) NP-40, 0.5 % (w/v) sodium deoxycholate, 
1mM EDTA in 1× TBS 
For 10 ml 1× RIPA buffer: 1 PhosSTOP phosphatase inhibitor and 1 cOmplete 
mini EDTA-free protease inhibitor cocktail tablet  
10 % SDS 10 % (w/v) SDS in ddH2O 
1× SDS running buffer 2.5 mM Tris, 19.2 mM glycine, 0.1% (w/v) SDS in ddH2O 
5× SDS sample buffer  
15 % (v/v) 2-marcaptoethanol, 15 % (w/v) SDS, 1.5 % (w/v) bromophenol blue, 
50 % (v/v) glycerol in 1× TBS 
Sirius red solution 0.1 % (w/v) Direct red 80 in picric acid solution 
1× Sodium citrate buffer 10 mM sodium citrate in ddH2O (pH 6.0) 
1× TBS 50 mM Tris, 150 mM NaCl in ddH2O (pH 7.6) 
1× TBS-T 1 % (v/v) Tween® 20 in 1× TBS 
1× Transfer buffer 
(for large proteins) 
10 mM Tris, 19.2 mM glycine, 0.01 % (w/v) SDS, 10 % (v/v) MeOH in ddH2O 
1× Transfer buffer 
(for normal proteins) 
10 mM Tris, 19.2 mM glycine, 0.01 % (w/v) SDS, 20 % (v/v) MeOH in ddH2O 
1 M Tris 1 M Tris in ddH2O (pH 6.8 or pH 8.8) 
1× TTE buffer 90 mM Tris, 30 mM taurine, 1 mM EDTA in ddH2O 
 
4.8 Consumable kits 
Table 9. Consumable kits 
Kit Company 
ApopTag® fluorescein in situ apoptosis detection kit  Millipore, Billerica, USA  
DC™ protein assay Bio-Rad Laboratories, Hercules, USA 
RNeasy® mini kit  Qiagen, Hilden, Germany 
 
4.9 PCR Primers 
All primers (including random hexamer primer for cDNA synthesis) were ordered from 
BioTeZ, Berlin, Germany. Primers were delivered in lyophilized form and were dissolved in 










Table 10. PCR Primers 
Primer pairs for genotyping 
Amplification 
product 
Primer name Sequence (5´ → 3´) Product size TA 
WT and “floxed” 
Hccs allele 
mHccs_FP GTTACGGAAAGGGTGAGTGA 380 bp (Hccs WT 




Nkx2-5 WT allele 
and Nkx2-5Cre 
knockin allele 





Together with  




WT and “floxed” 
Raptor allele 
mRaptor_FP CTCAGTAGTGGTATGTGCTCAG 141 bp (Raptor WT 
allele), 180 bp (“floxed” 







249 bp (for males) 60 °C 
mSRY_RP TCTTGCCTGTATGTGATGGC 
Primer pairs for quantitative real-time PCR 
Primer name Sequence (5´ → 3´) Concentration Product size TA 
mNppa cDNA_FP CAGCATGGGCTCCTTCTCCAT 
5 µM 89 bp 60 °C 
mNppa cDNA_RP TGTACACAGGATTTGCTCCAATATG  
mNppb cDNA_FP AGGACCAAGGCCTCACAAAA 
10 µM 108 bp 58 °C 
mNppb cDNA_RP TTGAGATATGTGTCACCTTGGAATTT 
mCol1a1 cDNA_FP CATGTTCAGCTTTGTGGACCT 
10 µM 153 bp 57 °C 
mCol1a1 cDNA_RP ATCAAGCATACCTCGGGTTTC 
mCol1a2 cDNA_FP TGTTGGCCCATCTGGTAAAGA 
5 µM 113 bp 57 °C 
mCol1a2 cDNA_RP CAGGGAATCCGATGTTGCC 
mCol3a1 cDNA_FP GGAACCTGGTTTCTTCTCACC 
5 µM 176 bp 57 °C 
mCol3a1 cDNA_RP ATGTCATCGCAAAGGACAGAT 
mCcnb1 cDNA_FP GCTGACCCAAACCTCTGTAG 
1 µM 132 bp 60 °C 
mCcnb1 cDNA_RP GAGGATAGCTCTCATGTTTCC 
mCcnd1_2 cDNA_FP GAAGTTGTGCATCTACACTGA C 
5 µM 132 bp 60 °C 
mCcnd1_2 cDNA_RP GAGAGGAAGTGTTCGATGAAATC 
mCcng1_2 cDNA_FP GGCCTCAGAATGACTGCAAG 
5 µM 158 bp 60 °C 
mCcng1_2 cDNA_RP CACCCAAGATGCTTCGCCTG 
mFn_2 cDNA_FP GGCAGTGGTCATTTCAGATGCG 
5 µM 139 bp 58 °C 
mFn_2 cDNA_RP CTCCCTTTCCATTCCCGAGG 
mGapdh cDNA_FP AGGTTGTCTCCTGCGACTTCA  
1 µM 101 bp 
56 – 
60 °C mGapdh cDNA_RP CCAGGAAATGAGCTTGACAAAGTT  
mMyh7 cDNA_FP CTAGAGTCAAAGTGGGCAACG 
5 µM 120 bp 60 °C 
mMyh7 cDNA_RP GTGTCACCATCCAGTTGAACA 
mCdkn1a _2 cDNA_FP CAGCTCCGGAGGACCACGTGGCC 
5 µM 150 bp 60 °C 
mCdkn1a _2 cDNA_RP CCAATCTGCGCTTGGAGTGATAG 
mCdkn1b cDNA_FP GACTCGTCAGACAATCCGG 
1 µM 155 bp 60 °C 
mCdkn1b cDNA_RP GTCTGCTCCACAGTGCCAG 
mTgfβ1 cDNA_FP TGGAGCAACATGTGGAACTC 
5 µM 101 bp 56 °C 
mTgfβ1 cDNA_RP AGACAGCCACTCAGGCGTAT 
mTgfβ3 cDNA_FP CTGGAAATCAGCATCCACTGT 
5 µM 119 bp 57 °C 
mTgfβ3 cDNA_RP CCATGGTCATCTTCATTGTCC 
mVim cDNA_FP GTTTCCAAGCCTGACCTCACT 
5 µM 188 bp 57 °C 
mVim cDNA_RP TGTCTCCGGTACTCGTTTGAC 








Source Dilution Company 
Primary antibody (1° AB) 
Anti-α-ACTININ 
A 7811  
 
mouse 1:500 in 5 % milk in 1× TBS-T Sigma-Aldrich, St. Louis, USA 
Anti-α-
TUBULIN 
T 9026 mouse 1:10,000 in 5 % milk in 1× TBS-T Sigma-Aldrich, St. Louis, USA 
Anti-p-4E-BP1 
(Ser65) 
9451 rabbit 1:1,000 in 5 % BSA in 1× TBS-T 




2855 rabbit 1:1,000 in 5 % BSA in 1× TBS-T 
Cell Signaling Technology, 
Danvers, USA 
Anti-p62 5114 rabbit 1:1,000 in 5 % BSA in 1× TBS-T 




4060 rabbit 1:2,000 in 5 % BSA in 1× TBS-T 




2971 rabbit 1:2,000 in 5 % BSA in 1× TBS-T 




2974 rabbit 1:2,000 in 5 % BSA in 1× TBS-T 




4858 rabbit 1:2,000 in 5 % BSA in 1× TBS-T 




4838 rabbit 1:1,000 in 5 % BSA in 1× TBS-T 




9234 rabbit 1:1,000 in 5 % BSA in 1× TBS-T 





mouse 1:40,000 in 5 % milk in 1× TBS-T 
Thermo Fisher Scientific, 
Waltham, USA 
Anti-RAPTOR 2280 rabbit 1:1,000 in 5 % BSA in 1× TBS-T 
Cell Signaling Technology, 
Danvers, USA 
Anti-RICTOR 2114 rabbit 1:1,000 in 5 % BSA in 1× TBS-T 
Cell Signaling Technology, 
Danvers, USA 
Anti-4E-BP1 9644 rabbit 1:1,000 in 5 % BSA in 1× TBS-T 
Cell Signaling Technology, 
Danvers, USA 
Anti-AKT 4691 rabbit 1:1,000 in 5 % BSA in 1× TBS-T 
Cell Signaling Technology, 
Danvers, USA 
Anti-MTOR 2983 rabbit 1:1,000 in 5 % BSA in 1× TBS-T 
Cell Signaling Technology, 
Danvers, USA 
Anti-S6 2217 rabbit 1:1,000 in 5 % BSA in 1× TBS-T 
Cell Signaling Technology, 
Danvers, USA 
Anti-S6K1 2708 rabbit 1:1,000 in 5 % BSA in 1× TBS-T 
Cell Signaling Technology, 
Danvers, USA 
Secondary antibody (2° AB) 
Anti-mouse IgG 
HRP-linked 
7076 horse 1:2,000 in 5 % milk in 1× TBS-T 




7074 goat 1:2,000 in 5 % milk in 1× TBS-T 














Source Dilution Company 
1° AB 
Anti-CYT c sc-13156 mouse 
1:50 in  
antibody solution 
Santa Cruz Biotechnology, 
Dallas, Texas 
Anti-KI67 MA1-90584 rabbit 
1:100 in  
antibody solution 





1:200 in  
antibody solution 
Cell Signaling Technology, 
Danvers, USA 
2° AB 
Anti-mouse IgG Alexa 
Fluor® 488-linked 
A11001 goat 
1:500 in  
antibody solution 
Invitrogen, Carlsbad, USA 
Anti-rabbit IgG Alexa 
Fluor® 555-linked 
A21428 goat 
1:500 in  
antibody solution 
Invitrogen, Carlsbad, USA 
 
4.11 Other substances for immunohistochemistry 





Alexa Fluor® 555-conjugated WGA W32464 1:500 in antibody solution Invitrogen, Carlsbad, USA 
ProLong® Gold antifade mountant P36934 n/a Invitrogen, Carlsbad, USA 
ProLong® Gold antifade mountant 
with DAPI 
P36941 n/a Invitrogen, Carlsbad, USA 
TO-PRO®-3 T3605 1:1,000 in antibody solution Invitrogen, Carlsbad, USA 
(n/a: not applicable) 
4.12 Software 
Table 14. Software 
Software Company 
Adobe Illustrator CS4  Adobe Systems, San Jose, USA 
Adobe Photoshop CS4 Adobe Systems, San Jose, USA 
BZ-8100 observation application (Biozero BZ-8100 fluorescence 
microscope) 
Keyence, Osaka, Japan 
BZ image analysis application (Biozero BZ-8100 fluorescence 
microscope) 
Keyence, Osaka, Japan 
FireCam control (Gel documentation system GelDoc2000) Leica Microsystems, Wetzlar, Germany 
ImageJ Open source 
Image Studio Ver2.0 (Imaging system Odyssey® Fc) LI-COR® Biosciences, Lincoln, USA 
Leica application suite advanced fluorescence (Confocal laser 
scanning microscope TSC SPE) 
Leica Microsystems, Wetzlar, Germany 
Leica application suite (Digital camera for microscope IC80 HD) Leica Microsystems, Wetzlar, Germany 
ND-1000 V3.8.1 (Spectrophotometer nanoDrop ND-1000) peqLab Biotechnology, Wilmingon, USA 
Office 2010 Microsoft, Redmond, USA 
PASWStatistics18 (SPSS) IBM, Armonk, USA 
Vevo® 2100 analysis software 1.5.0 (Vevo® 2100 System) 
FUJIFILM VisualSonics, Toronto, 
Canada 




4.13 Online tools 
Table 15. Online tools 
Tool URL Last use 
DAVID http://david.abcc.ncifcrf.gov/ 11
th
 October 2014 
NCBI PrimerBlast http://www.ncbi.nlm.nih.gov/tools/primer-blast/ 11
th







5.1 Animal experiments 
Animal experiments were carried out in strict accordance to the institutional guidelines of the 
Max Delbrück Center for Molecular Medicine in Berlin, Germany and had previously been 
approved by the responsible authority (State Office of Health and Social Affairs Berlin, 
Germany (“Landesamt für Gesundheit und Soziales” (LAGeSo)) (approval numbers 
G0027/10 and T0113/07)). All efforts were made to minimize suffering of the mice according 
to the ARRIVE guidelines202. 
Mice were kept in the animal facility of the Max Delbrück Center for Molecular Medicine in 
Berlin, Germany with a 12 h day and night cycle at 24±2 °C. If not stated differently, a 
commercially available dry food diet purchased from ssniff® (ssniff® M-Z autoclavable 
complete feed for mice - breeding, V1124-3) was fed. In any case, mice had unrestricted 
access to food and water.  
5.1.1 Mouse strains 
5.1.1.1 “Floxed” Hccs mice 
The “floxed” Hccs mouse strain carries two locus of X-over P1 (loxP) sites (a site on the 
bacteriophage P1 consisting of 34 bp) flanking the catalytic domain of the X-chromosomal 
holocytochrome c synthase (Hccs) gene (exon 5 to 7193). Mice were generated as previously 
described and are viable, fertile, normal in size and do not display any gross physical or 
behavioral abnormalities192. In this study, females homozygous for the “floxed” Hccs 
allele (♀ HccsloxP/loxP) were used to generate heart conditional Hccs knockout (KO) mice (see 
Chapter 5.1.2.1, Figure 6). 
5.1.1.2 Nkx2-5Cre mice 
Nkx2-5Cre mice were kindly provided by Professor Richard Harvey from the Victor Chang 
Cardiac Research Institute in Darlinghurst, Australia203. The Nkx2-5Cre strain carries a 
nuclear-localizing Cre recombinase sequence in the 3' untranslated region of the NK2 
homeobox 5 gene (Nkx2-5) on chromosome 17203. The cardiac homeobox transcription 
factor Nkx2-5 is a cardiac lineage marker activated in heart progenitors at early cardiac 
crescent stages204. Thus, Nkx2-5Cre mice express Cre recombinase in cardiac progenitor 
cells from 7.5 days post coitum (dpc) onwards205. These mice are viable, fertile, normal in 
size and do not display any gross physical or behavioral abnormalities203. In this study, Nkx2-
5Cre males heterozygous for the Nkx2-5Cre knockin allele (♂ Nkx2-5WT/Cre) were used to 
generate heart conditional Hccs KO mice (see Chapter 5.1.2.1, Figure 6). Nkx2-5Cre males 
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homozygous for the Nkx2-5Cre knockin allele (♂ Nkx2-5Cre/Cre) were used to generate heart 
conditional Raptor KO mice (see Chapter 5.1.2.2, Figure 7). 
5.1.1.3 “Floxed” Raptor mice 
The “floxed” Raptor mouse strain carries two loxP sites flanking exon 6 of the Raptor gene. 
Mice were generated as previously described and are viable, fertile, normal in size and do 
not display any gross physical or behavioral abnormalities206. Homozygous “floxed” Raptor 
mice (RaptorloxP/loxP), which were ordered from The Jackson Laboratory, Bar Harbor, 
USA (stock number: 013188), were used to generate heart conditional Raptor KO mice (see 
Chapter 5.1.2.2, Figure 7).  
5.1.2 Breeding strategies 
5.1.2.1 Generation of heart conditional Hccs KO mice 
Generation and characterization of heart conditional Hccs KO mice were described 
previously192. Briefly, HccsloxP/loxP females (see Chapter 5.1.1.1) were bred with Nkx2-5WT/Cre 
males (see Chapter 5.1.1.2) to allow cardiac-specific Cre/loxP recombination. This results in 
Cre-mediated excision of the loxP-flanked Hccs sequence (catalytic domain) in the offspring 
from 7.5 dpc onwards specifically in cardiomyocytes and some endocardial cells192. Thereby, 
healthy control female (♀ Hccs+/+) and male (♂ Hccs+/Y) offspring, which are heterozygous or 
hemizygous, respectively, for the “floxed” Hccs allele but do not express the Cre 
recombinase sequence, are generated (Figure 6). Besides, because the Hccs gene is 
subjected to X chromosome inactivation, outcomes in males and females carrying both, the 
“floxed” Hccs gene on the maternal X chromosome and the Cre recombinase gene on the 
paternal chromosome 17, differ (Figure 6). Heart conditional hemizygous Hccs KO 
males (cHccs-/Y) exhibit Hccs inactivation in the entire heart and die at midgestation due to 
dysfunction of the electron transport chain (ETC)192 (Figure 6). In contrast, females are 
considered heart conditional heterozygous Hccs KOs (cHccs+/-) (Figure 6). In these mice, 
50 % of cardiac cells have the “floxed” X chromosome silenced and remain healthy, while 
50 % of cardiomyocytes keep the “floxed” X chromosome active and consequently display 
disturbed ETC function192. At birth, control Hccs+/Y males and Hccs+/+ females as well as 
cHccs+/- females are born in equal ratios192. All experiments in this study were performed in 






Figure 6. Breeding strategy to generate heart conditional Hccs KO mice. 
Breeding of Hccs
loxP/loxP
 females with Nkx2-5
WT/Cre
 males allowed cardiac-specific Cre/loxP recombination in offspring carrying 
both, the “floxed” Hccs gene on the X chromosome and the Cre recombinase gene on chromosome 17, from 7.5 dpc onwards. 
cHccs
-/Y
 males die in utero, while cHccs
+/-
 females develop a cardiac mosaic for the “floxed” Hccs allele. Female Hccs
+/+
 
littermates were used as controls in all experiments in this study. (Cre: Cre recombinase sequence, dpc: days post coitum, 
ETC: electron transport chain, Hccs: gene for holocytochrome c synthase, KO: knockout, loxP: two locus of X-over P1, Nkx2-5: 
NK2 homeobox 5 gene, WT: wildtype, Y: Y chromosome) 
5.1.2.2 Generation of heart conditional Raptor KO mice 
Breeding of RaptorloxP/loxP females (see Chapter 5.1.1.3) with Nkx2-5Cre/Cre males (see 
Chapter 5.1.1.2) allowed cardiac-specific Cre-mediated excision of the loxP-flanked Raptor 
sequence in the offspring from 7.5 dpc onwards specifically in cardiac progenitor cells. All 
offspring in the first filial (F1) generation were heterozygous for the Nkx2-5-Cre knock-in and 
for the “floxed” Raptor allele, resulting in heterozygous cardiac-specific Raptor 
KOs (♂/♀ cRaptor+/-) (Figure 7). Breeding of F1 offspring among each other generated 
control males and females (♂/♀ Raptor+/+, 43.75 %) as well as heart conditional 
heterozygous (♂/♀ cRaptor+/-, 37.5 %) and homozygous Raptor KOs (♂/♀ cRaptor-/-, 
18.75 %) in the second filial (F2) generation (Figure 7). All experiments in this study were 






Figure 7. Breeding strategy to generate heart conditional Raptor KO mice. 
Breeding of Raptor
loxP/loxP
 females with Nkx2-5
Cre/Cre
 males allowed cardiac-specific Cre/loxP recombination in all offspring from 
7.5 dpc onwards, generating heterozygous heart-specific Raptor KOs (♂/♀ cRaptor
+/-
) in the F1 generation. Breeding of the F1 
offspring generated control males and females (♂/♀ Raptor
+/+
) as well as heart conditional heterozygous (♂/♀ cRaptor
+/-
) and 
homozygous Raptor KOs (♂/♀ cRaptor
-/-
) in the F2 generation. Cre-positive female littermates without “floxed” Raptor 
gene (Raptor
+/+
) were used as controls in all experiments in this study. (Cre: Cre recombinase sequence, F1/F2: first/second 
filial generation, KO: knockout, loxP: two locus of X-over P1, Nkx2-5: NK2 homeobox 5 gene, Raptor: gene for regulatory-
associated protein of mTOR, WT: wildtype) 
5.1.3 Mouse embryo and organ preparations 
5.1.3.1 Preparation of embryonic hearts 
Mating of mice was performed over night (o/n) and female mice were checked the next 
morning for vaginal plugs. Females positive for a vaginal plug were considered to be 
pregnant at 0.5 dpc. Plug-positive dams that exhibited obvious abdominal growth on the 
appropriate day of pregnancy were sacrificed by cervical dislocation. Mice were placed in a 
dorsal position and the abdominal wall as well as the abdominal cavity was opened to 
expose the uterus. The uterine wall was cut open longitudinally and the embryos, each still 
inside the amnion attached to the placenta, were removed from the left and the right uterus 
and placed in ice-cold 1× PBS. The amnion was opened and the umbilical cord, connecting 
the embryo to its placenta, was cut through. The developmental stage of the embryos was 
confirmed according to Theiler’s criteria207. If the embryo was required for histological 
analyses, the heart remained in situ. The head and the posterior part of the 
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embryo (including the tail and the hind limbs) were chopped off and the torso was fixed in 
4 % PFA solution and processed for histology. If the heart was designated for RNA or protein 
isolation, the embryo was placed in a dorsal position, the thorax was opened with precision 
tweezers and the whole heart (including ventricles and atria) was removed from the thoracic 
cavity by cutting through the outflow tract (OFT). The heart was cleaned from non-cardiac 
tissue, snap-frozen in liquid nitrogen and stored at -80 °C. The posterior part of the embryos 
was used for DNA isolation and subsequent genotyping. 
5.1.3.2 Preparation of hearts and organs from newborn mice  
Newborn mice prepared within the first 24 h after birth were considered neonatal mice, also 
referred to as postnatal day 1 (P1). P2 or P3 (postnatal day 2 or 3) relates to pups dissected 
within the first 48 h or 72 h after birth, respectively. Preparations always took place around 
noon of the appropriate day. After the body weight (BW) was measured on a precision scale, 
mice were killed by decapitation. The thorax was opened and the costal arches were forced 
apart. The heart was removed from the thoracic cavity by cutting through the OFT and 
washed in ice-cold 1× PBS to remove blood. Non-cardiac tissue was detached, hearts were 
dried on a paper towel and the heart weight (HW) was measured using a precision scale. 
The heart was snap-frozen in liquid nitrogen and stored at -80 °C or fixed in 4 % PFA 
solution for histological analyses. For kidney and lung explantation, the abdominal cavity of 
P1 mice was opened further sidewards to the spine. Both kidneys were removed from the 
retroperitoneum by transsecting the ureter and the renal artery and vein. Kidneys were dried 
on a paper towel and the combined weight of both kidneys was measured on a precision 
scale. Lung tissue was removed by cutting off half of the right lung. Kidney and lung tissue 
was washed in 1× PBS, snap-frozen in liquid nitrogen and stored at -80 °C. Tail tips of the 
pups were clipped and used for DNA isolation as well as subsequent genotyping.  
5.1.3.3 Preparation of hearts and organs from 3 week and 11 week old mice 
3 and 11 week old mice were killed by cervical dislocation and the BW was determined. Mice 
were placed in a dorsal position, the abdominal wall was opened and the costal arches were 
cut through along the lateral wall with dissecting scissors. To remove the heart from the 
thoracic cavity, the diaphragm was opened and the exposed heart was disconnected at the 
OFT and in the region of the ascending aorta. The explanted heart was washed in ice-cold 
1× PBS to remove remaining blood. Adherent lung and thymus tissue was removed, the 
heart was dried on paper towel and the HW was measured using a precision scale. The apex 
of the heart was cut off, bisected (one part for RNA isolation, one for protein isolation) and 
snap-frozen in liquid nitrogen. The remaining heart tissue was fixed in 4 % PFA solution for 
histological analyses. A part of the ear of 3 week and 11 week old mice was clipped and 
used for DNA isolation and subsequent genotyping. 
METHODS 
41 
In 11 week old adult mice, not only the heart but also other organs were prepared. After 
opening the abdominal cavity and the thorax, all organs were evaluated with respect to 
pathological phenotypes. All six liver lobes were removed in one piece by cutting the 
ligaments, the portal vein and the hepatic artery. The liver was transferred into ice-cold 
1× PBS and the gallbladder was removed. For explanting the spleen from the abdominal 
cavity, the mesenteries, the splenic artery and the splenic vein were carefully cut through and 
the spleen was also transferred into ice-cold 1× PBS. Both kidneys were explanted by 
removing the renal capsule and transsecting the ureter and the renal artery and vein. 
Subsequently, kidneys were washed in ice-cold 1× PBS. After drying all organs on paper 
towel, organ weights were measured using a precision scale and organs were snap-frozen in 
liquid nitrogen and stored at -80 °C. 
5.1.4 Rapamycin injection 
Rapamycin (Cayman chemical) was dissolved in a stock solution at 20 mg/ml in DMA and 
stored up to six months at -20 °C. Pregnant dams were treated with rapamycin by 
subcutaneous (s.c.) injections every 12 h during pregnancy from 11.5 dpc or 15.5 dpc until 
term. Each injection contained 5 mg rapamycin/kg BW diluted in 200 µl vehicle (10 % 
PEG 300 and 17 % Tween® 80 in 0.9 % NaCl solution). As controls, pregnant dams were 
injected with DMA-containing vehicle as described above. BW of pregnant dams was 
measured daily to constantly adjust rapamycin concentrations during the injection period. 
S.c. injections were administered alternating in the nuchal fold as well as in the right and the 
left leg fold. After birth, rapamycin injections ended and offspring were prepared immediately 
or were weaned after 3 weeks and prepared at the age of 11 weeks. 
5.1.5 Low protein diet 
Low protein-containing food with 8.8 % crude protein was purchased from ssniff® (ssniff® EF 
R/M Protein deficient experimental diet, E15202-24). Female and male mice were put on a 
low protein diet (LPD) two weeks prior to mating. Dams were kept on LPD during pregnancy 
and, depending on the experimental setup, hearts from offspring were prepared at 13.5 dpc 
or at P1. Alternatively, after birth mother and offspring were kept on LPD, offspring were 
weaned after 3 weeks, remained on LPD and were prepared at the age of 11 weeks. As 
controls, mice were treated the same way using the appropriate sniff® standard protein 
diet (SPD) containing 22 % crude protein (ssniff® M-Z autoclavable complete feed for mice - 
breeding, V1124-3). 
5.1.6 Evaluation of food intake  
To measure the food intake of adult mice, 5 months old non-pregnant females were kept 
isolated in separate cages. A defined amount of food was weighed and provided to the mice. 
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The remaining food as well as the BW were measured daily at the same time of day over a 
period of two weeks. To measure the food intake of pregnant mice, 5 months old pregnant 
dams were kept isolated in separate cages. A defined amount of food was provided at 
13.5 dpc. The remaining food as well as the BW was measured daily at the same time of day 
until the end of pregnancy. The food intake was calculated from the daily decline in food 
weight and is given in gram food per day per mouse per kilogram BW.  
5.1.7 Echocardiography 
Echocardiography is an ultrasound-based diagnostic imaging technique, which allows 
noninvasive visualization and analysis of the heart morphology and its functional parameters. 
The echocardiographic measurements and analyses in this study were performed in 
collaboration with Martin Taube and Stefanie Schelenz from the Technology Platform 
“Pathophysiology” at the Max Delbrück Center for Molecular Medicine in Berlin, Germany. 
Operators were blinded for mouse genotypes and groups during echocardiographic 
measurements as well as data analyses. 
11 week old adult mice were anesthetized by a 2.5 %-isofluran-oxygen-mixture using the 
Vevo® compact dual anesthesia system (FUJIFILM VisualSonics). Measurements on 
neonates were performed on awake pups. Mice were placed in a dorsal position on the 
heated (37 °C) stage of the Vevo® imaging station (FUJIFILM VisualSonics) and fixed with 
their paws on electrode gel-covered electrodes to monitor heart and respiratory rate. Body 
temperature of adult mice was controlled using a rectal temperature probe and was kept 
constant at 36 °C to 37 °C using a heat lamp. Body temperature of neonatal mice cannot be 
directly controlled, but the heat lamp was continuously directed to the pups to maintain the 
body temperature. To allow optimal imaging, chest fur of adult mice was removed with an 
electric razor and both, adult and neonatal mice were covered ventrally with 
preheated (37 °C) ultrasound transmission gel. Echocardiography was recorded using the 
Vevo® 2100 high frequency ultrasound system (FUJIFILM VisualSonics) with a MicroScanTM 
transducer MS400 (FUJIFILM VisualSonics) set to 30 MHz for adult mice or 
MS700 (FUJIFILM VisualSonics) set to 50 MHz for neonatal mice. Recorded 
echocardiographies were analyzed and evaluated with respect to heart morphology and 
function using the Vevo® 2100 analysis software. Brightness (B)-mode images were taken to 
display the two-dimensional parasternal long axis view of the heart. The fraction of blood 
ejected by the left ventricle (LV) during one contraction (ejection fraction (EF)) was measured 
by tracing the LV cavity in end-diastole and end-systole. Assessment of LV dimensions (LV 
internal diameter (LVID) in end-systole and end-diastole) and wall thickness (LV posterior 
wall (LVPW) thickness in end-systole and end-diastole, interventricular septum (IVS) 
thickness in end-systole and end-diastole) took place in motion (M)-mode images. From the 
measured parameters fractional shortening (FS) (fraction of LV dimension in end-diastole 
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that is shortened in end-systole) was calculated. Hearts of neonatal mice were prepared 
immediately after echocardiography. 
5.2 Bioinformatical methods 
Functional annotation of differentially regulated genes in neonatal cHccs+/- mice was done 
using the online database for annotation, visualization, and integrated discovery (DAVID)208. 
To identify differentially regulated genes, genome-wide microarray analysis using neonatal 
whole-heart RNA from cHccs+/- mice in comparison to female Hccs+/+ controls had been 
performed in the run-up to this study by Manuela Magarin during her PhD project at the Max 
Delbrück Center for Molecular Medicine in Berlin, Germany. Briefly, for these microarray 
expression analyses a total of eight Affymetrix GeneChip Mouse Genome 430 2.0 arrays 
was used. Three neonatal (P1) hearts of the same genotype were pooled and four pooled 
samples per genotype (Hccs+/+ and cHccs+/-) were analyzed. For unbiased functional group 
classification, only those genes were selected that were found to be differentially regulated in 
neonatal cHccs+/- hearts compared to neonatal cHccs+/- littermate control hearts with a fold 
change higher than +1.5 or lower than -1.5 in combination with a highly significant p-
value (p<0.01) (Supplementary Table S1). The resulting gene list was uploaded to DAVID 
using the gene functional annotation tool that is based on a novel biological module-centric 
algorithm to functionally analyze large gene lists208-210. The DAVID output was evaluated with 
regard to the enrichment score of the functional groups and only those gene clusters with a 
fold enrichment larger than 1.5 in combination with a significant p-value (p<0.05) were 
considered for further analyses. 
5.3 Molecular biological methods 
5.3.1 Mouse genotyping 
5.3.1.1 Isolation of genomic DNA from murine tissue 
Genomic DNA from murine tissue was isolated for subsequent genotyping. For embryonic 
samples, the posterior part of the body including the tail was used. For P1, P2 and P3 mice, 
DNA was isolated from the tail only. For 3 week and 11 week old mice, ear biopsies were 
used. The tissue was proteinase K (Carl Roth) digested in 200 µl 1× lysis buffer by 
incubation o/n at 55 °C with constant shaking at 11,000 rpm in a thermomixer (Eppendorf). 
The next day, the lysate was vortexed and centrifuged for 10 min at 16,000 × g at room 
temperature (RT) to remove undigested cell debris. 100 µl supernatant were diluted with 
100 µl 2-propanol, followed by immediate inversion to precipitate the DNA. After 5 min 
incubation at RT, the mixture was centrifuged for 5 min at 18,400 × g at RT and the 
supernatant was discarded. The DNA pellet was washed with 100 µl 70 % ethanol (EtOH) 
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followed by a second centrifugation step for 5 min at 18,400 × g at RT. The supernatant was 
again discarded and the pellet was air dried at 37 °C with constant shaking at 11,000 rpm 
using a thermomixer (Eppendorf) until no EtOH was left. Subsequently, the DNA pellet was 
resuspended in 100 µl double distilled water (ddH2O) at 50 °C with constant shaking at 
11,000 rpm for 1 h in a thermomixer (Eppendorf).  
5.3.1.2 DNA concentration measurement 
DNA concentration was measured at 260 nm using a nanoDrop spectrophotometer (peqLab 
Biotechnology) according to the manufacturer’s instructions. Then, 1.5 µl of isolated DNA 
was applied directly onto the measurement pedestal. The optical density (OD) was 
determined and the DNA concentration was automatically calculated with ddH2O serving as 
blank value. DNA quality was evaluated depending on the OD260/OD280 ratio. Only DNA 
samples with OD260/OD280 = 2.0±0.1 were used for genotyping. 
5.3.1.3 Genotyping by polymerase chain reaction 
Genotyping and sexing of embryos and mice was performed by polymerase chain 
reaction (PCR), which allows specific amplification of target DNA sequences211. Isolated 
genomic DNA was used as template after dilution to a final concentration of 50 ng/µl. The 
wildtype (WT) and the “floxed” Hccs allele as well as the Nkx2-5 WT allele and the Nkx2-
5Cre knockin allele were detected and differentiated according to their size (see Chapter 4.9, 
Table 10). Raptor animals were genotyped for the WT and the “floxed” Raptor allele as well 
as for the Nkx2-5 WT and Nkx2-5Cre knockin allele, respectively (see Chapter 4.9, Table 
10). Sex was determined in embryos and neonates by detection of the sex determining 
region of chromosome Y gene (Sry), which identifies males but not females. The PCR 
reaction mixtures were pipetted on ice into 8-well PCR strips and the PCR program was 
performed in a thermocycler (Bio-Rad Laboratories). Primer pairs (see Chapter 4.9, Table 
10) as well as PCR reaction and protocol (Table 16) were already well-established for all 
genotyping reaction in the run-up to this study. After the PCR run was completed, PCR 
products were stored at 4 °C or immediately loaded on an agarose gel. 
Table 16. Genotyping PCR setup 
PCR reaction mixture PCR program 
Component Volume Step Temperature Time Cycles 
10× PCR buffer 2.5 µl Initialization 95 °C 3 min 1 
10 µM forward primer  0.5 µl Denaturation 95 °C 30 s 
40 10 µM reverse primer 0.5 µl Primer annealing 60 °C 45 s 
2.5 mM dNTPs 1 µl Elongation 72 °C 1 min 
5 U/µl Taq polymerase 0.1 µl Final elongation 72 °C 8 min 1 
50 ng/µl genomic DNA 1 µl 
Final hold 4 °C ∞  ddH2O 19.4 µl 
Total volume 25 µl 
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5.3.1.4 Agarose gel electrophoresis 
To analyze the genotyping PCR reactions, the PCR products were separated according to 
their size in a horizontal 2 % (w/v) agarose gel. The agarose was dissolved in 1× TTE buffer 
by heating in a microwave. Ethidium bromide (EtBr) was added to the liquid gel solution with 
a final concentration of 0.2 µg/ml. After cooling down to 55 °C, the agarose-TTE-EtBr-
solution was poured into a gel cast and a comb was inserted. Following final gellation, 10 µl 
of the PCR reaction were loaded. The GenerulerTM 100 bp DNA ladder (Fermentas) served 
as size standard. The gel run was performed in an horizontal agarose electrophoresis unit at 
100 V – 130 V in 0.5 µg/ml EtBr-containing 1× TEE buffer. Electrophoresis was terminated 
when the orange running front of the PCR buffer reached the bottom of the gel. Separated 
PCR products were visualized under ultraviolet (UV) light (320 nm) in a gel documentation 
system (Bio-Rad Laboratories). 
5.3.2 RNA expression analyses 
5.3.2.1 RNA isolation 
Isolation of total RNA (including messenger (mRNA), ribosomal (rRNA) and transfer (tRNA) 
RNA) from murine myocardial tissue was performed under ribonuclease (RNase)-free 
conditions following the TRIzol® reagent (Invitrogen) method. Snap frozen whole embryonic 
hearts or approximately 20 mg of apical heart tissue from 11 week old mice were used. Adult 
heart tissue was transferred to an RNase-free 2-ml homogenization tube that contained a 
mixture of twelve 1.4 mm and five 2.8 mm ceramic beads (peqLab Biotechnology). Then, 
500 µl pre-cooled TRIzol® (Invitrogen) were added and tubes were arranged in the 
homogenizer system Precellys® 24 (peqLab Biotechnology), which was cooled down to 4 °C 
beforehand. The tissue was shredded twice with 5000 rpm for 20 s with a 20 s break. Whole 
embryonic hearts were homogenized on ice in 500 µl pre-cooled TRIzol® using a motorized 
micropestle (Carl Roth) for 30 s. The TRIzol® reagent is a mono-phasic solution of phenol 
and guanidine isothiocyanate (a protein denaturant that inactivates RNases) that promotes 
the release of nucleic acids. It maintains the integrity of the RNA during homogenization, 
while at the same time it disrupts cells and dissolves cell components. After homogenization, 
the tissue lysate was transferred into a new RNase-free 1.5-ml tube and incubated at RT for 
5 min. Following addition of 100 µl chloroform, the mixture was immediately inverted for 15 s 
and incubated for 3 min at RT. During subsequent centrifugation for 15 min at 16,500 × g 
and at 4 °C, the acidic phenol-chloroform-solution got separated into three phases: a lower 
red, phenol-chloroform organic phase containing cell fragments and proteins, a white viscous 
interphase containing DNA and on top a transparent aqueous RNA-containing phase. The 
upper transparent phase was transferred into a new RNase-free 2.0-ml tube and the RNA 
was further purified at RT following the RNeasy® Mini handbook (Qiagen) according to the 
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manufacturer’s instructions. An RNase-free deoxyribonuclease (DNAse) set (Qiagen) was 
used to digest genomic DNA contaminations directly on the RNA purification columns during 
a 15 min incubation step at RT. The RNA was eluted from the spin columns using 30 µl 
RNase-free water for embryonic samples, and 60 µl RNase-free water for adult samples. 
After RNA concentration measurement and quality control, the samples were stored 
at -80 °C or immediately processed for complementary DNA (cDNA) synthesis. 
5.3.2.2 RNA concentration measurement and quality control by RNA gel 
electrophoresis 
RNA concentration was measured at 260 nm using a nanoDrop spectrophotometer (peqLab 
Biotechnology) according to the manufacturer’s instructions. Thereby, 1.5 µl isolated RNA 
was applied directly onto the measurement pedestal. The OD was determined and the RNA 
concentration was automatically calculated. RNase-free water served as blank value. RNA 
quality was evaluated depending on the OD260/OD280 as well as on the OD260/OD230 ratios. 
Only high quality RNA samples with OD260/OD280 = 2.0±0.1 and OD260/OD230 = 2.0±0.1 were 
used for cDNA synthesis. 
Besides, quality was controlled by RNA gel electrophoresis. Isolated RNA was run on a 
horizontal 2 % (w/v) agarose gel. RNA was diluted with RNase-free water to a final 
concentration of 0.7 µg in a total volume of 10 µl. RNA was mixed to equal parts with 10 µl 
2× RNA loading dye (Fermentas). RNA samples as well as the RiboRulerTM low range RNA 
ladder (Fermentas), which served as size standard, were denatured for 10 min at 70 °C in a 
thermocycler (Bio-Rad Laboratories). The entire 20 µl RNA-loading dye-sample was loaded 
onto the gel. Gel preparation and gel run were performed as described above (see Chapter 
5.3.1.4), except the gel was run at 4 °C at low voltage (60 V). Electrophoresis was terminated 
when the blue running front of the RNA loading dye reached the bottom of the gel. Separated 
RNA was visualized under UV light (320 nm) in a gel documentation system (Bio-Rad 
Laboratories). Only RNA samples that revealed clear 28S and 18S rRNA bands and did not 
display RNA degradation in the RNA gel were used for cDNA synthesis.  
5.3.2.3 cDNA synthesis 
Isolated cardiac RNA was reversely transcribed into cDNA. RNA was diluted with RNase-free 
water to a final concentration of 0.9 µg in a total volume of 10 µl. After addition of 2 µl 50 µM 
random hexamer primer and 4 µl 2.5 mM dNTPs, samples were incubated for 5 min at 70 °C 
to denature the secondary structures of the RNA. Next, 2 µl 10× reverse transcriptase 
reaction buffer, 0.5 µl 40 U/µl RibiLock® ribonuclease inhibitor (Fermentas) and 1 µl 200 U/µl 
M-MuLV reverse transcriptase (NEB) were added such that the final volume of each reverse 
transcription reaction was 19.5 µl. Samples were incubated for 10 min at 25 °C to allow 
primer annealing and for 60 min at 42 °C to synthesize the complementary DNA strand. Last, 
METHODS 
47 
the enzyme was inactivated for 10 min at 90 °C. All steps were performed in a 
thermocycler (Bio-Rad Laboratories) using 8-well PCR strips. After successful reverse 
transcription, cDNA was diluted 1:3 in ddH2O. cDNA samples were stored at -20 °C or 
immediately used for quantitative real-time PCR. 
5.3.2.4 Quantitative real-time PCR 
5.3.2.4.1 Primer design and determination of optimal annealing temperature by gradient 
PCR 
Primer pairs used for quantitative real-time PCR (qPCR) (see Chapter 4.9, Table 10) were 
designed using the NCBI Primer-BLAST online tool. Primers were designed according to the 
following criteria: primer size between 18 bp and 26 bp, size of amplified product between 
80 bp and 190 bp, primer annealed within coding region of mRNA transcript, primer did not 
span exon-exon junctions and primer pairs were separated by at least one intron on the 
corresponding genomic DNA sequence, which was preferentially longer than 1 kb. Primer 
pairs were controlled for hairpin formation and self-annealing using the NCBI Primer-BLAST 
online tool. To determine the optimal annealing temperature for each primer pair, different 
annealing temperatures were tested by performing a gradient PCR. PCR setup was 
described above (see Chapter 5.3.1.3, Table 16), except applying 12 different annealing 
temperatures between 54 °C and 65 °C and using 1 µl 1:3 diluted cDNA (see Chapter 
5.3.2.3) as well as 1 µl 50 ng/µl genomic DNA (see Chapter 5.3.1.1) and 1 µl ddH2O as 
template, respectively. PCR products were separated in a horizontal 2 % (w/v) agarose gel 
as described before (see Chapter 5.3.1.4). PCR products were visualized and the optimal 
annealing temperature for subsequent qPCR was chosen, for which only one single PCR 
product of the predicted size in the cDNA template reaction was identified. Primer pairs 
resulting in primer dimers when ddH2O was used as template or primer pairs amplifying 
products when genomic DNA was used as template were rejected. 
5.3.2.4.2 Determination of optimal primer concentrations 
The specificity of each primer pair was confirmed by melt curve analyses and optimal primer 
concentrations were assessed by evaluation of PCR efficiency after performing qPCR using 
SYBR®Green. SYBR®Green is a cyanine dye that intercalates into newly synthesized PCR 
products. The resulting DNA-dye-complex absorbs blue light (497 nm) and emits green 
light (520 nm). The amount of synthesized DNA rises during the qPCR reaction, which 
results in increased SYBR®Green fluorescence intensity that can be detected after each 
PCR cycle. The point at which the fluorescent signal exceeds above a defined threshold is 
termed threshold cycle (CT), which in turn is a measure for the amount of template cDNA in 
the sample. The earlier the threshold is reached, the more template cDNA was present in the 
initial reaction mixture.  
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Predefined template cDNA dilution series (undiluted, 1:2, 1:4, 1:8 and 1:16 in ddH2O) were 
prepared and 1 µl per dilution was pipetted in triplicates into a 384-well reaction plate. 
Subsequently, 1.4 µl forward and 1.4 µl reverse primer, 10 µl Power SYBR®Green PCR 
master mix (Applied Biosystems) and 6.2 µl ddH2O were added per well to obtain a final 
qPCR reaction volume of 20 µl. Three primer concentrations (stock concentration: 1 µM, 
5 µM and 10 µM in ddH2O) were tested, each with a separate dilution series. The 384-well 
reaction plate was vortexed for 30 s and centrifuged at RT for 2 min at 3,220 × g. The qPCR 
run was performed using the ViiA™ 7 real-time PCR system (Applied Biosystems) at 95 °C 
for 10 min, followed by 40 cycles at 95 °C for 15 s, primer-optimized annealing 
temperature (as revealed by gradient PCR, see Chapter 4.9, Table 10 and Chapter 5.3.2.4.1) 
for 30 s and elongation at 72 °C for 30 s. The run was completed by a melt curve analysis. 
The ViiA™ 7 real-time PCR system automatically measures the SYBR®Green fluorescence 
in each well after every cycle. The CT threshold levels were set above background 
fluorescence and in the exponential phase of the PCR amplification curve. qPCR efficiency 
was determined based on the dilution series to identify the optimal primer concentration. 
Theoretically, due to the PCR amplification kinetics, doubling of the template amount results 
in a CT difference of 1, which gives a PCR efficiency for the dilution series of 100 %. Only 
primer pairs with a correlation coefficient above 0.99 and efficiency between 90 % and 110 % 
were used to analyze relative gene expression in qPCR screens. The melt curve was 
analyzed to confirm primer specificity. Only if one single peak, originating from one specific 
PCR product dissociating during melting, was visible, primers were used for further analysis. 
5.3.2.4.3 Gene expression analyses 
After determination of primer-specific annealing temperatures by gradient PCR, assessment 
of optimal primer concentration by determining qPCR efficiency and confirmation of primer 
specificity by melt curve analysis, relative gene expression of target genes was performed 
using SYBR®Green. Each cDNA sample was run in triplicates using the ViiA™ 7 real-time 
PCR system (Applied Biosystems) as described before (see Chapter 5.3.2.4.2). Target gene 
expression was normalized against the expression of glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh), which was previously shown to be the most stable reference gene 
in the heart conditional Hccs KO model (personal communication). Relative expression 
differences between groups were determined using the 2-ΔΔCT method (reviewed by Livak 
and Schmittgen212). After normalization to Gapdh expression (ΔCT), data were normalized to 
the vehicle or SPD Hccs+/+ control group, which was set to equal 1 (ΔΔCT). 
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5.3.3 Western blot analyses 
5.3.3.1 Protein isolation 
For isolation of total protein extracts from murine myocardial tissue whole embryonic, P1 and 
P3 hearts or approximately 20 mg of apical heart tissue from juvenile 3 week and adult 
11 week old mice were used. Snap frozen P1, P3, juvenile and adult heart tissue was 
transferred to a 2-ml homogenization tube that contained a mixture of twelve 1.4 mm and five 
2.8 mm ceramic beads (peqLab Biotechnology). 300 µl pre-cooled 
1× radioimmunoprecipitation assay (RIPA) buffer supplemented with proteinase (Roche 
Diagnostics) and phosphatase inhibitors (Roche Diagnostics) were added to P1 and P3 
samples, whereas 400 µl were used for juvenile and adult samples. Tubes were arranged in 
the homogenizer system Precellys® 24 (peqLab Biotechnology), which was cooled down to 
4 °C, and the tissue was shredded twice with 5000 rpm for 20 s with a 20 s break. Whole 
embryonic 10.5 dpc hearts were homogenized in 25 µl pre-cooled inhibitor-containing 
1× RIPA buffer by sonification in the Sonifier® cell disruptor 450 (Branson Ultrasonics) 
three times for 30 s with a 30 s break and an amplitude of 50 % at 4 °C. Whole embryonic 
13.5 dpc hearts were homogenized on ice in 80 µl pre-cooled inhibitor-containing 1× RIPA 
buffer using a motorized micropestle (Carl Roth) for 30 s. Afterwards, all samples were 
transferred into a new 1.5-ml tube, fixed on a MiniTwist nutating mixer (Select BioProducts) 
and incubated for 2 h with gentle agitation at 24 rpm at 4 °C to allow dissociation of the 
proteins out of the tissue. Subsequently, protein lysates were centrifuged at 16,800 × g for 
5 min at 4 °C to pellet cell debris. The protein-containing supernatant was collected, if 
applicable aliquoted in 100 µl fractions and stored at -80 °C or immediately used for 
concentration measurement and SDS-polyacrylamide gel electrophoresis. 
5.3.3.2 Protein concentration measurement 
Protein concentration was measured based on the Lowry principle213 using the DCTM protein 
assay (Bio-Rad Laboratories) according to the manufacturer’s protocol. Protein lysates 
isolated from embryonic, P1 and P3 hearts were diluted 1:5 in ddH2O. For protein lysates 
isolated from juvenile and adult hearts an additional 1:10 dilution was prepared. In parallel, a 
nine-step BSA dilution series (0 mg/ml – 2 mg/ml in ddH2O) was used for the calculation of a 
standard curve. All sample and BSA dilutions were prepared in a reaction volume of 25 µl in 
duplicates and 25 µl ddH2O served as blank value. Moreover, 25 µl 1:5 and 1:10 diluted 
inhibitor-containing 1× RIPA buffer were used as “pseudo”-blanks in order to measure the 
self-absorption of the inhibitor-containing 1× RIPA buffer. To each 25 µl sample (diluted heart 
lysates, BSA dilution series, blank, and “pseudo”-blanks) 122.5 µl protein assay 
reagent A (provided) and 2.5 µl protein assay reagent S (provided) were added. Samples 
were vortexed and reactions were incubated for 5 min at RT. Afterwards, 1 ml protein assay 
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reagent B (provided) was added. The samples were vortexed again and incubated for 15 min 
at RT in the dark. Immediately afterwards the absorption was determined photometrically in a 
spectrophotometer (Bio-Rad Laboratories) at a wavelength of 750 nm. The absorption values 
of the 1:5 and 1:10 diluted RIPA-“pseudo”-blanks were subtracted from the absorption values 
of the 1:5 or 1:10 diluted samples, respectively. A standard curve was calculated using the 
absorption values of the BSA dilution series. Considering the linear equation of the standard 
curve and the dilution factor of the protein lysates, the final protein concentration for each 
sample was determined. 
5.3.3.3 SDS-polyacrylamide gel electrophoresis 
Separation of proteins according to their size was performed under denaturing conditions by 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) according to Laemmli214. 
Discontinuous SDS-PAGE using a two-gel-system, consisting of a low-percentage stacking 
gel and a higher-percentage separating gel, was applied. 1 mm gels with 10 to 15 wells 
consisting of a 6 % to 12 % separating gel and a 4 % stacking gel (Table 17) were prepared 
using the Mini-PROTEAN® tetra handcast system (Bio-Rad Laboratories). Percentage of the 
separating gel was determined depending on the size of the proteins of interest.  




(30 % Acrylamid) 
ddH2O 
1 M Tris 
(pH 6.8) 







4 % stacking gel 667 µl 3.63 ml 625 µl - 50 µl 25 µl 5 µl 
6 % separating gel 2 ml 4.10 ml - 3.75 ml 100 µl 50 µl 10 µl 
10 % separating gel 3.33 ml 2.76 ml - 3.75 ml 100 µl 50 µl 10 µl 
12 % separating gel 4 ml 2.10 ml - 3.75 ml 100 µl 50 µl 10 µl 
 
For all samples on one gel, the same protein amount was loaded and varied between 20 µg 
to 100 µg depending on the abundance of the protein of interest in myocardial tissue as well 
as on the sensitivity of the primary (1°) antibody (AB). The volume of the protein lysates 
loaded was depending on the protein concentration and by addition of ddH2O the same final 
volume for all samples was adjusted. Next, 5× SDS sample buffer was added. Its volume 
was adapted to the sample volume to reach a 1× final concentration. Samples were 
incubated for 5 min at 95 °C in a thermocycler (Bio-Rad Laboratories) to denature the 
proteins by unfolding the secondary structure. The denatured proteins were loaded onto the 
SDS gel. PageRulerTM prestained protein ladder (Fermentas) as well as HiMarkTM prestained 
high molecular weight protein ladder (Invitrogen) served as size standards. The run was 
performed in a Mini-PROTEAN® tetra cell (Bio-Rad Laboratories) filled with 1× SDS running 
buffer for 30 min at 50 V at RT. After proteins were focused in a discrete band in the 4 % 
polyacrylamide stacking gel, the run was continued at 100 V and the proteins were separated 
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according to their size in the separating gel. The run was terminated once the blue running 
front had reached the end of the gels.  
5.3.3.4 Western blot analyses 
The analysis of separated proteins was performed using western blot following standard 
procedure. The assembly of the western blot sandwich took place in 1× transfer buffer for 
normal (i.e. containing 20 % methanol (MeOH)) or for large proteins of 
interest (> 150 kDa) (i.e. containing 10 % MeOH). Separating gel and nitrocellulose 
membrane (GE Healthcare) were placed between whatman® paper (GE Healthcare) and 
mounted inside of a Mini Trans-Blot® cell (Bio-Rad Laboratories). Tank blot was performed 
in the appropriate 1× transfer buffer. Transfer time was depending on the size of the proteins 
of interest and varied between 1 h and 3 h at 140 mA at 4 °C. Afterwards, the membrane 
was blocked for 1 h in 5 % milk in 1× TBS-T with gentle agitation at 40 rpm on an orbital 
shaker (GFL) to avoid unspecific binding of the 1° AB. Next, the membrane was incubated 
with 1° AB (see Chapter 4.10, Table 11) o/n at 4 °C with gentle agitation at 24 rpm on a 
MiniTwist nutating mixer (Select BioProducts). After washing the membrane three times for 
5 min in 1× TBS-T with gentle agitation at 40 rpm on an orbital shaker (GFL) at RT, it was 
incubated in horseradish peroxidase (HRP)-linked secondary (2°) AB (see Chapter 4.10, 
Table 11) for 1 h with gentle agitation at 24 rpm on a MiniTwist nutating mixer (Select 
BioProducts) at RT. Subsequently, the membrane was washed again as described before. 
Next, enhanced chemiluminescence (ECL) reaction was performed by incubating the 
membrane for 1 min in a 1:1-mixture consisting of ECL solution A and B. Light emission was 
detected with the imaging system Odyssey® Fc (LI-COR® Biosciences) or by exposure of 
the membrane to chemiluminescence-sensitive CL-XPosureTM films (Thermo Fischer 
Scientific). ImageJ software was used to perform densitometric analysis by quantifying size 
and intensity of detected protein bands. Results were used as a measure for total protein 
levels or the phosphorylation status of proteins of interest. For final quantification, total 
protein levels of proteins of interest were normalized against the protein levels of an 
appropriate and well-established loading control, such as α-ACTININ, α-TUBULIN or 
GAPDH (personal communication). The loading control was chosen depending on the size of 
the protein of interest. Band intensities for the phosphorylated forms of proteins of interest 
were normalized against the band intensities for the corresponding total protein. At the end, 




5.3.4.1 Paraffin embedding and sectioning  
For histological analyses, explanted P1 and adult hearts as well as embryonic torsos (heart 
in situ) were embedded into paraffin to allow sectioning. Tissue was first fixed in 4 % PFA 
solution for 48 h at 4 °C in order to cross-link amino groups in proteins through the formation 
of reversible methylene bridges. By stabilizing the protein structure, tissue was preserved 
from degradation and the structure of the cells and of sub-cellular components was 
maintained during histological analyses. At the same time, the tissue remained permeable for 
macro-molecules. Because hydrophobic paraffin is immiscible with water, tissue samples 
were afterwards dehydrated in an increasing EtOH series at RT: 70 % EtOH o/n, 80 % EtOH 
for 2 h, 90 % EtOH for 2 h, 96 % EtOH for 2 h and 99 % EtOH o/n. Subsequently, samples 
were cleared twice for 45 min each at RT in toluol to remove remaining ethanol. By 
incubating the tissue in three consecutive molten paraffin wax baths (60 °C) for 2 h, o/n and 
for 2 h, respectively, paraffin infiltrated the samples and replaced the toluol. Following 
embedding of the tissue into paraffin blocks using fresh molten paraffin wax and subsequent 
hardening, serial sections of 5 µm thickness were cut using a microtome (Leica 
Microsystems). Finally, sections were mounted on positively charged glass slides (Gerhard 
Menzel) using a 48 °C water bath (Leica Microsystems) and dried o/n at RT. 
5.3.4.2 Histological stainings 
Prior to histological stainings, paraffin sections were deparaffinized and rehydrated. At first, 
slides were incubated for 30 min at 60 °C in a hybridization oven (Biometra) to firmly attach 
the sections to the glass slides. After cooling down, tissue sections were deparaffinized at RT 
in three consecutive xylol baths for 5 min each; followed by rehydration at RT in a decreasing 
series of EtOH baths: twice 99 % EtOH for 3 min each, 96 % EtOH for 3 min, 80 % EtOH for 
3 min, 70 % EtOH for 3 min and twice ddH2O for 5 min each.  
5.3.4.2.1 Hematoxylin and eosin staining 
Heamtoxylin and eaosin (H&E) staining on paraffin sections was performed to assess overall 
cardiac morphology and tissue composition. Hematein, an oxidative product of hematoxylin, 
together with aluminum ions forms a complex called hemalum. The basic hemalum complex 
stains all acidic (basophil) cell structures, especially nuclei due to its content of nucleic acids, 
blue. The synthetic acidic dye eosin stains basic (acidophil) cell structures, particularly 
cytoplasmic proteins, pink. H&E staining was performed by incubating deparaffinized and 
rehydrated sections 30 s in filtered hematoxylin solution according to Harris (Carl Roth) 
followed by washing for 5 min under running tap water. Afterwards, tissue sections were 
stained for 8 min in filtered and acidified (two drops acetic acid per 100 ml) eosin G 
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solution (Carl Roth). Subsequently, sections were dehydrated (70 % EtOH for 1 min, 
96 % EtOH for 5 min, twice 99 % EtOH for 5 min each) and cleared twice in xylol for 5 min 
each. Finally, sections were mounted under glass coverslips with Eukitt® quick-hardening 
mounting medium (Sigma-Aldrich). 
5.3.4.2.2 Sirius red staining 
Sirius red staining on paraffin sections was performed to investigate the extent of interstitial 
extracellular matrix (ECM) within myocardial tissue. By this procedure, collagen fibers (the 
main components of ECM) are stained red and muscle fibers as well as the cytoplasm are 
colored yellow. To stain cell nuclei, deparaffinized and rehydrated paraffin sections were 
stained for 8 min in hematoxylin according to Weigert (Carl Roth) and washed for 5 min 
under running tap water. Afterwards, slides were incubated in Sirius red solution for 1 h and 
washed twice in acidified water for 10 s each; followed by dehydration and mounting as 
described above (see Chapter 5.3.4.2.1). 
5.3.4.3 Fluorescent and immunofluorescent stainings 
Paraffin sections used for fluorescent and immunofluorescent stainings were deparaffinized 
and rehydrated as described before (see Chapter 5.3.4.2). 
5.3.4.3.1 Fluorescent wheat germ agglutinin staining 
To evaluate cardiomyocyte cross sectional area (CSA) in tissue sections, cell membranes 
were stained with fluorochrome-conjugated wheat germ agglutinin (WGA), which selectively 
binds to N-acetylneuraminic acid residues215. Heat-mediated antigen retrieval was performed 
on deparaffinized and rehydrated paraffin sections using 1× sodium citrate buffer. Slides 
where repeatedly boiled in a microwave oven for a total of 20 min and subsequently allowed 
to cool down to RT. Afterwards, slides were washed three times for 5 min with gentle 
agitation at 40 rpm on an orbital shaker (GFL) in 1× TBS-T followed by a blocking step in 
blocking solution for 1 h at RT. Next, sections from neonatal hearts were incubated 
simultaneously with fluorochrome (Alexa Fluor® 555)-conjugated WGA (Invitrogen) and with 
the monomeric cyanine nucleic acid stain TO-PRO®-3 (Invitrogen) in a humidified opaque 
Stain TrayTM (Carl Roth) o/n at 4°C. In contrast, sections from adult hearts were stained with 
Alexa Fluor® 555-conjugated WGA only. Subsequently, sections were washed three times in 
the dark as described above, followed by mounting under glass cover slips with 
ProLong® Gold antifade mountant (Invitrogen) (neonatal hearts) or with ProLong® Gold 
antifade mountant with 4´,6-Diamidino-2-phenylindol (DAPI) (Invitrogen) (adult hearts) and 
stored in the dark.  
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5.3.4.3.2 Fluorescent terminal dUTP nick end labeling 
To investigate programmed cell death (apoptosis), terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) was conducted, a fluorescence method that detects nuclear 
DNA fragmentation (a major hallmark of apoptosis)216. The ApopTag® fluorescein in situ 
apoptosis detection kit (Millipore), which is based on template-independent identification of 
“blunt ends” of double stranded DNA breaks, was used according to the manufacturer’s 
instructions. Briefly, the enzyme terminal deoxynucleotidyl transferase (TdT) catalyzes the 
addition of digoxigenin-labelled deoxynucleotide triphosphates (dUTPs) to the 3´-hydroxyl 
termini of exposed DNA strand ends after fragmentation. Digoxigenin incorporation can then 
be recognized by anti-digoxigenin antibodies conjugated to the fluorescent dye fluorescein, 
which can be detected by fluorescence microscopy. If not stated differently, all steps were 
carried out at RT. Enzymatic antigen retrieval was performed on deparaffinized and 
rehydrated paraffin sections by incubation in proteinase K (Carl Roth) solution for 15 min. 
Slides were then washed twice for 2 min with gentle agitation at 40 rpm on an orbital 
shaker (GFL) in 1× TBS. A positive control was included, which was treated with RNase-free 
DNAse solution (Qiagen) (DNase 1:100 in RDD buffer) for 10 min to enzymatically digest the 
nuclear DNA and thus provoke DNA breaks. Afterwards, the positive control was washed 
three times for 5 min as described above. All samples were incubated in equilibration 
buffer (provided) for 10 s. Labelled dUTPs were added by incubating the samples with 
working strength TdT enzyme (provided) in reaction buffer (provided) at 37 °C for 1 h. The 
reaction was terminated by 10 min incubation in stop/wash buffer (provided). Next, slides 
were washed three times for 1 min as described above. Afterwards, working strength anti-
digoxigenin AB conjugate in blocking solution (provided) was added for 30 min in the dark. 
Slides were again washed three times for 2 min, followed by mounting under glass cover 
slips with ProLong® Gold antifade mountant with DAPI (Invitrogen) and light-protected 
storage.  
5.3.4.3.3 Immunofluorescent KI67 staining 
To assess proliferation rates in neonatal hearts, immunofluorescence staining for KI67 was 
performed. The KI67 antigen is a nuclear protein that is expressed during all active phases of 
the cell cycle but is absent in resting cells (reviewed by Scholzen and Gerdes217). Heat-
mediated antigen retrieval was performed on deparaffinized and rehydrated paraffin sections 
as described before (see Chapter 5.3.4.3.1). After washing and blocking (for details see 
Chapter 5.3.4.3.1), sections were incubated o/n with a rabbit anti-KI67 AB (see Chapter 4.10, 
Table 12) in a humidified Stain TrayTM (Carl Roth) at 4°C. The next day, sections were 
washed three times as described above and incubated with anti-rabbit IgG 
fluorochrome (Alexa Fluor® 555)-conjugated 2° AB (see Chapter 4.10,Table 12) for 1h at RT 
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in the dark. Sections were again washed three times, followed by mounting under glass 
cover slips with ProLong® Gold antifade mountant with DAPI (Invitrogen) and light-protected 
storage. 
5.3.4.3.4 Immunofluorescent phospho-histone H3 staining 
To assess proliferation rates in embryonic hearts, immunofluorescence staining for 
histone H3 (HH3) phosphorylation at serine 10 was performed. Phosphorylation of HH3 at 
serine 10 (p-HH3) is restricted to specific stages of mitosis and the late G2 phase of the cell 
cycle and is essential for cell passage from metaphase to anaphase218. Thus, p-HH3 is a 
commonly used mitosis specific marker in proliferating cells. Heat-mediated antigen retrieval 
was performed on deparaffinized and rehydrated paraffin sections as described before (see 
Chapter 5.3.4.3.1). After washing and blocking (see Chapter 5.3.4.3.1), sections were 
incubated simultaneously with a rabbit anti-p-HH3 AB (to detect proliferating cells) (see 
Chapter 4.10, Table 12), a mouse anti-CYT c AB to differentiate between Hccs-deficient and 
healthy myocardial cells (see Chapter 4.10, Table 12) and TO-PRO®3 (Invitrogen) to label 
nuclei in a humidified Stain TrayTM (Carl Roth) o/n at 4°C. The next day, sections were 
washed three times as described above and simultaneously incubated with anti-rabbit 
IgG Alexa Fluor® 555-conjugated 2° AB and anti-mouse IgG Alexa Fluor® 488-conjugated 
2° AB (see Chapter 4.10, Table 12) for 1h at RT in the dark. Again, sections were washed 
three times, followed by mounting under glass cover slips with ProLong® Gold antifade 
mountant (Invitrogen) and light-protected storage.  
5.3.4.4 Histological analyses 
5.3.4.4.1 Evaluation of H&E-stained embryonic, P1 and adult hearts 
To assess overall cardiac morphology and tissue composition, light microscopy images of 
H&E-stained hearts (see Chapter 5.3.4.2.1) were taken using the Biozero BZ-8100 
microscope (Keyence). For 10.5 dpc embryonic hearts 5-fold optical magnification, for 
13.5 dpc embryonic hearts 4-fold optical magnification and for P1 hearts 2-fold optical 
magnification was applied. Hearts of 11 week old adult mice were imaged with 2-fold optical 
magnification. Due to the size of the adult heart, however, four overlapping picture excerpts 
were taken, which were subsequently merged into a single image using the BZ image 
analysis application software (Keyence). Pictures of at least two non-adjacent 




5.3.4.4.2 Quantification of fibrosis in adult hearts 
Light microscopy images of Sirius red-stained hearts (see Chapter 5.3.4.2.2) from 
11 week old adult mice were taken using the Biozero BZ-8100 microscope (Keyence). By 
applying 5-fold optical magnification, 6 random fields of the left ventricular (LV) myocardium, 
including free wall and interventricular septum (IVS), were imaged, thereby covering the 
entire LV tissue. Two non-adjacent Sirius red-stained cross-sections per heart were used. 
The percentage of interstitial LV fibrotic tissue was quantified using the color-threshold-plugin 
of the ImageJ software, which measures the red stained area in relation to the total LV 
myocardial area. Fibrosis of all 12 images was averaged to give a mean estimate of fibrotic 
tissue for each heart. Perivascular fibrosis was excluded and was cut-out in the images 
before analysis. Imaging measurements as well as analyses took place in a blinded fashion, 
such that investigators were unaware of mouse genotypes or treatment groups.  
5.3.4.4.3 Measurement of cardiomyocyte cross sectional area in P1 and adult hearts 
To measure cardiomyocyte cross sectional area (CSA), WGA-stained P1 longitudinal or 
11 week old adult heart cross-sections were used (see Chapter 5.3.4.3.1). For P1, pictures 
were taken with the confocal laser scanning microscope TSC SPE (Leica Microsystems) 
applying 120-fold optical magnification. For adult hearts, pictures were taken with the Biozero 
BZ-8100 fluorescence microscope (Keyence) applying 20-fold optical magnification. For P1 
as well as adult hearts, 15 random fields of the LV myocardium, including free wall and IVS, 
were imaged and two non-adjacent WGA-stained sections per heart were used. At least 200 
cardiomyocytes per heart were measured using the area measurement tool of the 
Biozero BZ image analysis application software (Keyence). Only CSA of cardiomyocytes 
which were cut along their transverse axis and matched the following selection criteria was 
measured: visible central nucleus, cell shape close to circular, clear borders of cell 
discernible and visible cytoplasm. CSA of all cardiomyocytes analyzed were averaged to give 
a mean estimate of cardiomyocyte CSA for each heart. All measurements as well as 
analyses took place in a blinded fashion, such that investigators were unaware of mouse 
genotypes or treatment groups.  
5.3.4.4.4 Quantification of apoptosis rates in embryonic 13.5 dpc and P1 hearts 
To quantify the number of apoptotic cells, TUNEL-stained 13.5 dpc or P1 hearts were 
analyzed (see Chapter 5.3.4.3.2). Two longitudinal non-adjacent sections per heart were 
imaged and pictures of 6 random fields per heart section (entire LV and RV myocardium for 
13.5 dpc, LV myocardium for P1) were taken using the Biozero BZ-8100 fluorescence 
microscope (Keyence) with 15-fold optical magnification. Cells which exhibited nuclear 
colocalization of TUNEL and DAPI staining were considered apoptotic. Nuclei with positive 
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TUNEL staining as well as the total number of DAPI-stained nuclei were manually counted 
using the cell-counter-plugin of the ImageJ software. A total number of approximately 
7,000 cells per embryonic heart and 15,000 cells per P1 heart was analyzed. Apoptosis 
rates (given in percent) were calculated by relating the number of TUNEL-positive nuclei to 
the total number of nuclei as mean from all images per heart. All measurements as well as 
analyses took place in a blinded fashion, such that investigators were unaware of mouse 
genotypes or treatment groups.  
5.3.4.4.5 Quantification of proliferation rates in neonatal hearts 
To quantify the number of proliferating cells in P1 hearts, KI67-stained longitudinal 
sections (see Chapter 5.3.4.3.3) were imaged with 40-fold optical magnification using the 
Biozero BZ-8100 fluorescence microscope (Keyence). Pictures of 10 random fields of one 
heart section were taken within the LV myocardium, including the free wall and IVS. Cells 
that exhibited nuclear colocalization of KI67 and DAPI were considered as cycling. KI67-
positive nuclei and the total number of DAPI-stained nuclei were manually quantified using 
the cell-counter-plugin of the ImageJ software. A total number of approximately 5,000 cells 
per heart was evaluated with respect to their resting or proliferating stage. The proliferation 
rate per heart was calculated as the percentage of KI67-positive cells related to the total 
number of DAPI-stained nuclei. All measurements as well as analyses took place in a 
blinded fashion, such that investigators were unaware of mouse genotypes or treatment 
groups.  
5.3.4.4.6 Quantification of proliferation rates in embryonic 13.5 dpc hearts 
To quantify the number of proliferating cells in embryonic 13.5 dpc hearts, p-HH3-stained 
longitudinal sections (see Chapter 5.3.4.3.4) were imaged with 30-fold optical magnification 
using the confocal laser scanning microscope TSC SPE (Leica Microsystems). Pictures of 6 
to 11 random fields of two non-adjacent heart sections were taken within the LV and RV 
myocardium. Cells which exhibited nuclear colocalization of p-HH3 and TO-PRO®-3 were 
considered as cycling. P-HH3-positive nuclei and total number of TO-PRO®-3-stained nuclei 
was manually quantified using the cell-counter-plugin of the ImageJ software. The number of 
cells in mitosis was taken as the total p-HH3-positive cells over the total TO-PRO®-3-labeled 
nuclei of each cell population analyzed. Within cHccs+/- hearts, CYT c staining was used to 
differentiate between the healthy and Hccs-deficient myocardial cell population. The 
proliferation rate of healthy myocardial cells was calculated as the percentage of p-HH3-
positive cells related to the total number of TO-PRO®-3-stained nuclei within CYT c-positive 
cells. The proliferation rate of Hccs-deficient myocardial cells was calculated as the 
percentage of p-HH3-positive cells related to the total number of TO-PRO®-3-stained nuclei 
within CYT c-negative cells. In Hccs+/+ hearts, all cardiomyocytes were CYT c-positive and 
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the proliferation rate per heart was calculated as the percentage of p-HH3-positive cells 
related to the total number of TO-PRO®-3-stained nuclei. A total number of approximately 
5,000 cells per heart was evaluated with respect to their resting or proliferating stage. All 
measurements as well as analyses took place in a blinded fashion, such that investigators 
were unaware of mouse genotypes or treatment groups.  
5.4 Statistical analysis 
All results are presented as mean±standard error of the mean (SEM). All data sets were 
tested for normal distribution by Kolmogorov-Smirnov test and the homogeneity of variances 
was assessed by Levene’s test with Statistical Package for the Social 
Sciences (SPSS) (IBM). Given equal variances, differences between two groups were 
evaluated with unpaired, two-sided student’s t-test using excel 2010 (Microsoft) and those 
among multiple groups with one-way analysis of variance (ANOVA) followed by Bonferroni 
post-hoc test using SPSS (IBM). Differences between multiple groups with unequal 
variances were evaluated with non-parametric Kruskal-Wallis one-way analysis of variance 
followed by Mann-Whitney post-hoc test using SPSS (IBM). Genotype distributions were 
compared to expected Mendelian distribution by Chi-square test using Microsoft excel 
software. A probability (p) value less than 0.05 was considered to indicate statistical 





6.1 Gene clusters involved in cellular metabolism and amino acid 
homeostasis are enriched in neonatal cHccs
+/-
 hearts 
Impaired embryonic and fetal growth has various effects on the postnatal health in 
humans2,3,7. In this study, we used the heart conditional Hccs KO model (see Chapter 3.4) 
to investigate adaptive mechanisms of the myocardium in response to impaired intrauterine 
cardiac development and to potentially identify molecular mechanisms of developmental 
programming. Hearts of neonatal cHccs+/- mice were found to be hypoplastic, as evident by a 
reduced HW/BW ratio, thinner LV walls and a significant reduction of the cardiomyocyte 
number (unpublished data, see Chapter 3.4). To investigate the response and adaptation of 
the neonatal cHccs+/- heart to hypoplasia, genome-wide microarray RNA expression analysis 
using neonatal whole-heart RNA was performed in a previous study by Manuela Magarin, a 
former PhD student in the Thierfelder lab at the Max Delbrück Center for Molecular Medicine 
in Berlin, Germany. Affymetrix gene array analysis identified 811 genes as differentially 
regulated (p<0.05) in neonatal cHccs+/- mice in comparison to female Hccs+/+ littermate 
controls. Subsequently, as part of this study, unbiased functional group classification was 
performed using the online database DAVID208. Therefore, only those 213 differentially 
regulated genes were included that had a fold change higher than +1.5 or lower than -1.5 in 
combination with a highly significant p-value (p<0.01) (Supplementary Table S1.). DAVID 
functional annotation of these differentially expressed genes revealed many gene groups 
involved in unfolded protein response (UPR) and apoptosis as well as metabolism and amino 
acid homeostasis as significantly enriched in neonatal cHccs+/- mice. While another PhD 
project focuses on the role of DNA damage repair, apoptosis and UPR, this study 
concentrates on the enrichment of gene classes involved in transcriptional regulation, 
metabolism and amino acid homeostasis; a more detailed listing is included in the 
supplemental information section (Supplementary Table S2-4). 
Table 18. Neonatal cHccs+/- hearts display significant enrichment of genes involved in amino 
acid homeostatic and metabolism 
Functional group Fold enrichment p-value 
Positive regulation of transcription 3.84 2.69*10^-03 
DNA replication 3.48 2.90*10^-03 
DNA damage repair 2.94 1.74*10^-02 
Unfolded protein response 2.89 2.59*10^-03 
Programmed cell death (apoptosis) 2.26 1.57*10^-02 
Amino acid metabolism (Supplementary Table S2) 2.06 3.09*10^-02 
Amino acid transport (Supplementary Table S3) 1.63 2.85*10^-02 
Cellular metabolism (Supplementary Table S4) 1.55 3.68*10^-02 
DAVID functional annotation microarray analysis of gene class changes in neonatal cHccs
+/-
 hearts revealed enrichment of gene 




6.2 Enhanced mTOR pathway activity in neonatal cHccs
+/-
 hearts 
Postnatal cardiomyocyte hypertrophy is a major hallmark of heart-specific cHccs+/- hearts 
and accounts for the postnatal catch-up growth of the hypoplastic myocardium to 
compensate for the reduced set of cardiomyocytes (unpublished data, see Chapter 3.4). 
Given enrichment of genes involved in transcriptional regulation, amino acid homeostasis 
and cellular metabolism, it was hypothesized that the mechanistic target of 
rapamycin (mTOR) pathway, an important regulator of translation and transcription, postnatal 
cardiac metabolism as well as a key sensor of cellular amino acid availability (see Chapter 
3.3.4), is involved in the postnatal compensatory growth of hypoplastic neonatal cHccs+/- 
hearts. To investigate mTOR pathway activity, western blot analyses focusing on protein 
levels and phosphorylation status of the essential mTORC1 and mTORC2 components 
MTOR, RAPTOR and RICTOR (see Chapter 3.3.4, Table 1) were performed with whole 
heart protein extracts from Hccs+/+ and cHccs+/- neonates (Supplementary Figure 1A). 
Quantification of MTOR phosphorylation at serine 2448 and 2481 normalized to total MTOR 
and of total MTOR, RAPTOR and RICTOR protein levels normalized to α-TUBULIN revealed 
no significant differences between neonatal Hccs+/+ and cHccs+/- hearts (Supplementary 
Figure 1B+C). However, given that mTOR pathway regulation is much more complex and 
depends on the presence or absence of a number of different activators or inhibitors (see 
Chapter 3.3.4, Table 1), the phosphorylation status of downstream targets is the most 
commonly used indicator to evaluate mTOR pathway activity. Thus, western blot analyses 
were carried out to investigate S6 kinase 1 (S6K1) and S6 ribosomal protein (S6) 
phosphorylation; again using whole heart protein extracts from Hccs+/+ and cHccs+/- 
neonates (Figure 8A). Quantification of S6K1 phosphorylation at threonine 389 normalized to 
total S6K1 (Figure 8B) and of S6 phosphorylation at serine 235, 236, 240 and 244 
normalized to total S6 (Figure 8C) revealed a 2.52±0.45-fold increased S6K1 
phosphorylation (p<0.01), a 1.73±0.22-fold increased phosphorylation of S6 at serine 235 
and 236 (p<0.05) and a 1.59±0.15-fold increased phosphorylation of S6 at serine 240 and 
244 (p<0.05) in neonatal cHccs+/- hearts compared to littermate Hccs+/+ females. These 
findings indicate enhanced mTOR pathway activation in neonatal cHccs+/- hearts. 
Interestingly, when cHccs+/- hearts were analyzed at postnatal day 3 (P3) and at the age of 
3 weeks, no increased phosphorylation of S6 was observed (Supplementary Figure 2), 
suggesting that mTOR pathway activation might be a critical compensatory mechanism in 




Figure 8. Elevated mTORC1 activity in neonatal cHccs
+/- 
hearts. 
A) Western blots of whole heart protein extracts from neonates (P1) illustrating phosphorylation status of S6K1 at threonine 389 





) and C) of S6 phosphorylation normalized to total S6 revealed a significant increase in P1 cHccs
+/-
 hearts 
compared to littermate controls (n=6 per group), indicating enhanced mTORC1 activity. Statistical significance among groups 
was assessed using unpaired 2-tailed Student t-test (*p<0.05, **p<0.01). 
6.3 Consequences of prenatal mTORC1 inhibition by rapamycin on 
cardiac development, growth and function 
The mTOR pathway activity was demonstrated to be enhanced in hypoplastic neonatal 
cHccs+/- hearts (see Chapter 6.2, Figure 8). To investigate if this upregulation is essential for 
the embryonic regenerative capacity and the peri- and postnatal compensatory growth of 
cHccs+/- hearts and to study the role of the mTOR signaling cascade during heart 
development in general, we sought to establish a protocol for pharmacological mTORC1 
inhibition in fetal and neonatal mice. 
6.3.1 Prenatal mTORC1 inhibition by rapamycin treatment of pregnant mice 
To inhibit mTORC1 activity in fetal and neonatal mice, a pharmacological approach using 
rapamycin was applied. As previously shown, rapamycin is a potent inhibitor of mTORC1219 
that can pass the placental barrier177. We established a treatment protocol according to 
previously published approaches220 (see Chapter 5.1.4). Briefly, 5 mg rapamycin/kg body 
weight (BW) was injected subcutaneously in pregnant dams every 12 h from 15.5 days post 
coitum (dpc) until term. Rapamycin treated Hccs+/+ as well as cHccs+/- offspring were born 
alive (see Chapter 6.3.2). As controls, pregnant females were treated with rapamycin-free 
DMA-containing vehicle (10 % PEG 300 and 17 % Tween® 80 in 0.9 % NaCl solution) (see 
Chapter 5.1.4). Most of the offspring survived until adulthood (see Chapter 6.3.4); however, a 
minor percentage died within the first 3 days, independent of the genotype of the pup or the 
treatment substance. The reason for these occasionally cases of death within the first days 
after birth was not further investigated; though stressful pregnancy due to frequent injections 
might have caused rejection of offspring by some mothers.  
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To confirm mTORC1 inhibition, western blot analyses were performed (Figure 9A). 
Investigation of the phosphorylation status of the mTORC1 downstream targets S6K1 and S6 
revealed a severe reduction at various phosphorylation sites in neonatal rapamycin treated 
hearts compared to hearts from vehicle treated offspring (Figure 9A), indicating successful 
mTORC1 inhibition. In contrast, analyses of the phosphorylation status of the mTORC1 
downstream target 4E-BP1 at serine 65 and threonine 37 and 46 revealed unchanged 
phosphorylation in rapamycin treated neonatal hearts compared to their respective vehicle 
controls (Figure 9A). This suggests that either 4E-BP1 phosphorylation does not exclusively 
rely on mTORC1 activity or is independent of the mTORC1 activity targeted by rapamycin. 
Because rapamycin treatment is a systemic pharmacological approach, the entire organism 
is affected. Inhibition of mTORC1 in neonatal kidney and lung tissue was studied by western 
blot analyses focusing on the phosphorylation status of S6K1 and S6 (Supplementary Figure 
3A+B). A severe reduction of S6K1 and S6 phosphorylation in neonatal rapamycin treated 
kidney and lung tissue compared to tissue from vehicle treated offspring was 
observed (Supplementary Figure 3A+B), confirming mTORC1 inhibition in other organs. In 
some cell types, long-term treatment with rapamycin reduced mTORC2 signaling by 
suppressing mTORC2 assembly221,222. To exclude inhibition of mTORC2 by prenatal 
rapamycin treatment, western blot analyses focusing on the phosphorylation status of AKT at 
serine 473, the phosphorylation site targeted by mTORC2 (see Chapter 3.3.4.1, Figure 5), 
were performed with neonatal whole heart protein extracts (Figure 9A). Quantification of AKT 
phosphorylation normalized to total AKT revealed no differences between the genotypes or 
the treatment groups (Figure 9C). Moreover, the mTOR signaling cascade is known to inhibit 
autophagy, a basic catabolic mechanism during which unnecessary or dysfunctional cellular 
components (such as proteins or whole organelles) are degraded168-173,175. To study the 
impact of prenatal mTORC1 inhibition on autophagy, western blot analyses of p62 protein 
levels in neonatal whole heart protein extracts were performed (Figure 9B). The protein p62 
is one of the best characterized selective autophagy substrates, which targets proteins for 
autophagy, gets incorporated into autophagosomes and subsequently degraded223,224. 
Quantification of p62 protein levels normalized to GAPDH identified significantly (p<0.001) 
decreased p62 levels in hearts from rapamycin treated neonates (0.65±0.03 arbitrary 
units (AU) for Hccs+/+, 0.67±0.06 AU for cHccs+/-) but no significant differences between the 
genotypes (1.00±0.08 AU for vehicle Hccs+/+, 1.20±0.04 AU for vehicle cHccs+/-) (Figure 9D). 
Given that decreased p62 protein levels correlate with induction of autophagy, we conclude 
that prenatal mTORC1 inhibition results in activation of autophagy in neonatal hearts. All 
together, these findings indicate that prenatal rapamycin treatment of pregnant mice 
successfully inhibits mTORC1 in fetal and neonatal mice without affecting mTORC2 activity. 
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Rapamycin-mediated mTORC1 inhibition should eventually normalize after birth, given that 
pups are no longer exposed to the treatment. To narrow down the postnatal time window 
during which mTORC1 remains inhibited and to exclude that postnatal consequences are 
due to prolonged and irreversible impairment of the mTOR pathway, hearts from offspring of 
the same rapamycin treated litter were prepared either at postnatal day 1 (P1), 2 (P2) 
or 3 (P3), respectively. Western blot analyses of whole heart protein extracts examining the 
phosphorylation status of S6 were performed (Figure 9E). Inhibition of mTORC1 was still 
evident at P2 but pathway activity was restored by P3 as evident by normal phosphorylation 
levels of S6 (Figure 9E). 
Given that both Hccs+/+ as well as cHccs+/- mice survived fetal rapamycin treatment starting 
at 15.5 dpc, we were eager to investigate if mTORC1 inhibition already during embryonic 
development has differential effects on the survival of Hccs+/+ and cHccs+/- neonates. Thus, 
we injected rapamycin in pregnant mice starting at 11.5 dpc. Hccs+/+ as well as cHccs+/- 
embryos were subjected to intrauterine lethality, preterm birth at 16.5 dpc and demonstrated 
severe growth retardation and body malformations due to systemic effects of rapamycin on 
the entire organism (Supplementary Figure 4). This profound phenotype prevents 
investigations of the consequences of mTOR pathway inhibition on fetal and perinatal 
cardiac growth. Hence, these experiments were immediately abandoned as soon as the 
severe phenotype became apparent. Importantly, for this reason, all of the following results 
presented in this study are based on rapamycin injections from 15.5 dpc until birth. 
In summary, we successfully established a novel protocol to inhibit mTORC1 in hearts, but 
also other organs, of fetal and neonatal mice by rapamycin treatment of pregnant mice. 
Moreover, we could demonstrate that after termination of rapamycin treatment at birth, 
mTORC1 activity is restored by P3, indicating reversible mTORC1 inhibition and normal 




Figure 9. Successful mTORC1 inhibition in neonatal hearts. 
A) Western blots of whole heart protein extracts from neonates (P1) after prenatal vehicle or rapamycin treatment illustrating 
phosphorylation status of AKT, S6K1, S6 and 4E-BP1. Note the severe reduction of S6K1 and S6 phosphorylation in hearts of 
rapamycin treated neonates compared to vehicle treated offspring, indicating successful mTORC1 inhibition. Phosphorylation of 
4E-BP1 was demonstrated to be unaffected by prenatal rapamycin treatment. B) Western blots of whole heart protein extracts 




 mice after prenatal vehicle or rapamycin treatment. 
C) Quantification of AKT phosphorylation at serine 473 normalized to total AKT revealed no significant differences between the 
genotypes or the treatment groups, indicating that prenatal rapamycin treatment specifically inhibits mTORC1 but not mTORC2 
in P1 hearts (n=5 for vehicle and rapamycin Hccs
+/+
, n=6 for vehicle and rapamycin cHccs
+/-
). D) Quantification of p62 protein 
levels normalized to GAPDH revealed no significant differences between the genotypes but a significant decrease in both 
rapamycin groups compared to vehicle conditions, indicating autophagy activation upon prenatal mTORC1 inhibition (n=6 per 
group). E) Western blots of whole heart protein extracts from vehicle treated neonates at P1 and of rapamycin treated 
littermates at P1, P2, and P3 illustrating phosphorylation status of S6. Note that mTORC1 inhibition was still evident at P2, while 
S6 phosphorylation at P3 does not differ compared to P1 vehicle treated offspring, indicating restoration of mTOR pathway 
activity. For C)+D): Statistical significance among groups was assessed by one-way ANOVA followed by Bonferroni post-hoc 
test (§§§p<0.001 vs. vehicle Hccs
+/+
, ###p<0.001 vs. vehicle cHccs
+/-
). (R: rapamycin, V: vehicle) 
6.3.2 Prenatal mTORC1 inhibition neither affects litter size nor genotype distribution 
Given the fatal phenotype observed if rapamycin treatment is initiated at 11.5 dpc, we 
determined if prenatal mTORC1 inhibition from 15.5 dpc onwards also causes intrauterine 
lethality. For this purpose, litter size as well as genotype distribution within vehicle and 
rapamycin treated litters were compared at P1 (Figure 10). Pregnant dams treated with 
vehicle gave birth to 5.4±0.56 offspring per litter, while litter size for rapamycin treated dams 
was 6.0±0.44 (Figure 10A). The difference was not statistically significant. Besides, the 
applied breeding strategy theoretically generates 33.33 % Hccs+/Y control males, 33.3 % 
Hccs+/+ control females and 33.3 % cHccs+/- females, respectively (Figure 10B and see 
Chapter 5.1.2.1, Figure 6). In vehicle treated litters, 29.92±7.17 % control males, 
25.87±5.09 % control females, and 44.21±5.26 % cHccs+/- females were identified (Figure 
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10B). Rapamycin treated litters split up in 25.24±9.74 % control males, 40.89±10.30 % 
control females, and 33.87±10.43 % cHccs+/- mice (Figure 10B). Genotype distribution within 
vehicle as well as rapamycin treated litters compared to the expected genotype distribution 
was not significantly different as determined with chi-square test (Figure 10B). In line, 
unpaired 2-tailed Student t-tests comparing the genotype frequencies of control males, 
control females and cHccs+/- mice, respectively, between vehicle and rapamycin litters 
resulted in equal distribution independent of the expected frequencies (Figure 10B). In 
conclusion, prenatal mTORC1 inhibition does not cause general or genotype-specific 
intrauterine lethality. 
 
Figure 10. Prenatal mTORC1 inhibition neither changes litter size nor genotype distribution. 
A) Average litter size of vehicle and rapamycin treated dams did not differ. Statistical significance among groups was assessed 
by unpaired 2-tailed Student t-tests. B) Genotype distribution within vehicle as well as rapamycin treated litters was not 
significantly different from expected genotype frequencies. Statistical significance between treatment groups and expected 
genotype distribution was assessed by chi-square test. Statistical significance comparing the frequencies of all three genotypes, 
respectively, between vehicle and rapamycin treated litters independent of expected frequencies was assessed by unpaired 2-
tailed Student t-tests. For A)+B): n=9 litters for both treatment groups. 
6.3.3 Consequences of prenatal mTORC1 inhibition for neonatal hearts 
Even though mTOR is known to regulate cardiac cell and organ size during postnatal 
life58,117,184-186,225, its role during intrauterine growth is less well understood. For this reason, 
we analyzed organ size, proliferation and apoptosis rates as well as cardiomyocyte size and 
cardiac function in neonatal hearts after prenatal (15.5 dpc onwards) rapamycin-induced 
mTORC1 inhibition. 
6.3.3.1 Prenatal mTORC1 inhibition causes intrauterine growth restriction and 
cardiac developmental delay in neonatal mice 
To determine the effect of prenatal mTORC1 inhibition on fetal growth and cardiac 
development, neonatal mice after prenatal rapamycin treatment were analyzed at P1. 
Investigation of body size (Figure 11A) and weight (Figure 11B) revealed overall growth 
retardation in rapamycin treated neonates compared to vehicle treated animals. Prenatal 
rapamycin treatment reduced BW in Hccs+/+ controls by 16.4 % (p<0.001) and in cHccs+/- 
neonates by 14.5 % (p<0.01) (Figure 11B). Heart size (Figure 11C+D) and weight (Figure 
11E) were also extenuated in rapamycin treated neonates compared to the respective 
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vehicle treated control groups. Prenatal rapamycin treatment reduced HW in Hccs+/+ controls 
by 34.5 % (p<0.001) and in cHccs+/- by 35.3 % (p<0.001) (Figure 11E). Thus, the impact of 
mTORC1 inhibition on heart weight (HW) is more pronounced than on BW. Consequently, 
prenatal mTORC1 inhibition results in a significantly (p<0.001) decreased HW to 
BW (HW/BW) ratio in P1 rapamycin treated animals compared to their respective vehicle 
control groups (Figure 11F). While HW/BW ratio of vehicle Hccs+/+ controls was 
6.23±0.03 mg/g and of vehicle cHccs+/- animals 5.62±0.06 mg/g, HW/BW ratio of rapamycin 
Hccs+/+ controls was 4.87±0.02 mg/g and of rapamycin cHccs+/- animals 4.24±0.03 mg/g. 
Importantly, the hypoplastic cardiac phenotype (a major hallmark of the heart conditional 
Hccs KO model, reflected by significantly reduced HW and HW/BW ratio in neonatal 
mice (see Chapter 3.4)) was evident in the vehicle group and was still observed after 
prenatal mTORC1 inhibition (Figure 11E+F). Histological analyses of neonatal hearts 
confirmed reduced organ size in both genotypes after prenatal mTORC1 inhibition (Figure 
11D). Importantly, however, cHccs+/- hearts demonstrated a more profound phenotype with 
severe thinning and noncompaction of the ventricular myocardium obvious in the apical 
regions of both ventricles (Figure 11D, arrowheads). Because rapamycin treatment is a 
pharmacological approach that affects the entire organisms, consequences of prenatal 
mTORC1 inhibition on neonatal kidney weight (KW) were analyzed (Supplementary Figure 
3C). The accumulated weight of right and left kidney of newborn rapamycin treated Hccs+/+ 
controls (7.68±0.09 mg) and cHccs+/- animals (7.80±0.07 mg) was significantly lower 
compared to their corresponding vehicle control groups (9.56±0.23 mg for Hccs+/+, 
9.45±0.16 mg for cHccs+/-), which represents a reduction by 19.7 % in Hccs+/+ 
controls (p<0.01) and 17.5 % in cHccs+/- neonates (p<0.05) (Supplementary Figure 3C). Due 
to the parallel reduction of BW and KW, kidney weight to body weight (KW/BW) ratio in 
neonates was not significantly different between the genotypes or the treatment 
groups (Supplementary Figure 3D). Thus, prenatal mTORC1 inhibition reduced BW (Figure 
11B) and KW (Supplementary Figure 3C) to a similar extend, while the reduction of HW was 
much more pronounced (Figure 11E). These data support the hypothesis that the mTOR 
pathway has an important role during fetal heart development. In summary, prenatal 
mTORC1 inhibition induces overall growth restriction and developmental delay in neonatal 
mice, where cardiac development was especially affected and most severe consequences 




Figure 11. Prenatal mTORC1 inhibition induces overall growth restriction and reduces heart size in neonatal mice. 
A) Newborn offspring after prenatal rapamycin treatment were smaller compared to their vehicle treated controls (scale 
bar = 1 cm). B) BW of rapamycin treated neonates was significantly reduced compared to vehicle treated animals. C) Neonatal 
mice after prenatal rapamycin treatment had smaller hearts compared to their vehicle controls (scale bar = 1 mm). D) H&E-
stained longitudinal heart sections of neonatal mice after prenatal mTORC1 inhibition were morphologically characterized by 
developmental delay indicated by smaller heart size as well as thinning and noncompaction of the ventricular myocardium, 
which was most prominent in rapamycin treated cHccs
+/-
 hearts (arrowheads) (scale bar = 1 mm, Ao: aorta, IVS: interventricular 
septum, LA: left atrium, LV: left ventricle, RA: right atrium, RV: right ventricle). E)+F) Rapamycin treated neonates demonstrated 
significantly lower HW and HW/BW ratio compared to vehicle treated animals. Note that the reduced HW and HW/BW ratio in 
cHccs
+/-
 compared to Hccs
+/+
 newborn females, which is a major hallmark of the heart conditional Hccs
 
model, persisted after 
prenatal mTORC1 inhibition. For B)+E)+F): Statistical significance among groups was assessed by one-way ANOVA followed 
by Bonferroni post-hoc test (**p<0.01, ***p<0.001, §§§p<0.001 vs. vehicle Hccs
+/+
, ###p<0.001 vs. vehicle cHccs
+/-










6.3.3.2 Prenatal mTORC1 inhibition reduces cardiomyocyte size, induces apoptosis 
but does not affect proliferation in neonatal hearts  
We observed significantly reduced heart size in neonatal mice after prenatal mTORC1 
inhibition. Theoretically, this reduced heart size can be caused by a decreased cell number or 
a reduced cell size or a combination of both. To elucidate these options, we investigated 
proliferation and apoptosis rates as well as cardiomyocyte size in neonatal hearts after 
prenatal vehicle or rapamycin treatment. Proliferation rates were assessed by 
immunofluorescence staining for KI67, a marker that labels proliferating cells in all active 
phases of the cell cycle217 (Figure 12A). Quantification of KI67-positive nuclei in the LV 
myocardium revealed no significant differences between the treatment groups or the 
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genotypes (38.55±2.68 % for vehicle Hccs+/+, 40.47±1.89 % for vehicle cHccs+/-, 35.77±0.85 % 
for rapamycin Hccs+/+, 37.27±1.15 % for rapamycin cHccs+/-) (Figure 12C). To investigate if 
prenatal mTORC1 inhibition also provokes apoptosis, terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) stainings were conducted, a fluorescence based method that 
detects nuclear DNA fragmentation (a major hallmark of apoptosis)216 (Figure 12B). 
Quantification of TUNEL-positive nuclei in the LV myocardium of vehicle treated neonates 
revealed 0.07±0.02 % apoptotic cells in Hccs+/+ controls and 0.12±0.02 % in cHccs+/- 
animals (Figure 12D). In contrast, apoptosis rates in rapamycin treated neonates were 
significantly (p<0.001) increased (0.20±0.01 % for Hccs+/+, 0.28±0.03 % for cHccs+/-) (Figure 
12D). Importantly, significantly (p<0.05) more TUNEL-positive cells were identified in 
rapamycin cHccs+/- neonatal hearts compared to rapamycin Hccs+/+ controls (Figure 12D). 
Thus, prenatal mTORC1 inhibition generally induces apoptosis in neonatal hearts with a 
higher extend in cHccs+/- neonates. To measure cell size, cardiomyocyte cross sectional 
area (CSA) was studied by wheat germ agglutinin (WGA) fluorescence staining of cell 
membranes, where WGA selectively binds to N‑acetylneuraminic acid residues215 (Figure 
12E). Cardiomyocytes within the LV myocardium of hearts from rapamycin treated neonates 
were significantly (p<0.001) smaller (42.8±0.44 µm2 for Hccs+/+, 31.4±1.34 µm2 for cHccs+/-) 
compared to those of vehicle treated animals (64.7±2.45 µm2 for Hccs+/+, 63.3±1.92 µm2 for 
cHccs+/-) (Figure 12F). Interestingly, within the rapamycin treated group, cardiomyocyte CSA 
of cHccs+/- hearts was significantly (p<0.05) reduced compared to Hccs+/+ control 
hearts (Figure 12F). Hence, mTORC1 inhibition decreases cell size in both genotypes with 
more pronounced consequences on the compensatory growth of cHccs+/- hearts. In summary, 
prenatal inhibition of mTORC1 reduces neonatal heart size by affecting cardiomyocyte 




Figure 12. Prenatal mTORC1 inhibition does not affect cardiomyocyte proliferation rates but induces apoptosis and 
reduces cardiomyocyte size in neonatal hearts. 
A) Immunofluorescence images of KI67-labeled nuclei (red) within the left ventricular (LV) myocardium of neonatal hearts. 
Nuclei were stained in blue with DAPI. Cycling cardiac cells exhibit colocalization of DAPI and KI67 and hence appear 
pink (arrowheads) (scale bar = 50 μm). B) Fluorescence terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
stainings (green) within the LV myocardium of neonatal hearts. Nuclei were stained in blue with DAPI. Cells in apoptosis exhibit 
colocalization of DAPI and TUNEL (arrowheads) (scale bar = 50 µM). C) Quantification of KI67-positive nuclei revealed 





, n=12 for rapamycin Hccs
+/+
, n=13 for rapamycin cHccs
+/-
). D) Quantification of TUNEL-positive 
nuclei revealed significantly increased programmed cell death in hearts after prenatal mTORC1 inhibition, with apoptosis in 
rapamycin cHccs
+/-
 hearts being significantly higher than in rapamycin Hccs
+/+
 controls. Statistical significance among groups 





, n=4 for vehicle Hccs
+/+
, n=6 for vehicle cHccs
+/-




). E) Fluorescence 
images of cross-sectioned cardiomyocytes within the LV myocardium of neonatal hearts. Cardiomyocyte membranes were 
stained in red with wheat germ agglutinin (WGA) and nuclei in blue with TO-PRO®-3. Only cardiomyocytes that matched the 
defined measurement criteria were analyzed (arrowheads) (confocal microscopy, scale bar = 25 μm). F) Prenatal rapamycin 
treatment significantly reduced cardiomyocyte cross sectional area (CSA) in both genotypes, and cardiomyocytes in rapamycin 
cHccs
+/-
 hearts were significantly smaller compared to rapamycin Hccs
+/+









). For C)+F): Statistical significance among groups was assessed using Kruskal-Wallis one-way 
analysis of variance followed by Mann-Whitney post-hoc test (*p<0.05, §§§p<0.001 vs. vehicle Hccs
+/+
, ###p<0.001 vs. vehicle 
cHccs
+/-
). (R: rapamycin, V: vehicle) 
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6.3.3.3 Cardiac function in neonatal mice is largely unaffected by prenatal mTORC1 
inhibition 
Given the severe phenotype in neonatal hearts after prenatal mTORC1 inhibition, we were 
eager to investigate if this results in altered cardiac function at birth. Thus, echocardiographic 
measurements in neonatal Hccs+/+ and cHccs+/- mice after prenatal vehicle or rapamycin 
treatment were performed (Figure 13 and Supplementary Table S5). Thickness of the 
interventricular septum (IVS, 0.27±0.01 mm for vehicle Hccs+/+, 0.26±0.01 mm for vehicle 
cHccs+/-, 0.24±0.01 mm for rapamycin Hccs+/+, 0.23±0.02 mm for rapamycin cHccs+/-) (Figure 
13A) and of the left ventricular posterior wall (LVPW, 0.27±0.02 mm for vehicle Hccs+/+, 
0.27±0.01 mm for vehicle cHccs+/-, 0.26±0.01 mm for rapamycin Hccs+/+, 0.23±0.02 mm for 
rapamycin cHccs+/-) (Figure 13B) in end-diastole were not significantly different between the 
treatment groups and the genotypes. Left ventricular internal diameter (LVID) in end-diastole 
was significantly reduced in rapamycin Hccs+/+ controls (1.27±0.05 mm) compared to vehicle 
treated Hccs+/+ mice (1.50±0.04 mm) (p<0.01), but missed statistical significance 
between the cHccs+/- groups (1.41±0.05 mm for vehicle cHccs+/-, 1.27±0.05 mm for 
rapamycin cHccs+/-) (Figure 13C). However, in line with the results obtained from explanted 
neonatal hearts (see Chapter 6.3.3.1, Figure 11E), a trend toward a reduction in all three 
parameters (IVS, LVPW, LVID) was obvious for rapamycin treated neonatal hearts compared 
to their corresponding vehicle control groups (Figure 13A-C). Importantly, histological 
analyses (see Chapter 6.3.3.1, Figure 11D) as well as the weight data (see Chapter 6.3.3.1, 
Figure 11E) provided strong indications for reduced chamber dimensions and wall thickness. 
However, this could only partially be confirmed by echocardiographic measurements and for 
most parameters the reduction is obvious just as a trend (Figure 13A-C). This deviation might 
be explained by the exceptionally small rapamycin treated hearts, which pose a resolution 
challenge for echocardiography, even though a high frequency ultrasound system with a 
50 MHz transducer was used. So, clearly determining the epi- and endocardial layers on 
these images to analyze wall thickness is difficult, resulting in a certain degree of deviation 
and error. 
Surprisingly, analysis of the left ventricular contractile parameters FS (fractional shortening, 
fraction of LV dimension in end-diastole that is lost in end-systole, 31.86±1.46 % for vehicle 
Hccs+/+, 31.98±1.42 % for vehicle cHccs+/-, 29.50±1.65 % for rapamycin Hccs+/+, 
27.36±1.53 % for rapamycin cHccs+/-) (Figure 13D) and EF (ejection fraction, blood volume 
ejected by LV during one contraction, 63.05±1.92 % for vehicle Hccs+/+, 64.06±1.98 % for 
vehicle cHccs+/-, 61.38±3.00 % for rapamycin Hccs+/+, 55.60±1.77 % for rapamycin 
cHccs+/-) (Figure 13E) revealed only a slight trend (though not significant) regarding FS 
reduction and a significant reduction of EF (p<0.05) in rapamycin cHccs+/- neonates 
compared to vehicle cHccs+/- mice. In contrast, in rapamycin Hccs+/+ neonates, FS and EF 
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remained normal (Figure 13D+E). These findings suggest that prenatal mTORC1 inhibition 
slightly reduces cardiac contractility in neonatal cHccs+/- mice, while heart function in 
rapamycin Hccs+/+ neonates is mainly unaffected. However, even an EF of 55.60±1.77 % in 
cHccs+/- neonates can still be considered as being normal and does not indicate severe 
problems regarding cardiac contractility. Taken together, it rather came as a surprise to us 
that prenatal mTORC1 inhibition causes a severe phenotype in neonatal hearts but only 
marginally affects heart function in newborn mice. 
 
Figure 13. Echocardiographic measurements in neonatal mice after prenatal mTORC1 inhibition revealed largely 
normal cardiac function.  
A) Interventricular septum (IVS) and B) left ventricular posterior wall (LVPW) thickness in end-diastole (dia) was slightly reduced 
after prenatal rapamycin treatment in both genotypes without reaching statistical significance. C) End-diastolic left ventricular 
internal diameter (LVID) was marginally smaller in neonatal cHccs
+/-
 mice and significantly reduced in Hccs
+/+
 controls after 
prenatal mTORC1 inhibition. D)+E) Fractional shortening (FS) and ejection fraction (EF) remained unchanged in Hccs
+/+
 
controls and EF was significantly but not severely reduced in cHccs
+/-
 mice after prenatal rapamycin treatment, indicating largely 
normal heart function in both genotypes. For A)-E): Statistical significance among groups was assessed by one-way ANOVA 
followed by Bonferroni post-hoc test (§§p<0.01 vs. vehicle Hccs
+/+
, #p<0.05 vs. vehicle cHccs
+/-





, n=6 for vehicle cHccs
+/-
 and rapamycin Hccs
+/+
). 
6.3.4 Consequences of prenatal mTORC1 inhibition for adult hearts  
According to the concept of developmental programming, IUGR can have various 
consequences on cardiac growth and function in adulthood (see Chapter 3.2). To address 
the question if prenatal mTORC1 inhibition affects heart morphology, size and function later 
in life, 11 week old adult animals were analyzed. 
6.3.4.1 Prenatal mTORC1 inhibition does not affect cardiac morphology and size of 
adult hearts 
To determine if prenatal mTORC1 inhibition impacts on cardiac morphology and growth later 
in life, 11 week old adult mice after prenatal vehicle or rapamycin treatment were analyzed 
with respect to BW and HW as well as cardiac morphology (Figure 14). H&E-stained heart 
cross-sections revealed no histological, structural or pathological abnormalities between the 
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genotypes or the treatment groups (Figure 14A). Reduction in BW, as evident in neonatal 
rapamycin treated animals (see Chapter 6.3.3.1, Figure 11B), remained as trend (p=0.055) in 
adult Hccs+/+ control mice (15.26±0.51 g) and was significant (p<0.05) in cHccs+/- 
adults (15.78±1.08 g) compared to vehicle treated animals (16.91±0.61 g for Hccs+/+, 
18.67±0.57 g for cHccs+/-) (Figure 14B). HW was also reduced in neonatal mice after 
prenatal mTORC1 inhibition (see Chapter 6.3.3.1, Figure 11E). For both genotypes, a slight 
reduction in HW persists in adulthood (94.47±3.59 mg for vehicle Hccs+/+, 105.68±8.60 mg 
for vehicle cHccs+/-, 87.53±4.08 mg for rapamycin Hccs+/+, 89.25±4.81 mg for rapamycin 
cHccs+/-); which, however, missed statistical significance (Figure 14C). In neonatal rapamycin 
mice, HW/BW ratio was significantly reduced compared to vehicle treated neonates with a 
higher level of reduction in cHccs+/- neonates (see Chapter 6.3.3.1, Figure 11F). In adult 
mice, due to the slight reduction of both, BW and HW, HW/BW ratio was 
unchanged (5.59±0.12 mg/g for vehicle Hccs+/+, 5.64±0.37 mg/g for vehicle cHccs+/-, 
5.75±0.22 mg/g for rapamycin Hccs+/+, 5.69±0.10 mg/g for rapamycin cHccs+/-) (Figure 14D). 
HW/BW ratio was significantly smaller in neonatal rapamycin treated cHccs+/- mice compared 
to rapamycin treated Hccs+/+ controls (see Chapter 6.3.3.1, Figure 11F). Importantly, HW and 
HW/BW ratio was not different between the genotypes in adult mice after prenatal mTORC1 
inhibition (Figure 14C+D). This observation suggests that postnatal catch-up growth after 
prenatal mTORC1 inhibition is enhanced in the cHccs+/- heart compared to the whole body.  
To further investigate cardiac size and function, echocardiographic measurements were 
performed (Figure 14E-G and Supplementary Table S6). End-diastolic IVS (0.74±0.02 mm 
for vehicle Hccs+/+, 0.76±0.06 mm for vehicle cHccs+/-, 0.62±0.04 mm for rapamycin Hccs+/+, 
0.63±0.04 mm for rapamycin cHccs+/-) (Figure 14E) and LVPW thickness (0.75±0.02 mm for 
vehicle Hccs+/+, 0.76±0.04 mm for vehicle cHccs+/-, 0.61±0.04 mm for rapamycin Hccs+/+, 
0.63±0.04 mm for rapamycin cHccs+/-) (Figure 14F) as well as end-diastolic 
LVID (3.66±0.11 mm for vehicle Hccs+/+, 3.96±0.18 mm for vehicle cHccs+/-, 3.64±0.08 mm 
for rapamycin Hccs+/+, 3.91±0.13 mm for rapamycin cHccs+/-) (Figure 14G) were not 
significantly different between the treatment groups and the genotypes. However, in line with 
the results obtained from explanted adult hearts (Figure 14C) a slight reduction in LV wall 
thickness was obvious in both genotypes after prenatal mTORC1 inhibition (Figure 14E+F). 
Neonatal mice after prenatal mTORC1 inhibition demonstrated reduced KW (see Chapter 
6.3.3.1, Supplementary Figure 3C). In adult mice, absolute organ weight as well as organ 
weight normalized to BW for liver, kidney and spleen were investigated (Supplementary 
Figure 5). Liver, kidney and spleen weights were slightly reduced in adult rapamycin treated 
mice of both genotypes; even though the difference was not statistically 
significant (Supplementary Figure 5A+C+E). When normalized to BW, no significant 
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differences between the treatment groups or the genotypes were demonstrated for all three 
organs (Supplementary Figure 5B+D+F). 
 
Figure 14. Adult mice after prenatal mTORC1 inhibition demonstrate partial normalization of body and heart weight. 
A) No major morphological changes within the left ventricle (LV), interventricular septum (IVS) or right ventricle (RV) were 
observed in both genotypes after prenatal mTORC1 inhibition when H&E-stained heart cross-sections were compared with 
those from adult vehicle treated animals (scale bar = 1 mm). B) Body weight (BW) in adult rapamycin cHccs
+/-
 animals was 
significantly lower compared to the corresponding vehicle group. A similar trend was observed in adult Hccs
+/+
 controls, 
indicating incomplete normalization of BW during postnatal life in both genotypes. C) Heart weight (HW) in adult rapamycin 
treated animals demonstrated a slight reduction in both genotypes compared to the corresponding vehicle groups, again 
suggesting partial normalization of HW in adulthood. D) HW to BW (HW/BW) ratio in adult animals after prenatal mTORC1 
inhibition was not different between the treatment groups or the genotypes. Note that the reduced HW/BW ratio observed in 
neonatal vehicle and rapamycin cHccs
+/-
 mice compared to the corresponding Hccs
+/+
 controls is no longer evident in adult 
animals. E) Echocardiographic measurements of the thickness of the interventricular septum (IVS) as well as of F) the left 
ventricular posterior wall (LVPW) in end-diastole in adult mice revealed a slight reduction after prenatal rapamycin treatment in 
both genotypes without reaching statistical significance. G) End-diastolic left ventricular internal diameter (LVID) in adult hearts 
was not different between the treatment groups and the genotypes. For B)+D): Statistical significance among groups was 
assessed using Kruskal-Wallis one-way analysis of variance followed by Mann-Whitney post-hoc test (#p<0.05 vs. vehicle 
cHccs
+/-
). For C)+E)-G): Statistical significance among groups was assessed by one-way ANOVA followed by Bonferroni post-
hoc test. For B)-G): n=7 for vehicle Hccs
+/+
, n=6 for vehicle and rapamycin cHccs
+/-
, n=9 for rapamycin Hccs
+/+
. 
In summary, reduction of BW and HW after prenatal mTOR inhibition, as observed in 
neonatal mice, was mainly normalized during postnatal life in both genotypes; however, it did 
not completely reach the level of vehicle treated mice by the age of 11 weeks. Importantly, 
HW/BW ratio was reduced in neonates (see Chapter 6.3.3.1, Figure 11F) but not adult 
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mice (Figure 14D) after prenatal mTORC1 inhibition. In contrast, KW/BW ratio was neither 
reduced in rapamycin treated neonates (see Chapter 6.3.3.1, Supplementary Figure 3D) nor 
in adult mice after prenatal mTORC1 inhibition (Supplementary Figure 5D). These data 
suggest faster postnatal catch-up growth in the heart as compared to the whole body. 
6.3.4.2 Prenatal mTORC1 inhibition increases cardiomyocyte size but does not 
induce pathological remodeling or left ventricular dysfunction in adult 
hearts 
Even though it was shown that prenatal mTORC1 inhibition results in reduced cardiomyocyte 
CSA (see Chapter 6.3.3.2, Figure 12F) as well as reduced HW and HW/BW ratio in neonatal 
hearts (see Chapter 6.3.3.1, Figure 11E+F), HW and HW/BW ratio normalized until 
adulthood (see Chapter 6.3.4.1, Figure 14C+D). Given that the mTOR pathway plays an 
important role is postnatal cardiomyocyte growth, we further investigated how cardiomyocyte 
size develops during postnatal life. To this intend, we measured cardiomyocyte CSA in the 
LV myocardium of adult hearts after prenatal vehicle or rapamycin treatment on WGA-
stained heart sections (Figure 15A). Cardiomyocytes CSA of adult rapamycin hearts was 
significantly larger (403.35±59.38 µm2 for Hccs+/+ (p<0.01), 427.50±89.05 µm2 for cHccs+/- 
(p<0.05)) compared to the vehicle control groups (280.03±14.66 µm2 for Hccs+/+, 
330.11±29.60 µm2 for cHccs+/-) (Figure 15B). Interestingly, compensatory postnatal 
cardiomyocyte hypertrophy in cHccs+/- hearts (a major hallmark of the heart conditional Hccs 
KO model (see Chapter 3.4)) that was apparent under vehicle conditions, was lost after 
prenatal rapamycin treatment (Figure 15B). These findings indicate that prenatal mTORC1 
inhibition increases adult cardiomyocyte size in both genotypes (thereby allowing 
normalization of HW/BW ratio until adulthood) but impairs postnatal compensatory 
hypertrophic growth in cHccs+/- mice. 
Although cardiomyocytes make up the bulk of the myocardial volume, the myocardium 
additionally consists of various nonmyocytes. Cardiac fibroblasts are the most abundant non-
myocyte cell type in the heart and synthesize extracellular matrix (ECM), which is mainly built 
up of collagen fibers. Besides cardiomyocyte enlargement, physiological postnatal heart 
growth is achieved through ECM synthesis and deposition. However, excessive deposition of 
ECM by fibroblasts is an indicator of pathological myocardial remodeling (termed fibrosis), 
and can cause myocardial dysfunction226,227. IUGR has been shown to increase ECM 
deposition in the postnatal heart, thereby potentially contributing to increased disease 
susceptibility26,28. The percentage of interstitial fibrosis was investigated within the LV 
myocardium of adult mice after prenatal vehicle or rapamycin treatment by Sirius red 
staining (Figure 15E). Quantification revealed no differences between the genotypes or the 
treatment groups (1.20±0.17 % for vehicle Hccs+/+, 1.13±0.26 % for vehicle cHccs+/-, 
1.05±0.04 % for rapamycin Hccs+/+, 1.25±0.22 % for rapamycin cHccs+/-), indicating normal 
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collagen deposition (Figure 15C). These results demonstrate that postnatal normalization of 
heart size after prenatal rapamycin treatment is achieved by increased cell size, but not 
increased physiological ECM deposition or pathological fibrosis. 
 
Figure 15. Prenatal mTORC1 inhibition increases cardiomyocyte CSA but does not cause pathological remodeling or 
impaired cardiac function in 11 week old adult hearts. 
A) Fluorescence images of cross-sectioned cardiomyocytes within the left ventricular (LV) myocardium of adult hearts. 
Cardiomyocyte membranes were stained in orange with wheat germ agglutinin (WGA) and nuclei in blue with DAPI. Only 
cardiomyocytes that matched the defined measurement criteria were analyzed (arrowheads) (scale bar = 100 μm). 
B) Cardiomyocyte cross sectional area (CSA) was significantly larger in hearts exposed to prenatal rapamycin (R) treatment 
compared to vehicle (V) treated groups. Note that compensatory cardiomyocyte hypertrophy in cHccs
+/-
 mice, evident in the 
vehicle group, was lost in adult rapamycin treated hearts (n=6 for vehicle Hccs
+/+





). C) Quantification of fibrotic cardiac tissue within the LV myocardium of adult mice did not reveal 





, n=8 for vehicle cHccs
+/-
). D) Relative natriuretic peptide type A (Nppa), β-myosin heavy chain 7 (Myh7) 
and natriuretic peptide type B gene (Nppb) mRNA levels in adult hearts were determined using qPCR. No significant 
upregulation of all three heart failure marker genes was observed in rapamycin groups compared to vehicle groups (n=8 for all 
groups). E) Random images of the LV myocardium of Sirius red stained heart cross-sections of adult mice demonstrated only 
minor collagen deposition in all four groups. White arrowheads highlight the red appearance of fine threads of interstitial 
collagen. Black arrowheads highlight perivascular fibrosis, which was excluded for quantification (scale bar = 300 µm). 
F) Echocardiographic measurements revealed that left ventricular fractional shortening (FS) and G) ejection fraction (EF) in 
adult mice were neither different between the genotypes nor the treatment groups, indicating that prenatal mTORC1 inhibition 
did not impair cardiac function in adulthood (n=7 for vehicle Hccs
+/+
, n=6 for vehicle and rapamycin cHccs
+/-
, n=9 for rapamycin 
Hccs
+/+
). For B)+C): Statistical significance among groups was assessed using Kruskal-Wallis one-way analysis of variance 
followed by Mann-Whitney post-hoc test (**p<0.05, §§ p<0.01 vs. vehicle Hccs
+/+
, #p<0.05 vs. vehicle cHccs
+/-
). For D), F), 
G): Statistical significance among groups was assessed by one-way ANOVA followed by Bonferroni post-hoc test (*p<0.05).  
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To further analyze if prenatal mTORC1 inhibition causes pathological conditions in the heart 
and eventually leads to impaired cardiac function in adulthood, RNA expression analyses of 
“heart failure marker genes” were performed (Figure 15D). Moreover, heart function was 
measured by echocardiography (Figure 15F+G and Supplementary Table S6). As reviewed 
by McMullen and Jennings, elevated cardiac expression of the fetal genes natriuretic peptide 
type A (Nppa), natriuretic peptide type B (Nppb) and β-myosin heavy chain (Myh7) is 
associated with cardiac stress116. Hence, the expression of these “heart failure marker 
genes” is an indication for molecular adaptations of the heart in response to pathological 
conditions116. Relative Nppa, Myh7 and Nppb expression in adult hearts after prenatal 
rapamycin treatment were not significantly different compared to mRNA levels in adult 
vehicle treated hearts (Figure 15D). Furthermore, the LV contractile parameters 
FS (21.66±1.53 % for vehicle Hccs+/+, 23.07±2.81 % for vehicle cHccs+/-, 22.21±2.37 % for 
rapamycin Hccs+/+, 23.58±2.45 % for rapamycin cHccs+/-) and EF (43.64±2.38 % for vehicle 
Hccs+/+, 45.18±4.64 % for vehicle cHccs+/-, 45.71±3.70 % for rapamycin Hccs+/+, 
47.17±4.12 % for rapamycin cHccs+/-) remained unchanged, indicating normal heart 
function (Figure 15F+G and Supplementary Table S6).  
In summary, no indications for pathological conditions or myocardial tissue remodeling were 
observed in adult hearts after prenatal mTORC1 inhibition. Moreover, cardiac function in 
adulthood was normal, indicating that the normal heart function in neonatal rapamycin 
treated mice (see Chapter 6.3.3.3, Figure 13D+E) is maintained during postnatal life and 
might even improve in rapamycin cHccs+/- females. 
6.4 Consequences of cardiac-specific Raptor ablation on heart 
development and survival  
Prenatal mTORC1 inhibition by rapamycin treatment is a pharmacological approach that 
affects the entire fetal as well as maternal organism. Although this certainly resembles the 
situation of classical IUGR models (see Chapter 3.2.2), direct consequences for the heart are 
difficult to differentiate from secondary effects caused by rapamycin-induced changes in 
other organs. Moreover, effects on the maternal metabolism and fetal blood, oxygen and 
nutritional supply, including proper growth and development of the placenta, are conceivable 
confounding factors. Despite intriguing findings regarding the consequences of prenatal 
rapamycin treatment in the neonatal heart, this does not allow a general conclusion about the 
role of the mTOR pathway during heart development.  
Thus, to more precisely analyze the consequences of heart-specific mTORC1 inhibition 
during development, a genetic approach using a mouse strain that carries two loxP sites 
flanking exon 6 of the Raptor gene206 (see Chapter 5.1.1.3) has been carried out. RAPTOR is 
an essential component of mTORC1 and regulates its assembly, localization and substrate 
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binding120,121. By analyzing liver protein lysates, Sengupta et al. demonstrated that, upon 
liver-specific Cre-mediated excision of the “floxed” Raptor sequence, mTORC1 activity was 
completely eliminated206. Importantly, to date, almost nothing is known about mTOR pathway 
function in the embryonic heart and no conclusive KO approach of any of the mTORC1 
components has been published before. In our study, breeding of these “floxed” Raptor mice 
with mice carrying the Cre recombinase sequence under the control of the cardiac Nkx2-5 
promoter allowed tissue specific excision of the loxP-flanked Raptor sequence in offspring 
from 7.5 dpc onwards (see Chapter 5.1.2.2, Figure 7).  
6.4.1 Cardiac-specific Raptor ablation causes embryonic lethality 
The conventional KO of both Mtor and Raptor results in embryonic lethality in mice between 
5.5 dpc - 6.5 dpc, shortly after implantation178-180. Thus, we were eager to investigate the 
survival rate of heart-specific Raptor KO mice. The applied breeding strategy is assumed to 
generate 43.75 % WT Raptor mice (Raptor+/+), 37.50 % cardiac-specific heterozygous 
Raptor KOs (cRaptor+/-) and 18.75 % cardiac-specific homozygous Raptor KOs (cRaptor-/-) 
(see Figure 16A and Chapter 5.1.2.2, Figure 7). When we analyzed the genotype distribution 
of alive newborn offspring at birth and of alive 13.5 dpc embryos, we identified Raptor+/+ and 
heterozygous cRaptor+/- but no homozygous cRaptor-/- mice (Figure 16A). Interestingly, 
during preparation of 13.5 dpc litters, dead pups were observed that were estimated to be 
arrested in development at approximately 11.5 dpc and were genotyped as being 
homozygous for the Raptor KO. Consequently, genotype distribution of 10.5 dpc litters was 
investigated. All offspring analyzed were found to be alive and 41.59±8.83 % Raptor+/+, 
35.02±4.93 % cRaptor+/- and 23.39±5.03 % cRaptor-/- embryos were identified (Figure 16A). 
In summary, the homozygous cardiac-specific Raptor KO results in embryonic lethality 
between 10.5 dpc and 11.5 dpc, while all heterozygous cardiac-specific Raptor KO mice are 
born alive with no sign of prenatal lethality.  
6.4.2 Cardiac-specific Raptor ablation results in hypoplastic embryonic hearts 
To investigate the cause of embryonic lethality, morphology of 10.5 dpc cRaptor+/- and 
cRaptor-/- hearts in comparison to 10.5 dpc WT hearts on H&E-stained sections was 
analyzed. At this stage, all cRaptor-/- mice are alive (see Chapter 6.4.1). Hearts of 10.5 dpc 
cRaptor-/- embryos revealed a severe phenotype with thinning of the compact as well as 
underdevelopment of the trabeculated myocardium resulting in hypoplastic hearts (Figure 
16E). In contrast, 10.5 dpc cRaptor+/- hearts did not show any morphological 




Figure 16. Cardiac-restricted Raptor KO mice (cRaptor
-/-
) die in utero. 
A) Genotype distribution of alive offspring at postnatal day 1 (P1), embryonic day 13.5 dpc and embryonic day 10.5 dpc 
compared to the expected genotype distribution demonstrated that cRaptor
-/-
 mice die in utero after 10.5 dpc (n=5 litter for P1, 
n=3 litter for 13.5 dpc, n=10 litter for 10.5 dpc). B) Quantification of total RAPTOR protein levels normalized to α-ACTININ, 
C) S6 phosphorylation at serine 235 and serine 236 normalized to total S6 and D) 4E-BP1 phosphorylation at serine 65 
normalized to total 4E-BP1 revealed significantly reduced mTORC1 activity in 10.5 dpc cRaptor
+/-
 hearts and almost complete 
impairment of mTORC1 activity in 10.5 dpc cRaptor
-/-
 hearts. Statistical significance among groups was assessed by one-way 
ANOVA followed by Bonferroni post-hoc test (**p<0.01, ***p<0.001, §p<0.05 vs. Raptor
+/+












 mice revealed that cardiac-restricted Raptor KO causes developmental delay of the heart indicated by thinning of the 
compact as well as underdevelopment of the trabeculated myocardium resulting in a hypoplastic phenotype, an observation that 
was not present in 10.5 dpc cRaptor
+/-
 hearts (scale bar = 300 µm, AVCu: atrioventricular cushions, CA: common atrium, 
CoM: compact myocardium, CV: common ventricle, EnC: endocardium, EpC: epicardium, TrM: trabeculated myocardium, 







mice revealed significantly decreased phosphorylation of S6 and 4E-BP1 as well as significantly reduced total RAPTOR levels 
in cRaptor
+/-
 hearts and completely undetactable phosphorylation of S6 and 4E-BP1 and RAPTOR protein expression in 
cRaptor
-/-
 hearts.  
6.4.3 Cardiac-specific Raptor ablation blocks mTORC1 activity in embryonic hearts 
To confirm that heart-specific Raptor ablation inhibits mTORC1 activity, western blot 
analyses of 10.5 dpc whole heart protein extracts were performed (Figure 16F). Investigation 
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of total RAPTOR protein levels as well as of the phosphorylation status of the mTORC1 
downstream targets S6 at serine 235 and 236 and 4E-BP1 at serine 65 revealed a significant 
reduction in 10.5 dpc cRaptor+/- hearts and complete absence in 10.5 dpc cRaptor-/- 
hearts (Figure 16F). Quantification of RAPTOR total protein levels normalized to α-ACTININ 
as well as S6 and 4E-BP1 phosphorylation normalized to total S6 and total 4E-BP1, 
respectively, confirmed significant reduction (p<0.05/p<0.01) in 10.5 dpc cRaptor+/- hearts by 
50 % to 65 % and a highly significant reduction (p<0.001) in 10.5 dpc cRaptor-/- hearts by 
92 % to 98 % compared to 10.5 dpc WT Raptor+/+ hearts (Figure 16B-D). Taken together, 
these findings indicate that prenatal cardiac-specific Raptor ablation impairs mTORC1 
activity resulting in hypoplastic hearts and intrauterine lethality. 
6.5 Consequences of pre- and postnatal amino acid restriction on cardiac 
development, growth and function 
Functional annotation analysis of microarray expression data revealed an enrichment of 
genes involved in amino acid homeostasis in neonatal cHccs+/- hearts (see Chapter 6.1, 
Table 18 and Supplementary Table S2-S4). These findings together with the upregulation of 
one of the most important sensors of cellular amino acid availability, MTOR (see Chapter 6.2, 
Figure 8), gave rise to the question if an increased amino acid demand or biosynthesis is 
essential for the embryonic regenerative capacity and the postnatal compensatory growth of 
cHccs+/- hearts. To test this hypothesis and to analyze the role of amino acid homeostasis 
during cardiac development in general, amino acid availability was restricted during 
intrauterine and postnatal growth by feeding mice a low protein diet (LPD) containing only 
8.8 % crude protein (see Chapter 5.1.5). Female and male mice were put on LPD two weeks 
prior to mating. Pregnant dams were kept on LPD during pregnancy and offspring were 
prepared immediately after birth or remained on LPD during lactation and after weaning. In 
parallel, as controls, mice were treated the same way using normal standard protein 
diet (SPD) food containing 22 % crude protein. 
6.5.1 Mice on LPD do not compensate for the reduced protein content by increased 
food intake  
Mice on LPD might compensate for the reduced amino acid availability by increasing their 
ingestion. Therefore, the food intake of non-pregnant and pregnant adult female mice on 
LPD was analyzed in comparison to mice on SPD. The daily food intake of non-pregnant 
5 months old females was measured over a time period of 10 days and normalized to BW. 
While SPD mice ate 0.20±0.014 g food per day and gram BW (4.5±0.327 g per day if not 
normalized to BW), LPD mice ate 0.17±0.008 g food per day and gram BW (3.7±0.234 g per 
day if not normalized to BW) (Figure 17A). The difference was not statistically significant. 
With respect to the amount of crude protein taken up with the food, SPD animals ingested 
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4.4±0.319 mg crude protein per day and gram BW (99±6.99 mg crude protein per day if not 
normalized to BW), while LPD animals ingested 1.5±0.070 mg crude protein per day and 
gram BW (33±2.12 mg crude protein per day if not normalized to BW) (Figure 17A). To 
measure the food intake during pregnancy, the daily ingestion of 5 months old pregnant mice 
on LPD in comparison to SPD was analyzed from 13.5 dpc until the end of pregnancy. While 
pregnant SPD mice ate 0.13±0.003 g food per day and gram BW (4.5±0.238 g per day if not 
normalized to BW), pregnant LPD mice ate 0.12±0.013 g food per day and gram 
BW (4.4±0.280 g per day if not normalized to BW) (Figure 17B). The difference was not 
statistically significant. Regarding the uptake of crude protein, pregnant SPD mice ingested 
2.9±0.064 mg crude protein per day and gram BW (99±5.23 mg crude protein per day if not 
normalized to BW), while pregnant LPD mice ingested 1.1±0.115 mg crude protein per day 
and gram BW (39±2.46 mg crude protein per day if not normalized to BW) (Figure 17B). In 
summary, these results indicate that LPD animals do not compensate for the reduced amino 
acid availability in the food by increasing their ingestion, suggesting that they are indeed 
exposed to amino acid restriction. 
 
Figure 17. Food intake of non-pregnant and pregnant adult females on SPD and LPD does not differ. 
A) The daily food intake of non-pregnant 5 months old female mice on SPD and LPD was measured over a time period of 10 
days and normalized to body weight (BW). No significant differences between the diet groups were observed. B) The daily food 
intake of 5 months old pregnant mice on SPD and LPD was measured from 13.5 dpc until the end of pregnancy. No significant 
differences between the treatment groups were observed. Statistical significance among groups was assessed using unpaired 
2-tailed Student t-tests. Numbers above the bars correspond to the average amount of crude protein that was taken up per day 
normalized to BW. Note that LPD animals took up less crude protein than mice on SPD. For A)+B): n=3 per group. 
6.5.2 Prenatal amino acid restriction neither affects litter size nor genotype 
distribution 
Given that we hypothesized that amino acid availability might be critical for embryonic heart 
regeneration and compensatory growth in cHccs+/- females, we investigated if amino acid 
restriction during pregnancy induces prenatal lethality. For this purpose, we compared litter 
size as well as genotype distribution within SPD and LPD litters (Figure 18). Pregnant dams 
fed SPD gave birth to 5.1±0.46 offspring per litter, while litter size of LPD fed dams was 
4.9±0.55 (Figure 18A). The difference was not statistically significant. Besides, the applied 
breeding strategy theoretically generates Hccs+/Y control males, Hccs+/+ control females and 
cHccs+/- females to equal parts (33.33 %, Figure 18B and see Chapter 5.1.2.1, Figure 6). In 
SPD litters, 34.88±9.16 % control males, 26.79±6.81 % control females, and 38.33±10.48 % 
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cHccs+/- were identified at P1 (Figure 18B). LPD litters split up in 37.29±7.02 % control 
males, 27.76±6.66 % control females, and 34.95±10.17 % cHccs+/- mice (Figure 18B). 
Genotype distribution within SPD as well as LPD fed litters compared to the expected 
genotype distribution was not significantly different as determined with chi-square 
test (Figure 18B). In line, 2-tailed Student t-tests comparing genotype frequency of control 
males and females as well as of cHccs+/- mice, respectively, between SPD and LPD litters 
resulted in equal distribution independent of expected frequencies (Figure 18B). In 
conclusion, amino acid restriction during pregnancy does not cause general or genotype-
specific embryonic lethality. 
 
Figure 18. Intrauterine amino acid restriction neither affects litter size nor genotype distribution. 
A) Average litter size of dams receiving SPD or LPD food does not differ. Statistical significance among groups was assessed 
using unpaired 2-tailed Student t-tests. B) Genotype distribution within litters from SPD and LPD female mice was not 
significantly different from the expected genotype frequencies. Statistical significance between the groups and the expected 
genotype distribution was assessed using chi-square test. Statistical significance comparing the frequencies of all three 
genotypes, respectively, between SPD and LPD litters independent of expected frequencies was assessed by unpaired 2-tailed 
Student t-tests. For A)+B): n=10 litters for both diet groups. 
6.5.3 Consequences of prenatal amino acid restriction for neonatal hearts 
6.5.3.1 Prenatal amino acid restriction does not change cardiac morphology but 
reduces HW/BW ratio in neonatal cHccs+/- mice  
To determine the effect of amino acid restriction during pregnancy on cardiac development 
and growth, H&E-stained longitudinal heart sections from neonatal SPD and LPD P1 
offspring were analyzed. No major histological, structural or pathological abnormalities (e.g. 
thinning of the LV wall or ventricular/atrial septum defects) were observed between the 
genotypes or the diet groups (Figure 19A). In addition, BW and HW were measured and the 
HW/BW ratio was determined (Figure 19B+C). BW in newborn mice upon intrauterine amino 
acid restriction was not significantly different between the genotypes or the diet 
groups (1.44±0.03 g for SPD Hccs+/+, 1.42±0.02 g for SPD cHccs+/-, 1.44±0.03 g for LPD 
Hccs+/+, 1.44±0.04 g for LPD cHccs+/-) (Figure 19B). Furthermore, no significant differences 
in HW were observed between all four groups (7.68±0.26 g for SPD Hccs+/+, 7.48±0.25 g for 
SPD cHccs+/-, 8.24±0.16 g for LPD Hccs+/+, 7.52±0.27 g for LPD cHccs+/-) (Figure 19C). 
However, LPD Hccs+/+ controls demonstrate a clear trend toward increased HW compared to 
SPD Hccs+/+ controls (Figure 19C). HW/BW ratio in Hccs+/+ and cHccs+/- LPD neonates was 
unchanged compared to their corresponding SPD control groups (5.33±0.15 mg/g for SPD 
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Hccs+/+, 5.25±0.13 mg/g for SPD cHccs+/-, 5.77±0.19 mg/g for LPD Hccs+/+, 5.23±0.10 mg/g 
for LPD cHccs+/-) (Figure 19D). However, interestingly, exposure to LPD during gestation 
results in a trend toward increased HW/BW ratio in LPD Hccs+/+ controls compared to SPD 
Hccs+/+ mice (probably due to the increase in HW), which results in a significant difference in 
HW/BW ratio between LPD cHccs+/- females and LPD Hccs+/+ controls by 
10 % (p<0.05) (Figure 19D). Taken together, even though cardiac morphology and LV 
dimensions at birth were not affected by prenatal LPD, the HW/BW ratio data indicate that 
restriction of intrauterine amino acid availability causes an increase in HW/BW ratio in 
Hccs+/+ controls, which is not obvious in the cHccs+/- neonates. Assuming that the increase in 
HW and HW/BW ratio in Hccs+/+ controls represents the normal situation upon prenatal 
amino acid restriction, these data suggest growth inhibition by prenatal LPD exposure in P1 
cHccs+/- hearts. 
 
Figure 19. Prenatal LPD exposure does not change cardiac morphology of neonatal hearts but reduces HW/BW ratio in 
cHccs
+/-
 newborns compared to Hccs
+/+
 controls. 
A) Longitudinal H&E-stained sections of neonatal control and cHccs
+/-
 hearts after intrauterine amino acid restriction revealed no 
histological, structural or pathological abnormalities compared to hearts of neonatal SPD offspring (scale bar = 1 mm, Ao: aorta, 
IVS: interventricular septum, LA: left atrium, LV: left ventricle, RA: right atrium, RV: right ventricle). B) No significant differences 
in body weight (BW) were observed between the genotypes and the diet groups at birth. C) No significant differences in heart 
weight (HW) were observed between diet groups at birth. Neonatal cHccs
+/-
 hearts on LPD demonstrated a trend of reduction in 
weight compared to LPD Hccs
+/+
 hearts, which did not reach statistical significance. D) Significant reduction of HW to 
BW (HW/BW) ratio in cHccs
+/-
 females compared to controls on LPD but not SPD. For B)-D): Statistical significance among 







, n=15 for LPD Hccs
+/+
). 
6.5.3.2 Prenatal amino acid restriction increases cardiomyocyte CSA but does not 
affect proliferation rates in neonatal hearts 
Given that intrauterine amino acid restriction results in slightly increased HW and HW/BW 
ratio in neonatal Hccs+/+ controls but not in cHccs+/- newborns, we speculated that this 
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discrepancy might be mediated by either different cardiomyocyte size or different 
cardiomyocyte number or a combination of both. Previous studies from our lab already 
assessed the proliferation rates in LV myocardium of female control (41.75±6.01 %) and 
cHccs+/- (41.33±11.41 %) neonatal hearts under SPD conditions by KI67 staining and 
revealed no significant difference between the genotypes (unpublished data). Here, 
proliferation rates in the LV myocardium of neonatal mice exposed to prenatal amino acid 
restriction were also similar in Hccs+/+ control (47.27±2.08 %) and cHccs+/- 
hearts (48.41±1.19 %) (Figure 20C), as assessed by KI67 staining on longitudinal heart 
sections (Figure 20A). Moreover, the percentage of KI67-positive cells in neonatal LPD 
hearts (Figure 20C) closely matches the values determined in neonatal SPD hearts in 
previous studies (unpublished data). Thus, prenatal amino acid restriction does not impair 
the proliferative potential of neonatal hearts in general and of neonatal cHccs+/- hearts in 
particular. To investigate if cell size was affected by prenatal amino acid restriction, 
cardiomyocyte CSA in the LV myocardium of neonatal hearts after SPD and LPD 
pregnancies was measured (Figure 20B). Surprisingly, cardiomyocyte CSA of neonatal LPD 
cHccs+/- hearts (54.76±2.18 µm2) was significantly increased compared to SPD cHccs+/- 
hearts (36.71±3.73 µm2) (p<0.01) (Figure 20D). The same trend was observed for neonatal 
LPD Hccs+/+ control hearts (37.30±5.15 µm2 for SPD Hccs+/+, 48.28±2.18 µm2 for LPD 
Hccs+/+), even though the difference missed statistical significance (Figure 20D). Besides, 
neonatal LPD cHccs+/- cardiomyocytes CSA appeared slightly larger than neonatal LPD 
Hccs+/+ cardiac cells (Figure 20D). Taken together, these data indicate that prenatal amino 
acid restriction neither reduced proliferation rates nor cardiomyocyte CSA in neonatal 
cHccs+/- hearts. Hence, the reason for the reduced HW/BW ratio in neonatal LPD cHccs+/- 
mice is left unknown at that point. Strikingly, increased cardiomyocyte CSA (Figure 20D) 
might be responsible for the increased HW in neonatal LPD Hccs+/+ controls (see Chapter 
6.5.3.1, Figure 19C). In contrasts, HW in LPD cHccs+/- neonates was unchanged (see 
Chapter 6.5.3.1, Figure 19C) despite a significantly increased cell size (Figure 20D). In 










 neonatal hearts. 
A) Immunofluorescence images of KI67-labeled nuclei (red) within the left ventricular (LV) myocardium of neonatal hearts. 
Nuclei were stained in blue with DAPI. Cycling cardiac cells exhibit colocalization of DAPI and KI67 and hence appear 
pink (arrowheads) (scale bar = 50 μm). B) Fluorescence images of cross-sectioned cardiomyocytes within the LV myocardium 
of neonatal hearts exposed to SPD or LPD intrauterine conditions. Cardiomyocyte membranes were stained in red with wheat 
germ agglutinin (WGA) and nuclei in blue with TO-PRO®-3. Only cardiomyocytes that matched the defined measurement 
criteria were analyzed (arrowheads) (confocal microscopy, scale bar = 25 μm). C) Quantification of KI67-positive nuclei revealed 




 animals, indicating that prenatal 
amino acid restriction does not affect cardiac proliferation in neonatal mice. Statistical significance among groups was assessed 
using unpaired 2-tailed Student t-tests (n=8 for LPD Hccs
+/+
, n=7 for LPD cHccs
+/-
). D) Cardiomyocyte cross sectional area 
(CSA) in neonatal cHccs
+/-
 mice exposed to prenatal amino acid restriction was significantly larger compared to neonatal SPD 
cHccs
+/-
 cardiomyocytes. The same trend was observed for LPD Hccs
+/+
 hearts, but missed statistical significance. Statistical 
significance among groups was assessed by one-way ANOVA followed by Bonferroni post-hoc test (##p<0.01 vs. SPD cHccs
+/-
, 




, n=7 for LPD Hccs
+/+
, n=8 for LPD cHccs
+/-
).  
6.5.4 Consequences of prenatal amino acid restriction for embryonic 13.5 dpc hearts 
The lower HW/BW ratio in neonatal LPD cHccs+/- animals (see Chapter 6.5.3.1, Figure 19D) 
was not attributable to a decrease in cardiomyocyte size or proliferation rate at birth. Thus, it 
was postulated that the reduction in heart size might be due to a decrease in cell number, 
caused by cellular events during embryogenesis when amino acids are restricted. To 
investigate the effect of amino acid restriction on compensatory growth of 13.5 dpc 
embryonic cHccs+/- hearts as well as on Hccs+/+ controls, overall cardiac morphology as well 
as apoptosis and proliferation rates within the embryonic ventricular myocardium were 
analyzed. Importantly, genes involved in amino acid homeostasis were found to be enriched 
in 13.5 dpc embryonic cHccs+/- hearts (unpublished data), which provides further evidence 
that an increased amino acid availability might thus be essential to allow normal cardiac 
development in cHccs+/- mice. Moreover, cardiomyocyte CSA in LPD neonates was found to 
be enhanced (see Chapter 6.5.3.2, Figure 20D), while HW was not significantly different (see 
Chapter 6.5.3.1, Figure 19C). These observations provide further support for a cell number 
defect in neonatal LPD hearts.  
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6.5.4.1 Prenatal amino acid restriction does not affect mTOR pathway activity and 
does not change cardiac morphology in 13.5 dpc embryonic hearts 
mTOR pathway activity is highly sensitive to amino acid availability. The pathway is activated 
if amino acids are abundant and inactivated if they are restricted under conditions of nutrient 
starvation144,145. To analyze mTORC1 activity in our LPD model, western blot analyses were 
performed with whole heart protein extracts from 13.5 dpc embryos under both normal 
conditions and prenatal amino acid restriction (Figure 21A). The phosphorylation status of 
the mTORC1 upstream and mTORC2 downstream target AKT at serine 473 and of the 
mTORC1 downstream target S6 at serine 240 and 244 was investigated (Figure 21A). After 
quantification and normalization to total protein levels, the relative phosphorylation was 
quantified and depicted as fold change in relation to the SPD Hccs+/+ control group (Figure 
21B+C). To further monitor mTOR activity and to additionally evaluate whether LPD induces 
autophagy, total protein levels of p62 (an important indicator for autophagy that is normally 
inhibited by mTOR pathway activity223,224), were quantified and normalized to GAPDH protein 
levels (Figure 21D). No significant differences were apparent in any of the analyzed 
upstream or downstream mTOR pathway mediators when comparing all four groups (Figure 
21B-D), indicating that mTOR pathway activity and autophagy in embryonic hearts are not 
affected by prenatal LPD treatment. 
Furthermore, cardiac morphology was analyzed in H&E-stained longitudinal heart sections of 
13.5 dpc Hccs+/+ and cHccs+/- embryos upon intrauterine SPD or LPD exposure (Figure 21E). 
The extent of trabeculation and ventricular wall thickness was appropriate for LPD embryonic 
hearts compared to SPD embryos (Figure 21E). The size and thickness of the atrial 
myocardium was also inconspicuous (Figure 21E). Atrioventricular cushions (AVCu), which 
can be seen as two thickenings in the lumen of the atrio-ventricular canal and later form the 
valve leaflets (see Chapter 3.3.1, Figure 3), developed adequately upon amino acid 
restriction, providing no indication of structural cardiac conditions (Figure 21E). In summary, 
due to the normal cardiac phenotype in LPD treated embryos, prenatal amino acid restriction 
does not appear to impair early cardiac development and growth in neither Hccs+/+ nor 




Figure 21. LPD 13.5 dpc hearts demonstrate normal mTOR pathway activity and resemble SPD 13.5 dpc hearts in 
morphology. 
A) Western blots of whole heart protein extracts from 13.5 dpc embryos comparing the phosphorylation status of AKT and S6 as 




 mice upon intrauterine SPD or LPD exposure. B) Quantification 
of AKT phosphorylation at serine 473 normalized to total AKT, C) S6 phosphorylation at serine 240 and 244 normalized to total 
S6 and D) p62 protein levels normalized to GAPDH revealed no significant differences between the genotypes or the diet 
groups, indicating that prenatal amino acid restriction neither affects mTOR pathway activity nor the regulation of autophagy in 
13.5 dpc embryonic hearts (n=6 for SPD Hccs
+/+
, n=6/7 for SPD cHccs
+/-
, n=8 LPD Hccs
+/+
, n=7 for LPD cHccs
+/-
). Statistical 
significance among groups was assessed by one-way ANOVA followed by Bonferroni post-hoc test. E) Longitudinal H&E-




 mice were compared with those exposed to 
intrauterine amino acid restriction. No major morphological changes in overall organ size, atria and ventricular wall thickness, 
ventricle trabeculation or atrioventricular cushions (AVCu) were observed (scale bar = 600 µM, IVS: interventricular septum, LA: 
left atrium, LV: left ventricle, RA: right atrium, RV: right ventricle). 
6.5.4.2 Prenatal amino acid restriction neither affects apoptosis nor proliferation 
rates but does alter the expression of cell cycle regulating genes in 13.5 dpc 
embryonic hearts 
It was speculated that the reduced HW/BW ratio in neonatal protein restricted cHccs+/- mice 
might be caused by a lower cardiomyocyte number due to a reduced proliferative capacity or 
increased apoptosis rates of cardiomyocytes (and potentially other cell types) during 
intrauterine development. This hypothesis is in line with studies in newborn LPD rats, which 
revealed a significantly reduced cardiomyocyte number compared to SPD conditions23. Thus, 
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in the study on hand proliferation in the 13.5 dpc ventricular myocardium was analyzed by 
immunostaining for histone H3 phosphorylation at serine 10 (p-HH3) (Figure 22A), which 
marks mitotic cells218. Thereby, 13.5 dpc heart sections of Hccs+/+ and cHccs+/- mice upon 
intrauterine SPD and LPD exposure were used. At this developmental stage, 
hyperproliferation of healthy cells is most prominent while at the same time sufficient Hccs-
deficient cells can be detected192. This allows differentiated analyses of proliferation rates in 
healthy and Hccs-deficient cells, respectively.  
As described (see Chapter 3.4), under SPD conditions, the functional loss of 50 % cardiac 
cells in cHccs+/- hearts at mid-gestation (10.5 dpc) is compensated via hyperproliferation of 
the remaining healthy cardiomyocyte population during the second half of gestation192. Thus, 
for 13.5 dpc cHccs+/- hearts, the proliferation rate was investigated separately for each of the 
two cell populations within the ventricular myocardium (Hccs-positive and Hccs-negative) by 
co-staining for cytochrome (CYT) c (Figure 22A). In 13.5 dpc embryonic Hccs+/+ control 
hearts, all cardiac cells are normal and hence appear CYT c-positive as indicated by the 
green mitochondrial staining (Figure 22A). In contrast, in 13.5 dpc embryonic cHccs+/- hearts, 
approximately 30 % cardiac cells are Hccs-deficient, thus appear negative for CYT c 
staining, while 70 % cardiac cells are normal and hence appear positive for CYT c192 (Figure 
22A). Quantification of p-HH3-positive cells within the ventricular myocardium revealed that 
the compensatory hyperproliferation of Hccs-positive cells in 13.5 dpc embryonic cHccs+/- 
hearts was still detectable in the corresponding LPD animals (1.25±0.11 % for SPD healthy 
cells, 0.41±0.05 % for SPD Hccs-deficient cells, 1.52±0.16 % for LPD healthy cells, 
0.36±0.06 % for LPD Hccs-deficient cells) (p<0.01 for all comparisons within one treatment 
group) (Figure 22B). Importantly, not only is increased proliferation of healthy cells 
maintained upon intrauterine LPD exposure but also are the absolute values not different 
between both conditions (Figure 22B). Besides, the decreased proliferative capacity of Hccs-
deficient cells was also not affected by prenatal amino acid restriction (Figure 22B). Thus, the 
cell populations contributing to the growth of the embryonic cHccs+/- heart are not changed 
after exposure to intrauterine amino acid restriction. Proliferation rates in 13.5 dpc LPD 
Hccs+/+ control hearts also remain unchanged compared to SPD (0.75±0.06 % for SPD 
Hccs+/+, 0.77±0.08 % for LPD Hccs+/+) (Figure 22B). In summary, no major changes in 
proliferation at 13.5 dpc can be put forward to explain the reduced HW/BW ratio in neonatal 
cHccs+/- hearts. Furthermore, our data indicate that LPD does not affect proliferation rates in 
the embryonic heart, not even if compensatory hyperproliferation is demanded to restore 
tissue homeostasis.  
Even though no differences in proliferation rates were detected in 13.5 dpc embryonic 
hearts (Figure 22B), intrauterine amino acid restriction might cause changes in the 
expression pattern of cell cycle regulating genes (e.g. reduced expression of cell cycle 
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promoting cyclins or increased expression of cell cycle inhibitors), which do not necessarily 
manifest in proliferation differences at that stage. Hence, the expression of genes involved in 
cell cycle regulation was investigated by qPCR in 13.5 dpc embryonic hearts. Progression 
through the different cell cycle phases is tightly controlled by the internal signaling system, 
which consists of cell cycle promoting cyclins (CCNs), their associated kinases (CDKs) and 
CDK inhibitors228-230. The expression of three cell cycle activators (Ccnb1 (cyclin B1), 
Ccnd1 (cyclin D1) and Ccng1 (cyclin G1)) as well as of two cell cycle 
inhibitors (Cdkn1a (p21) and Cdkn1b (p27)) was analyzed. CCNB1 is involved in the entry to 
and transition through M phase of the cell cycle, while D-type cyclins (e.g. CCND1) drive 
G1/S phase transition231. In contrast, CCNG1 has been linked to both positive and negative 
regulation of cell cycle progression and growth232 and a putative role in G2/M checkpoint 
control was suggested233. Expression of Ccng1 is furthermore induced by DNA damage in a 
p53-dependent manner234. The analyzed CDK inhibitors CDKN1A and CDKN1B cause cell 
cycle arrest in the G1 phase235-238. Importantly, CDKN1A and CDKN1B mRNA and protein 
levels increase in response to amino acid deprivation239. In this study, Ccnb1 expression was 
not significantly different between the treatment groups or the genotypes (Figure 22C). In 
Hccs+/+ hearts the mRNA level of Ccnd1 was significantly decreased when animals undergo 
amino acid restriction (p<0.001) (Figure 22C). In addition, for SPD but not LPD animals, 
there was a slight yet significant decrease in Ccnd1 expression in cHccs+/- hearts when 
compared to healthy controls (p<0.05) (Figure 22C). Ccng1 expression was upregulated by 
2.49±0.22-fold in embryonic cHccs+/- hearts and by 1.77±0.64-fold in embryonic Hccs+/+ 
control hearts on LPD compared to SPD (p<0.01) (Figure 22C). No significant differences 
between the genotypes within the treatment groups were observed for Ccng1 (Figure 22C). 
Interestingly, CCNG1 fulfills cell cycle inhibitory functions in the heart, where it is involved in 
prenatal cardiomyocyte cell cycle arrest and binucleation240. Hence, it behaves differently 
compared to the D-type cyclins, such as CCND1, but similar to the cell cycle inhibitor 
CDKN1B. The expression of the CDK inhibitor Cdkn1b remained unchanged between the 
genotypes (Figure 22C). However, both embryonic cHccs+/- (p<0.05) and Hccs+/+ 
hearts (p<0.01) demonstrated increased Cdkn1b expression when compared to their 
respective SPD control groups (Figure 22C). This suggests that whilst Cdkn1b expression 
was not affected by Hccs-deficiency, prenatal amino acid restriction resulted in an increased 
Cdkn1b expression in the embryonic 13.5 dpc hearts. Focusing on the CDK inhibitor 
CDKN1A in SPD 13.5 dpc embryonic hearts, its expression was not affected by prenatal 
amino acid restriction, but does exhibit an increased expression during embryonic heart 
regeneration in cHccs+/- embryos (p<0.001) (Figure 22C). This increase was also apparent in 
the microarray results from previous studies (unpublished data) and might be associated with 




Figure 22. Prenatal amino acid restriction neither induces apoptosis nor reduces proliferation but does affect the 
expression of cell cycle regulating genes in 13.5 dpc embryonic hearts. 
A) Immunofluorescence images of phospho-histone H3 protein (p-HH3)-labeled nuclei (red) within the ventricular myocardium 




 hearts exposed to SPD or LPD intrauterine conditions. Co-staining with cytochrome (CYT) c 
allows identification of healthy cells within the cHccs
+/-
 myocardium by green mitochondrial staining. Hccs-deficient cells appear 
negative for CYT c staining. Nuclei were stained in blue with TO-PRO®-3. Cycling cardiac cells exhibit colocalization of TO-
PRO®-3 and p-HH3 (arrowheads) (confocal microscopy, scale bar = 75 μm). B) Quantification of p-HH3-positive nuclei revealed 
unchanged cell cycle activity within the ventricular myocardium of embryonic SPD and LPD hearts. Note that previously 
reported hyperproliferation of healthy cells within the embryonic SPD cHccs
+/-
 myocardium persisted in LPD embryonic hearts, 
indicating that prenatal amino acid restriction neither affects proliferation rates of distinct cell populations within the embryonic 
cHccs
+/-
 myocardium nor alters cardiac proliferation in Hccs
+/+
 controls. Statistical significance among groups was assessed 
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using Kruskal-Wallis one-way analysis of variance followed by Mann-Whitney post-hoc test (**p<0.01, n=7 for SPD Hccs
+/+
, n=6 
for SPD and LPD cHccs
+/-
, n=5 for LPD Hccs
+/+
). C) Relative expression of the cell cycle regulators Ccnb1, d1 and g1 and of the 
cell cycle inhibitors Cdkn1a and Cdkn1b in embryonic 13.5 dpc hearts upon intrauterine SPD or LPD exposure were determined 
by qPCR (n=6 or 7 for SPD Hccs
+/+
, n=7 for SPD cHccs
+/-
, n=8 LPD Hccs
+/+
, n=6 for LPD cHccs
+/-
). D) Fluorescence terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) stainings within the ventricular myocardium of SPD and LPD 
13.5 dpc hearts. Nuclei were stained in blue with DAPI. Apoptotic cells were labeled with TUNEL in green. Cells in apoptosis 
exhibit colocalization of DAPI and TUNEL (arrowheads) (scale bar = 100 µM). E) Quantification of TUNEL-positive nuclei 
revealed no significant differences in programmed cell death between genotypes and treatment groups (n=6 per group). For 
C)+E): Statistical significance among groups was assessed by one-way ANOVA followed by Bonferroni post-hoc test (*p<0.05, 
***p<0.001, §p<0.05 vs. SPD Hccs
+/+
, §§p<0.01 vs. SPD Hccs
+/+
, §§§p<0.001 vs. SPD Hccs
+/+
, #p<0.05 vs. SPD cHccs
+/-
). 
(Ccnb1: cyclin B1 gene, Ccnd1: cyclin D1 gene, Ccng1: cyclin G1 gene, Cdkn1a: cyclin-dependent kinase inhibitor 1A gene, 
Cdkn1b: cyclin-dependent kinase inhibitor 1B gene) 
Various cyclins and cell cycle inhibitors within embryonic cHccs+/- or Hccs+/+ control hearts 
did not show consistent or homogenous expression patterns (Figure 22C), which only allows 
limited conclusions about cell cycle regulation in impaired or normal cardiac growth after 
exposure to maternal amino acid restriction. Thus, the initial hypothesis (prenatal amino acid 
restriction reduces expression of cell cycle promoting cyclins and increases expression of 
cell cycle inhibitors thereby potentially impairing cardiac proliferation) could certainly not be 
confirmed. This is in accordance with unchanged proliferation rates in 13.5 dpc embryonic 
hearts (Figure 22B). Taken together, downregulation of CCND1 as well as upregulation of 
CCNG1 and CDKN1B could point toward cell cycle delay or inhibition in 13.5 dpc hearts. 
Considering the complexity of cell cycle regulation and the multitude of control mechanisms, 
the functional significance of these differentially regulated genes remains yet to be 
determined.  
Given that 13.5 dpc cHccs+/- hearts are still composed of approximately 30 % Hccs-deficient 
cells192, increased amino acid availability and protein homeostasis might be essential to 
prevent those cells from undergoing apoptosis. Thus, reduced HW/BW ratio in neonatal LPD 
cHccs+/- hearts might result from increased apoptosis rates in 13.5 dpc embryonic hearts. 
Cells undergoing apoptosis were scored by DNA fragmentation evident as positive TUNEL 
staining (Figure 22D). Quantification of TUNEL-positive cells within the ventricular 
myocardium of embryonic 13.5 dpc hearts revealed no significant differences between the 
genotypes or the treatment groups (0.36±0.05 % for SPD Hccs+/+, 0.29±0.10 % for SPD 
cHccs+/-, 0.24±0.03 % for LPD Hccs+/+, 0.17±0.03 % for LPD cHccs+/-) (Figure 22E). 
Surprisingly, rather a slight trend toward reduced apoptosis was suggested upon 
LPD (Figure 22E). Hence, we excluded the possibility that increased apoptosis causes 
reduced cell number in 13.5 dpc cHccs+/- LPD hearts and thus explains the reduced HW/BW 
ratio in neonatal cHccs+/- hearts.  
In summary, analyses of embryonic 13.5 dpc cHccs+/- hearts upon prenatal amino acid 
restriction did not confirm our hypothesis regarding cell number reduction. Neither decreased 
proliferation nor increased apoptosis rates were revealed. Thus, the underlying molecular 
and cellular mechanisms responsible for the reduced HW/BW ratio in neonatal cHccs+/- 
hearts upon intrauterine amino acid restriction remain to be investigated and may be found in 
RESULTS 
91 
later fetal stages. Generally, our data demonstrate for the first time that intrauterine LPD 
does not impair proliferation or induce apoptosis in 13.5 dpc hearts. Hence, the embryonic 
murine heart appears to be surprisingly resistant to intrauterine amino acid restriction. These 
findings suggest that the fetal stage might be the more vulnerable phase during 
development, which might have major implications in the context of IUGR and developmental 
programming. 
6.5.5 Consequences of combined pre- and postnatal amino acid restriction for adult 
hearts  
In well-established IUGR models (see Chapter 3.2.2), the IUGR insult is normally released at 
birth, which for instance causes normalization of heart size until weaning in LPD rats25. 
However, postnatal catch-up growth is known to additionally promote the manifestation of 
adulthood disease following IUGR and developmental programming15,16. In this context, we 
aimed at investigating in which way postnatal conditions that resemble that of in utero affect 
cardiac growth and function in adulthood. Furthermore, we were eager to analyze if cHccs+/- 
hearts are particularly affected by postnatal amino acid restriction when compared to controls 
and if the reduced HW/BW ratio seen in newborn LPD cHccs+/- mice can be normalized 
during adulthood. To address these questions, long-term LPD studies were performed and 
offspring exposed to intrauterine LPD were postnatally kept on LPD and analyzed at the age 
of 11 weeks. 
6.5.5.1 Pre- and postnatal amino acid restriction does neither affect mTOR pathway 
activity nor cardiac morphology and size of adult hearts  
Analyses of the activity status of the mTOR signaling cascade in embryonic 13.5 dpc hearts 
revealed no effect of prenatal amino acid restriction (see Chapter 6.5.4.1, Figure 21A-D). 
However, prolonged amino acid restriction during pre- and postnatal development might 
impact on mTOR pathway activity in adulthood. To analyze this hypothesis, western blot 
analyses were performed with heart protein extracts from 11 week old adult animals after 
both normal and pre- and postnatal SPD or LPD exposure (Figure 23A). To this extend, the 
phosphorylation status of the mTORC1 upstream and mTORC2 downstream target AKT at 
serine 473 and of the mTORC1 downstream target S6 at serine 235, 236, 240 and 244 was 
investigated (Figure 23A-D). Additionally, protein levels of the autophagy marker p62 were 
quantified and normalized to GAPDH protein levels (Figure 23A+E). No significant 
differences were apparent in any of the analyzed upstream or downstream mTOR pathway 
components when comparing all four groups (Figure 23B-E), indicating that mTOR pathway 




Figure 23. Pre- and postnatal amino acid restriction neither alters mTOR pathway activity nor causes overall growth 
retardation or heart size reduction in 11 week old adult mice. 
A) Western blots of heart protein extracts from adult mice comparing the phosphorylation status of AKT and S6 as well as the 




 animals after pre- and postnatal SPD or LPD exposure. B) Quantification 
of AKT phosphorylation at serine 473 normalized to total Akt, C)+D) S6 phosphorylation at serine 235, 236, 240 and 244 
normalized to total S6 and E) p62 protein levels normalized to GAPDH revealed no significant differences between the 
genotypes or the diet groups, indicating that pre- and postnatal amino acid restriction does not affect mTOR pathway activity or 





were compared with those exposed to pre- and postnatal amino acid restriction. No major morphological changes within the left 





hearts (scale bar = 1 mm). G) No significant differences in body weight (BW) between the genotypes or the treatment groups 
were determined in adult mice. H) Heart weight (HW) was not affected by pre- and postnatal amino acid restriction. I) Analysis 
of the HW to BW (HW/BW) ratio in adult animals revealed no significant differences between the treatment groups or the 
genotypes. Note that the reduced HW/BW ratio observed in neonatal LPD cHccs
+/-
 mice was no longer obvious in adult cHccs
+/-
 






, n=13 for LPD cHccs
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. For B)-E)+G)-I): Statistical significance among groups was assessed 
by one-way ANOVA followed by Bonferroni post-hoc test. 
As described, postnatal cardiac growth in mammals is mainly achieved by cardiomyocyte 
hypertrophy (see Chapter 3.3.3), a process that requires sufficient protein synthesis and 
mTOR pathway activity. It is therefore possible that amino acid restriction might negatively 
impact on protein biosynthesis, consequently impairing postnatal heart growth. H&E-stained 
heart cross-sections from adult SPD and LPD mice revealed no major histological, structural 
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or pathological abnormalities between the genotypes or the treatment groups (Figure 23F). 
Besides, BW, HW as well as HW/BW ratio in adult SPD and LPD mice were 
measured (Figure 23G-I). Pre- and postnatal LPD neither affects BW (22.29±0.38 g for SPD 
Hccs+/+, 20.70±0.33 g for SPD cHccs+/-, 19.85±0.54 g for LPD Hccs+/+, 19.53±0.61 g for LPD 
cHccs+/-), or HW (111.20±2.17 mg for SPD Hccs+/+, 106.12±3.54 mg for SPD cHccs+/-, 
104.64±4.00 mg for LPD Hccs+/+, 100.54±5.07 mg for LPD cHccs+/-) nor the HW/BW 
ratio (4.99±0.09 mg/g for SPD Hccs+/+, 5.13±0.15 mg/g for SPD cHccs+/-, 5.32±0.30 mg/g for 
LPD Hccs+/+, 5.20±0.30 mg/g for LPD cHccs+/-) in adulthood (Figure 23G-I). This indicates 
that amino acid restriction does not affect postnatal heart growth on the organ level. 
Furthermore, the reduced HW/BW ratio observed in neonatal LPD cHccs+/- mice (see 
Chapter 6.5.3.1, Figure 19D) was no longer obvious in adult LPD animals (Figure 23I). Thus, 
postnatal compensatory growth of cHccs+/- hearts is not primarily dependent on amino acid 
availability. 
6.5.5.2 Pre- and postnatal amino acid restriction reduces cardiomyocyte size 
without inducing fibrosis in adult hearts  
Although long-term LPD does not seem to affect cardiac organ size in adulthood, we were 
still interested whether it has an impact on the cellular level or changes tissue composition. 
Cardiomyocytes in neonatal hearts upon intrauterine amino acid restriction demonstrated 
increased CSA compared to SPD conditions (see Chapter 6.5.3.2, Figure 20D). To evaluate 
whether this increased cell size is maintained until adulthood, it was investigated how 
cardiomyocyte size develops during postnatal life if amino acid restriction persists. Therefore, 
cardiomyocyte CSA was measured in the LV myocardium of adult hearts after pre- and 
postnatal SPD and LPD exposure on WGA-stained heart sections (Figure 24A). Interestingly, 
cardiomyocytes of adult LPD hearts were found to be significantly smaller (213.9±6.50 µm2 
for LPD Hccs+/+ (p<0.01), 249.2±18.96 µm2 for LPD cHccs+/- (p<0.05)) compared to their 
corresponding SPD counterparts (286.0±10.68 µm2 for SPD Hccs+/+, 303.8±9.61 µm2 for 
SPD cHccs+/-) (Figure 24C). However, compensatory postnatal cardiac hypertrophy in 
cHccs+/- females compared to controls, a major hallmark of the heart conditional Hccs KO 
model (see Chapter 3.4), persists after LPD exposure, even though it missed statistical 
significance for both diet groups in this study (Figure 24C). These findings indicate that 
amino acid restriction affects cardiomyocyte size in both genotypes in adulthood but does not 
specifically impair compensatory postnatal hypertrophy in cHccs+/- mice. Importantly, 
however, these findings contradict the HW and cardiac organ size data (see Chapter 6.5.5.1, 




Figure 24. Pre- and postnatal amino acid restriction results in reduced cardiomyocyte size but does not induce 
compensatory fibrosis in 11 week old adult hearts.  
A) Fluorescence images of cross-sectioned cardiomyocytes within the left ventricular (LV) myocardium of hearts from SPD and 
LPD treated adult animals. Cardiomyocyte membranes were stained in orange with wheat germ agglutinin (WGA) and nuclei in 
blue with DAPI. Only cardiomyocytes that matched the defined measurement criteria were analyzed (arrowheads) (scale 
bar = 100 μm). B) Random images of the LV myocardium of Sirius red stained heart cross-sections of adult mice after pre- and 
postnatal SPD or LPD treatment, respectively, demonstrate only minor collagen deposition in all four groups. White arrowheads 
highlight the red appearance of fine threads of interstitial collagen. Black arrowheads highlight perivascular fibrosis, which was 
excluded for quantification (scale bar = 300 µm). C) Average cardiomyocyte cross sectional area (CSA) revealed significantly 
smaller cardiomyocytes in mice exposed to pre- and postnatal amino acid restriction. Note that compensatory cardiomyocyte 
hypertrophy in cHccs
+/-
 compared to Hccs
+/+
 mice persists in adult LPD animals, even though it misses statistical significance. 
Statistical significance among groups was assessed using Kruskal-Wallis one-way analysis of variance followed by Mann-
Whitney post-hoc test (§§ p<0.01 vs. SPD Hccs
+/+
, #p<0.05 vs. SPD cHccs
+/-




 and LPD 
cHccs
+/-
, n=4 for LPD Hccs
+/+
). D) Quantification of fibrotic cardiac tissue within the LV myocardium of SPD and LPD adult mice 
did not reveal differences in collagen deposition in LPD treated hearts, indicating that pre- and postnatal LPD exposure does not 
induce LV interstitial fibrosis in adult mice (n=4 per SPD group, n=6 per LPD group). E) Relative fibronectin 1 (Fn1), 
vimentin (Vim), collagen type I alpha 1/2 and type III alpha 1 (Col1a1, Col1a2, Col3a1), transforming growth factor-β 1 (Tgfβ1) 
and 3 (Tgfβ3b) mRNA levels in adult hearts after pre- and postnatal SPD or LPD exposure were determined using qPCR. No 
differential expression was observed in LPD groups compared to SPD groups or between the genotypes (n=7 for all groups). 
For D)+E): Statistical significance among groups was assessed by one-way ANOVA followed by Bonferroni post-hoc test 
(§p<0.05 vs. SPD Hccs
+/+





It was speculated that an increase in extracellular matrix deposition within the myocardium 
after pre- and postnatal amino acid restriction compensates for the reduced cell size in 
adulthood, thereby resulting in normal HW. The percentage of interstitial fibrosis within the 
LV myocardium of adult mice was investigated by Sirius red staining (Figure 24B). 
Quantification of collagen deposition did not reveal differences between the genotypes and 
no evidence for induction of interstitial fibrosis after pre- and postnatal LPD exposure was 
obvious (1.06±0.10 % for SPD Hccs+/+, 1.52±0.30 % for SPD cHccs+/-, 0.65±0.10 % for LPD 
Hccs+/+, 0.90±0.08 % for LPD cHccs+/-) (Figure 24D). Instead, rather a trend toward reduced 
collagen deposition was demonstrated (Figure 24D). Consequently, accumulation of ECM 
does not account for the normalization of HW in adult LPD hearts to compensate for the 
reduced cardiomyocyte size.  
Even though Sirius red staining is the standard method to detect fibrosis in pathological 
settings, it might not be sensitive enough to assess increased ECM deposition in 
physiological cardiac growth. Hence, cardiac expression of genes that encode for ECM 
components was investigated in adult hearts after pre- and postnatal LPD exposure 
compared to SPD treated animals by qPCR analyses (Figure 24E). These ECM components 
comprised fibronectin 1 (FN1) (a high-molecular weight glycoprotein of the ECM that 
connects cells with collagen fibers), three different types of collagen (COL1A1, COL1A2, 
COL3A1) (the most abundant protein of ECM), two different isoforms of the inflammatory 
mediator transforming growth factor-β (TGFβ1, TGFβ3) as well as vimentin (VIM) (the major 
cytoskeleton component of mesenchymal cells and a marker for fibroblasts) (Figure 24E). 
Cardiac expression of all these genes was not significantly different among the genotypes or 
the different diet groups (Figure 24E), indicating that pre- and postnatal LPD does not 
change the expression of genes involved in ECM composition, which is in line with the 
unchanged percentage of fibrotic tissue (Figure 24D). Hence, the molecular and cellular 
mechanisms that compensate for the reduced cell size and thereby ensure normal HW in 
LPD adult mice remain to be investigated.  
In summary, we revealed that pre- and postnatal LPD exposure reduces cardiomyocyte size 
but does not alter tissue composition with regard to ECM deposition and fibrosis in adult 
hearts. 
 
6.5.5.3 Pre- and postnatal amino acid restriction does not cause cardiac 
dysfunction 
Given that cardiac fibrosis is unaltered in adult hearts upon LPD exposure, pathological 
cardiac remodeling is unlikely. However, investigations on the molecular level might be more 
sensitive than the detection of fibrosis. Thus, to analyze if pre- and postnatal amino acid 
restriction causes molecular signs of cardiac stress in adulthood, qPCR expression analysis 
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of “heart failure marker genes” were performed (Figure 25A) (for gene details see Chapter 
6.3.4.2). Nppb expression was unchanged between the genotypes and the diet 
groups (Figure 25A). Nppa and Myh7 expression were slightly increased in adult cHccs+/- 
SPD hearts compared to SPD controls; even though the difference misses statistical 
significance (Figure 25A). Besides, the expression of Nppa and Myh7 was significantly 
decreased comparing adult cHccs+/- LPD with cHccs+/- SPD hearts (p<0.05) (Figure 25A). 
However, in conclusion, on the molecular level there was no indication for increased cardiac 
stress imposed by LPD conditions, since the expression of these three “heart failure marker 
genes” was not significantly increased after pre- and postnatal amino acid restriction 
compared to SPD. 
Cardiomyocyte CSA was found to be reduced in adult hearts (see Chapter 6.5.5.2, Figure 
24C), while HW was normal (see Chapter 6.5.5.1, Figure 23H), which represents a 
contradiction at that point. To investigate overall cardiac morphology in more detail and to 
measure heart function, echocardiography in adult mice after pre- and postnatal amino acid 
restriction were performed (Figure 25B-D and Supplementary Table S7). Analysis of end-
diastolic LVPW thickness (0.65±0.03 mm for SPD Hccs+/+, 0.69±0.03 mm for SPD cHccs+/-, 
0.74±0.02 mm for LPD Hccs+/+, 0.75±0.05 mm for LPD cHccs+/-) (Figure 25B) as well as of 
end-diastolic LVID (3.96±0.07 mm for SPD Hccs+/+, 4.01±0.09 mm for SPD cHccs+/-, 
3.70±0.06 mm for LPD Hccs+/+, 3.68±0.13 mm for LPD cHccs+/-) (Figure 25C) revealed no 
significant differences between the diet groups and the genotypes, indicating normal overall 
cardiac morphology and LV wall thickness. These findings are in line with the results 
obtained from explanted hearts regarding morphology and HW (see Chapter 6.5.5.1, Figure 
23F+H). Moreover, analysis of the LV contractile parameters FS (31.03±3.23 % for SPD 
Hccs+/+, 27.71±1.90 % for SPD cHccs+/-, 29.38±4.56 % for LPD Hccs+/+, 27.71±4.21 % for 
LPD cHccs+/-) and EF (59.12±4.50 % for SPD Hccs+/+, 53.09±3.51 % for SPD cHccs+/-, 
56.23±7.33 % for LPD Hccs+/+, 53.64±5.31 % for LPD cHccs+/-) did not reveal impaired heart 
function (Figure 25D and Supplementary Table S7). Again, these findings are consistent with 
unchanged deposition of fibrotic tissue (see Chapter 6.5.5.2, Figure 24D) and normal 
expression of genes associated with cardiac stress and heart failure (Figure 25E).  
In summary, pre- and postnatal amino acid restriction neither induces cardiac stress nor 
reduces cardiac function in adulthood under baseline conditions, since no indication for 
pathological responses or remodeling were observed. Furthermore, adult cHccs+/- hearts 
were not found to be specifically affected by pre- and postnatal amino acid restriction with 




Figure 25. Pre- and postnatal amino acid restriction neither induces the expression of genes associated with cardiac 
stress nor alters cardiac function in 11 week old adult LPD mice. 
A) Relative natriuretic peptide type A (Nppb), β-myosin heavy chain 7 (Myh7) and natriuretic peptide type B gene (Nppb) mRNA 
levels in adult hearts after pre- and postnatal SPD or LPD exposure were determined using qPCR. No significant upregulation of 
all three heart failure marker genes was observed in LPD groups compared to SPD groups or between the genotypes (n=7 for 
all groups). B) Echocardiographic measurements revealed that left ventricular posterior wall thickness in end-diastole (LVPW 
dia), C) left ventricular internal diameter in end-diastole (LVID dia), as well as D) fractional shortening (FS) of the left ventricle 
are neither different between the genotypes nor the diet groups. Together, these data indicate no difference in overall cardiac 
morphology and function (n=7 for SPD Hccs
+/+
 and LPD cHccs
+/-
, n=6 for SPD cHccs
+/-
 and LPD Hccs
+/+
). For A)-D): Statistical 






7.1 The role of the mTOR pathway during heart development and 
consequences of prenatal mTOR pathway inhibition for postnatal 
health 
The mTOR pathway has been implicated in controlling cardiac organ size and regulating 
physiological and pathological cardiac hypertrophy58. On a cellular level, the mTOR signaling 
cascade is a key sensor of cell nutrition and energy status and acts as master regulator of 
cell growth, metabolism, proliferation and survival. Even though there is a large body of 
evidence emphasizing the role of the mTOR pathway in the adult heart, only little is known 
about its function during prenatal and perinatal cardiac development. Moreover, previous 
studies suggested that developmental programming affects metabolic processes (reviewed 
by Barker18, McMillen and Robinson19 and Rinaudo and Wang241). Given that the mTOR 
pathway is an important metabolic regulator, it might also be a target of developmental 
programming mechanisms. Experimental support for this hypothesis comes from studies in 
fetal lambs, which revealed that intrauterine growth restriction (IUGR) affects the expression 
of components of the insulin-like growth factor (IGF)-AKT signaling axis (upstream of 
mTORC1)242,243. Interestingly, these changes were proposed to result in cardiac hypertrophy 
in adulthood242,243. However, in these studies it was not analyzed if the observed changes 
translate into altered mTOR pathway activity at any developmental stage. Importantly, our 
initial experiments demonstrated increased mTOR pathway activity in neonatal cHccs+/- 
hearts (see Chapter 6.2, Figure 8). Thus, the aim of the first part of this PhD project was to 
investigate the role of the mTOR signaling cascade for embryonic cardiac regeneration and 
postnatal compensatory heart growth of cHccs+/- mice. Furthermore, we aimed at analyzing 
the general role of the mTOR pathway in the heart during prenatal development as well as in 
the neonatal period. To address these questions, we successfully inhibited mTORC1 by 
rapamycin injections in pregnant dams during the last trimester of prenatal 
development (fetal phase) (see Chapter 6.3.1, Figure 9).  
7.1.1 Rapamycin injection in pregnant dams specifically inhibits mTORC1 but not 
mTORC2 in the offspring heart 
The MTOR protein forms the catalytic subunit of the two multiprotein complexes mTORC1 
and mTORC2 (see Chapter 3.3.4, Table 1). mTORC1 is a physiological target of the 
macrolipid rapamycin (see Chapter 3.3.4.1, Figure 5), which induces its inhibition157,158. 
Rapamycin associates with a cellular protein called FKBP12, and this complex binds MTOR 
adjacent to its kinase domain in the FKBP12-rapamycin-binding (FRB) region leading to 




inhibits mTORC1 remains incompletely understood, rapamycin weakens the interaction 
between MTOR and RAPTOR246 and thus reduces mTORC1 intrinsic kinase activity247.  
Despite the fact that rapamycin is generally considered to be a specific inhibitor of mTORC1, 
cell culture experiments revealed that high-dose and long-term treatment with rapamycin 
reduces mTORC2 signaling in certain cell types by also impeding mTORC2 assembly222,248. 
Furthermore, recent in vivo studies demonstrated that daily rapamycin treatment over a 
period of 2 to 4 weeks in adult mice (intraperitoneal (i.p.), 2 mg rapamycin/kg BW) disrupts 
the association of MTOR with the essential mTORC2 component RICTOR in liver, muscle 
and white adipose tissue249. In line, the results of another study revealed that daily rapamycin 
injections for 4 weeks in adult mice (i.p., 2 mg rapamycin/kg BW) result in reduced AKT 
phosphorylation at the mTORC2 phosphorylation site serine 473 in the heart, indicating 
impaired cardiac mTORC2 activity185. 
Importantly, we demonstrated that prenatal rapamycin treatment does not inhibit mTORC2 
activity in neonatal hearts, as evident by unchanged phosphorylation of AKT at 
serine 473 (see Chapter 6.3.1, Figure 9A+C). In our experimental setup, we 
subcutaneously (s.c.) injected 5 mg rapamycin/kg BW every 12 hours in pregnant dams from 
15.5 dpc until birth, which corresponds to a total of only 4 days. Hence, the fetal and 
neonatal heart appears to be resistant for mTORC2 inhibition by short-term rapamycin 
treatment (even though a higher daily rapamycin dose was applied), while the adult heart 
responds to chronic rapamycin treatment with impaired mTORC2 activity. It is important to 
stress that i.p. rapamycin injections in adult mice and rapamycin treatment of fetal mice by 
s.c. injections in pregnant dams, which requires passage of the placental barrier, are 
fundamentally different approaches. This makes it difficult to compare the mTORC2 activity 
outcomes. In conclusion, methodological differences, especially different treatment durations, 
might explain the differences in mTORC2 inhibition between neonatal and adult mice.  
7.1.2 Prenatal mTORC1 inhibition by rapamycin is a new model for IUGR in mice 
Prenatal mTORC1 inhibition by rapamycin treatment from 15.5 dpc until birth induces 
profound growth retardation in neonatal mice as evident by a significant reduction of BW, HW 
and KW (see Chapter 6.3.3.1, Figure 11B+E and Supplementary Figure 3C). These findings 
are in line with conventional IUGR models, which also demonstrated lower BW and HW in 
neonates after intrauterine low protein diet (LPD)23 or placental insufficiency33. Importantly, 
prenatal rapamycin treatment impairs heart growth to a larger extend than intrauterine LPD 
and placental insufficiency do. Intrauterine LPD was shown to reduce BW by ~ 17 % and HW 
by ~ 10 % at birth compared to newborn standard protein diet (SPD) rats23. Placental 
insufficiency caused BW and HW reduction in neonatal rats by ~ 16 % and ~ 20 %, 
respectively33. In the study presented here, prenatal rapamycin treatment provoked BW 
reduction in neonatal mice to a similar extend than observed in the well-established IUGR 
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models (16.4 % for Hccs+/+ and 14.5 % for cHccs+/-) (see Chapter 6.3.3.1, Figure 11B). 
However, compared with intrauterine LPD and placental insufficiency, the reduction in 
neonatal HW was more severe after prenatal rapamycin treatment (34.5 % for Hccs+/+ and 
35.3 % for cHccs+/-) (see Chapter 6.3.3.1, Figure 11E). 
Developmental programming induced by IUGR is a systemic process, in which multiple 
changes in different organs interact and influence each other. Even though this allows 
analyses of organ specific adaptations to growth restriction, classical IUGR models can only 
be used to a limited extend to study developmental programming mechanisms in one 
particular organ. This makes developmental programming studies quite complex and 
explains why only few mechanistic insights have been uncovered to date, although the first 
papers by Barker et al. were published more than 25 years ago250. Importantly, even though 
rapamycin treatment is also a systemic approach that affects the entire organism, we provide 
evidence that prenatal mTORC1 inhibition (in contrast to the well-established IUGR models) 
more severely affects heart growth than the development of other organ systems. While 
HW/BW ratio in neonates after intrauterine LPD is unchanged due to BW and HW reduction 
to a similar extend23, in our model neonatal HW/BW ratio is reduced (see Chapter 6.3.3.1, 
Figure 11F), while KW/BW ratio stays the same (see Supplementary Figure 3D).  
Hearts of neonatal mice upon intrauterine mTORC1 inhibition (especially cHccs+/- hearts) 
exhibit a profound morphological phenotype. They are characterized by severe thinning and 
noncompaction of the ventricular myocardium, developmental delay and immature 
myocardial morphology (see Chapter 6.3.3.1, Figure 11D). Given that prenatal rapamycin 
treatment results in severe growth retardation in neonatal mice (especially within the heart), 
we suggested that this approach serves as a novel model for IUGR and thus for studying 
developmental programming mechanisms particularly in the fetal and neonatal phase of 
cardiac development. IUGR is defined as impaired growth of the unborn organism due to an 
intrauterine insult that is immediately released after birth (see Chapter 3.2.2). We revealed 
that mTORC1 signaling fully recovers at postnatal day 3 (P3) (see Chapter 6.3.1, Figure 9E), 
such that an important prerequisite in comparison to IUGR is met. However, the prenatal 
rapamycin approach displays crucial differences compared to well-established IUGR models. 
LPD and placental insufficiency normally persist throughout gestation23,33, whereas 
rapamycin treatment affects only the final trimester. Hence, every developmental 
programming occurring before the injection period was initiated (15.5 dpc) will be missed. 
When we initiated rapamycin treatment from 11.5 dpc onwards, we observed preterm birth 
and demonstrated severe growth retardation and body malformations (see Chapter 6.3.1 and 
Supplementary Figure 4). Thus, adjusting the rapamycin treatment protocol, e.g. reducing 




earlier treatment. Thereby, one could fully assess the usefulness of the rapamycin model to 
study IUGR and developmental programming.  
7.1.3 Reduced cardiomyocyte size and increased apoptosis rates are responsible for 
cardiac growth retardation in neonates after prenatal mTORC1 inhibition 
We were eager to identify the cellular mechanisms that induce the cardiac phenotype in 
neonates after prenatal mTORC1 inhibition. Postnatal heart growth is primarily achieved by 
hypertrophy64. Interestingly, the mTOR pathway was shown to be of particular importance in 
the regulation of cardiomyocyte size and hypertrophic growth in adult murine hearts; both 
under physiological as well as pathological conditions117. Exercise training-induced (treadmill 
running) physiological hypertrophy was demonstrated to be associated with activation of the 
mTOR signaling pathway in adult mice, as identified by increased phosphorylation of the 
mTORC1 downstream targets S6K1 and S6117. These molecular changes were accompanied 
by increased cardiomyocyte size117. The role of the mTOR signaling cascade in physiological 
postnatal heart growth was additionally supported by the observation that treatment of 
3 week old mice with rapamycin results in smaller hearts at the age of 4 weeks190. In 
contrast, pressure overload-induced pathological hypertrophy after transverse aortic 
constriction (TAC) was associated with inactivation of the mTOR signaling pathway, as 
indicated by reduced phosphorylation levels of S6K1 and S6117. Additionally, inhibition of 
mTORC1 by rapamycin as well as cardiac-specific Mtor or Raptor ablation in adulthood 
attenuates stress-induced pathological cardiac hypertrophy182-186. This is mainly mediated by 
preventing increased cardiomyocyte growth182-184.  
To date, the role of the mTOR pathway in the regulation of cardiomyocyte size in the 
perinatal and neonatal period remains obscure. Importantly, we revealed that prenatal 
rapamycin treatment reduces cardiomyocyte cross sectional area (CSA) in neonates (see 
Chapter 6.3.3.2, Figure 12F). These data suggest an important role of the mTOR signaling 
cascade in fetal and neonatal cell size regulation in the heart, similar to adult stages. 
Reduced cardiomyocyte CSA was also observed in one of the few studies analyzing the 
effects of mTOR pathway inhibition during heart development. Cardiac-specific Rheb 
KOs (cRheb-KO), the most important upstream regulator of mTORC1, remained 
inconspicuous until postnatal day 8189. Afterwards, they presented signs of dilated 
cardiomyopathy, such as significantly lower HW, HW/BW ratios, reduced cardiomyocyte CSA 
and cardiac dysfunction189. cRheb-KOs demonstrated unchanged HW and cardiomyocyte 
CSA at P3 and P5189. Unfortunately, neonatal (P1) cRheb-KO mice were not analyzed189. 
Strikingly, we revealed a rather severe phenotype with regard to reduced HW and 
cardiomyocyte CSA at P1 after prenatal rapamycin treatment (see Chapter 6.3.3.1, Figure 
11E and Chapter 6.3.3.2, Figure 12F). The difference might be explained by basic 
mechanistic differences between the rapamycin approach and cRheb-KO mice. Systematic 
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rapamycin treatment inhibits mTORC1 in the entire organism from 15.5 dpc onwards. In 
contrast, Rheb deficiency was achieved by Cre/loxP recombination189. For this purpose, an 
α-myosin heavy chain promoter-driven Cre recombinase was used189, which resulted in 
inactivation of the floxed Rheb gene in cardiomyocytes between 7.5 dpc and 8.0 dpc251. 
Analysis of phosphorylation levels of S6 and 4E-BP1 were not affected in P3 cRheb-KO 
hearts189, indicating preservation of mTORC1 signaling. From postnatal day 5 onwards, 
cRheb-KO mice demonstrated attenuated cardiac mTORC1 activity189. Rapamycin treated 
hearts displayed severely reduced mTORC1 activity already at P1 (see Chapter 6.3.1, Figure 
9A). Thus, these data suggest that mTORC1 is essential for fetal and neonatal heart growth, 
while RHEB is dispensable for the mTORC1 activation during neonatal cardiac development 
soon after birth. The authors proposed that an isoform of RHEB (e.g. RHEBL1252) partially 
compensates for the loss of RHEB189. The results furthermore indicate that RHEB-
independent mTORC1 activation might play an important role in cardiac development until 
postnatal day 3. This might be of major importance with regard to future analyses focusing 
on upstream signaling pathways that are responsible for the increased mTOR pathway 
activity in neonatal cHccs+/- hearts. Therefore, attention should be paid on the role of the 
mTORC1 upstream stimuli AKT and AMPK (see Chapter 3.3.4.1, Figure 5) during fetal and 
perinatal heart development. 
Besides decreased cardiomyocyte CSA, HW reduction in neonatal rapamycin treated mice 
might additionally be caused by alterations in cell number. Hence, we investigated 
programmed cell death (autophagy and apoptosis) as well as cell proliferation (see Chapter 
6.3.3.2, Figure 12A-D). Importantly, the mTOR signaling cascade is known to inhibit 
autophagy (see Chapter 3.3.4.1, Figure 5), a highly regulated cellular degradation process 
important for protein turn-over, recycling of damaged organelles and consequently 
organismal and cellular adaptation to nutrient starvation168-173,175. The protein p62 is one of 
the best characterized selective autophagy substrates, which targets proteins for autophagy, 
gets incorporated into autophagosomes and subsequently degraded223,224. Interestingly, our 
results revealed evidence for enhanced autophagy in neonatal hearts after prenatal 
rapamycin treatment, as indicated by decreased p62 protein levels (see Chapter 6.3.1, 
Figure 9B+D). Even though autophagy was originally believed to temporary protect cells from 
apoptosis during times of unfavorable growth conditions253, recent studies demonstrated that 
the association between apoptosis and autophagy is by far more complex and that 
unrestrained autophagy can also promote apoptosis254,255. Importantly, studies in adult mice 
after cardiac-specific Mtor or Raptor ablation revealed induced apoptosis of 
cardiomyocytes182,183. Thus, it is reasonable to speculate that prenatal mTORC1 inhibition 
has similar effects in neonatal hearts. Indeed, studies in 10.5 dpc and 12.5 dpc embryonic 




pathway inactivation, revealed increased apoptosis of cardiomyocytes191. In these mice, 
cardiac-specific Mtor KO was achieved by using a myosin heavy chain-driven Cre 
recombinase191. The authors observed mosaic expression of Cre recombinase and hence 
only a subset of cardiomyocytes displays Mtor inactivation191. Whether the increase in 
cardiac apoptosis is really due to the cardiac Mtor KO or might be a secondary effect 
resulting from cell competition remains obscure. Unfortunately, autophagy was not analyzed 
in embryonic cMtor-KO hearts191. Strikingly, we observed not only increased autophagy (see 
Chapter 6.3.1, Figure 9B+D) but also significantly enhanced apoptosis rates in neonatal 
hearts after prenatal rapamycin treatment (see Chapter 6.3.3.2, Figure 12D). However, 
further investigations to explore the role of autophagy in our rapamycin model and to 
elucidate if the increase in cardiomyocyte apoptosis is indeed autophagy-mediated, are 
required. Analyzing protein levels of LC3B-II, which is essential for the formation of 
autophagosomes256, as well as investigating the cellular abundance and localization of 
LC3B-II by immunohistochemistry stainings might help to uncover the effects of prenatal 
mTORC1 inhibition on cardiac autophagy. During the time of the study we intensively tried to 
perform western blot analyses and immunohistochemistry stainings using a LC3B-II 
antibody. Unfortunately, we experienced serious technical problems, which require special 
attention in future studies. Assuming that autophagy turns out to be not the main trigger of 
increased apoptosis, the latter might be a secondary effect maybe due to mechanical left 
ventricular (LV) wall stress or metabolic alterations.  
As stated (see Chapter 3.3.2), fetal cardiac growth mainly occurs through cardiomyocyte 
proliferation. Thus, the reduced HW in rapamycin treated neonates might furthermore be 
caused by decreased proliferation rates. However, neonatal cardiomyocyte proliferation rates 
were found to be unaffected by prenatal mTORC1 inhibition (see Chapter 6.3.3.2, Figure 
12C). Though, it remains obscure if rapamycin treatment affects cardiac proliferation in 
earlier stages.  
In summary, we conclude that changes in cardiomyocyte size and apoptosis are part of the 
cascade of events that cause the profound cardiac phenotype in neonatal hearts after 
prenatal mTORC1 inhibition.  
7.1.4 Prenatal mTORC1 inhibition does not affect cardiac regeneration of cHccs+/- 
mice but alters apoptosis and cell growth in the neonatal cHccs+/- myocardium 
We found increased mTOR pathway activity in neonatal cHccs+/- mice (see Chapter 6.2, 
Figure 8). Hence we hypothesized that this activation is crucial in our model to sustain 
cardiac regeneration during the second half of gestation. However, prenatal mTORC1 
inhibition did not cause embryonic lethality (see Chapter 6.3.2, Figure 10A) and cHccs+/- mice 
were born in expected Mendelian ratios (see Chapter 6.3.2, Figure 10B). Consequently, 
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enhanced mTOR pathway activity is not essential to ensure survival of cHccs+/- mice. 
Importantly, the period of embryonic heart regeneration in cHccs+/- mice, which shows the 
most dramatic shift in the cell populations, takes place between 10.5 dpc and 13.5 dpc (see 
Chapter 3.4)192. This developmental phase is not affected by the rapamycin treatment, which 
is initiated at 15.5 dpc. At that stage, the ratio of Hccs-deficient versus healthy tissue is 
already 20:80192. Hence, the rapamycin approach is not targeting the actual regenerative 
phase but rather the “consolidation” phase of fetal compensatory growth in cHccs+/- mice. 
Strikingly, HW and HW/BW ratio of neonatal cHccs+/- hearts after prenatal mTORC1 
inhibition were significantly reduced compared to rapamycin treated Hccs+/+ neonates (see 
Chapter 6.3.3.1, Figure 11E+F). The same proves true after prenatal vehicle treatment (see 
Chapter 6.3.3.1, Figure 11E+F). This is in line with our current understanding of the heart 
conditional Hccs KO model, because formation of the heart from just 50 % of embryonic 
cardiomyocytes results in a hypoplastic cardiac phenotype at birth evident by a reduced 
HW/BW ratio, thinner LV walls and significantly reduced cardiomyocyte number (unpublished 
data, see Chapter 3.4). Thus, the observation that HW and HW/BW ratio in neonatal 
rapamycin treated cHccs+/- mice is reduced might not be a specific effect of prenatal 
mTORC1 inhibition but instead might reflect the hypoplastic phenotype which is maintained 
after rapamycin treatment.  
Moreover, prenatal mTORC1 inhibition caused cardiac apoptosis in both genotypes with a 
higher extend in neonatal cHccs+/- hearts (6.3.3.2, Figure 12D). It was demonstrated that 
approximately 10 % Hccs-deficient cells remain in the neonatal myocardium192. Hence, 
prenatal rapamycin treatment might more severely affect these Hccs-deficient cells, which 
are normally not actively eliminated192. A cardiac protective role of the mTOR pathway was 
previously reported, since tamoxifen-inducible cardiac-specific Mtor as well as Raptor 
deletion in the adult mouse myocardium was demonstrated to cause cardiac dysfunction and 
heart failure with chamber dilation and wall thinning182,183. Furthermore, in a mouse model for 
ischemia-reperfusion injury the mTOR signaling cascade was found to be activated and its 
inhibition by rapamycin increased injury257. Consistently, mTOR pathway activation was also 
protective in isolated cardiomyocytes upon oxidative stress257. Increased TUNEL-rates in 
neonatal rapamycin treated cHccs+/- hearts might therefore suggest that prenatal mTORC1 
inhibition causes apoptosis in general but additionally affects survival of Hccs-deficient cells. 
Unfortunately, the method applied (see Chapter 5.3.4.3.2) does not allow differentiation 
between healthy and Hccs-deficient cells. Thus, immunohistochemistry using antibodies for 
cytochrome c (to differentiate between healthy and Hccs-deficient myocardial cells) and 
cleaved caspase 3 (a marker for apoptotic cells258) should be performed.  
Neonatal cardiomyocyte CSA was reduced after prenatal mTORC1 inhibition in both 




was significantly smaller than in rapamycin Hccs+/+ neonates (see Chapter 6.3.3.2, Figure 
12F). In vehicle treated neonatal hearts, cardiomyocyte CSA was not different between the 
genotypes (see Chapter 6.3.3.2, Figure 12F). These data suggest that in untreated neonatal 
cHccs+/- hearts elevated mTOR pathway activity is required to achieve normal cell size but is 
unable to elevate CSA above the control level to e.g. compensate for the reduced 
cardiomyocyte number. Prevention of elevated cell growth might be beneficial, as it could 
otherwise be the turning point toward pathological remodeling. Hence, cardiomyocyte growth 
might have reached its physiological limit and further cell growth might even be restricted by 
the activity of certain inhibitors. A potential candidate that might be involved in prevention of 
pathological hypertrophy in response to mTOR pathway hyperactivation is 5´-adenosine 
monophosphate-activated protein kinase (AMPK), which is closely linked to the mTOR 
signaling cascade by acting as indirect mTORC1 inhibitor144,145 (see Chapter 3.3.4.1, Figure 
5). Interestingly, we have found elevated AMPK activity in cHccs+/- neonatal hearts in recent 
pilot experiments (data not shown) and further investigations are currently ongoing. AMPK 
was shown to contribute to the protection of the heart against hypoxic injury, as 
demonstrated in neonatal rat cardiomyocytes after exposure to hypoxia259. Moreover, 
increased cardiomyocyte CSA in adult mice was identified in a mouse model for impaired 
AMPK activity, suggesting restriction of cardiomyocyte growth by AMPK260. Taken together, 
cell size is tightly controlled and kept within a certain range irrespective of cell number in the 
neonatal heart. Further studies are currently performed to more precisely focus on these 
cardiac control mechanisms that prevent overshooting cell size upon mTOR pathway 
hyperactivation in the neonatal stage. 
In conclusion, these findings indicate that the mTOR signaling cascade indeed has specific 
consequences for fetal cardiac growth in the heart conditional Hccs KO model but its 
inhibition still allows survival of cHccs+/- offspring until birth. Because apoptosis rates and 
cardiomyocyte CSA in cHccs+/- neonatal hearts after prenatal rapamycin treatment are 
altered to a larger extend than in Hccs+/+ neonates, one might expect reduction of HW and 
HW/BW ratio. However, as discussed above, the degree of reduction between vehicle and 
rapamycin groups does not differ when comparing the genotypes (see Chapter 6.3.3.1, 
Figure 11E+F). Importantly, due to the extremely small HW, precise measurement is 
technically limited even when using highly sensitive laboratory scales. Hence, further 
reduction of HW and HW/BW ratio in cHccs+/- neonates after prenatal mTORC1 inhibition 
might be below the threshold of detection. 
7.1.5 Prenatal mTORC1 inhibition by rapamycin does not severely impair heart 
function in neonates 
The profound morphological phenotype of rapamycin treated neonatal hearts led us to 
speculate that prenatal mTORC1 inhibition might impair cardiac function at birth. However, 
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analyses of the left ventricular contractile parameters fractional shortening (FS) and ejection 
fraction (EF) revealed only slight reductions after prenatal rapamycin treatment in cHccs+/- 
neonates and no differences in controls (see Chapter 6.3.3.3, Figure 13D+E and 
Supplementary Table S5). The slightly reduced contractile function in cHccs+/- neonates 
might be explained by the increased apoptosis rates as well as the smaller cardiomyocyte 
size (see Chapter 6.3.3.2, Figure 12D+F). Support comes from studies that suggested that 
increased apoptosis, even at low levels, eventually result in heart failure261. In this context, 
adult transgenic mice with inducible cardiomyocyte apoptosis demonstrated lethal, dilated 
cardiomyopathy261. Moreover, pathological hypertrophy is known to go along with increased 
cell size and transiently increased contractility to maintain cardiac output e.g. during pressure 
overload100. Hence, the decreased cell size after prenatal rapamycin treatment, most 
prominent in cHccs+/- neonates (see Chapter 6.3.3.2, Figure 12F), might increase the 
susceptibility to cardiac dysfunction. 
Importantly, in adulthood rapamycin treatment as well as cardiac-specific Mtor and Raptor 
ablation impair cardiac contractility182-184,186. Tamoxifen-inducible cardiac-specific Raptor KO 
mice develop spontaneous cardiomyopathy and die 5 weeks after tamoxifen injection183. 
Tamoxifen-inducible cardiac-specific Mtor deletion in the adult mouse myocardium leads to 
lethal, dilated cardiomyopathy and mice started dying 4 weeks after tamoxifen injection182. 
Hence, it was surprising to assess that prenatal mTORC1 inhibition causes a severe 
phenotype in neonatal hearts but at the same time only marginally affects heart function. 
Thus, the fetal and perinatal heart can maintain cardiac contractility upon mTORC1 inhibition 
while the adult heart cannot. This discrepancy might be explained by the impressive 
regenerative capacity of the fetal heart262. The transition from fetal and perinatal hyperplastic 
to postnatal hypertrophic growth is accompanied by major changes in cardiac metabolism 
and substrate utilization86-88,92, which might also result in different susceptibilities to 
rapamycin. Hence, differences in the compensatory plasticity might be associated with 
metabolic adaptations of the fetal and neonatal heart in order to adapt to prenatal mTORC1 
inhibition and thus maintain cardiac function (see Chapter 3.3.2). Eventually, the neonatal 
heart is furthermore subjected to a lower contractile demand and work load than the adult 
heart, which might also allow better maintenance of cardiac function upon mTORC1 
inhibition.  
7.1.6 Limitations of the rapamycin approach and suggestions for improvement 
Importantly, rapamycin treatment is a systemic approach that does not only affect the heart 
but also disturbs growth and maturation of other organ systems. This could potentially result 
in secondary consequences for the myocardium, which cannot be dissected from primary 
effects of cardiac mTORC1 inhibition. Even though this is in consistence with the classical 




analysis of the role of mTOR signaling specifically within the heart. Although our rapamycin 
approach has more severe consequences on cardiac development than on other organ 
systems and thus allows investigation of the role of mTOR during fetal and neonatal 
development with special emphasis on the heart to a certain extent, its unspecific effects 
should be kept in mind. 
Furthermore, rapamycin might also affect the mother with respect to placental or mammary 
gland development. Given that we did not investigate these options, consequences resulting 
from maternal disturbances cannot be excluded. mTOR is known to be highly expressed in 
the syncytiotrophoblast of the human placenta263. Inhibition of placental mTORC1 decreases 
the cell surface abundance of amino acid transporters in the trophoblast264. Hence, it was 
suggested that trophoblast mTORC1 signaling links maternal nutrient availability to fetal 
growth by modulating the flux of amino acids across the placenta264. Interestingly, placental 
mTORC1 activity was demonstrated to be reduced in human IUGR263. Moreover, mTOR was 
shown to be required for trophoblast development by controlling trophoblast cell growth and 
proliferation265. Together, these data indicate that the neonatal phenotype of rapamycin 
treated mice might at least be partially and additionally mediated by mTORC1 inhibition in 
the maternal placenta. Furthermore, studies with purified mammary epithelial cells revealed 
that decreased mTOR pathway activity results in reduced cell proliferation and lactation266. 
Given that the ability of mammary glands to produce milk is determined by the number of 
cells and their level of viability266, mTORC1 inhibition by rapamycin might also affect 
mammary gland development and thereby negatively impacts on development of newborn 
mice. 
We observed mTOR pathway upregulation in neonatal cHccs+/- hearts (see Chapter 6.2, 
Figure 8) and we initially proposed that the mTOR signaling cascade plays an essential role 
in the cHccs+/- myocardium. However, after mTORC1 inhibition, Hccs+/+ and cHccs+/- mice 
both survived in expected Mendelian ratios (see Chapter 6.3.2, Figure 10B). The rapamycin 
dose applied (s.c. 5 mg rapamycin/BW every 12 h) might be too high to tease out differences 
between the genotypes. Completely whipping out mTORC1 activity, as it is the case for the 
prenatal rapamycin treatment presented here (see Chapter 6.3.1, Figure 9A), might equalize 
the rather severe phenotype in both genotypes. Studies in adult mice demonstrated that 
already daily i.p. 2 mg rapamycin/BW injections over a period of one week are sufficient to 
inhibit cardiac mTORC1 activity184. However, i.p. rapamycin injections in adult mice and 
rapamycin treatment of fetal mice by s.c. injections in pregnant dams are fundamentally 
different approaches, which makes it difficult to adopt the dose and treatment regime. Ideally, 
one would aim for a dose that reproducibly reduces mTOR pathway activity but does not 
cause a phenotype in neonatal Hccs+/+ controls. This could eventually unmask a specific 
mTOR function in cHccs+/- neonates. Hence, reducing the rapamycin dose or the injection 
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frequency and at the same time starting the injection period before 15.5 dpc might 
specifically affect survival of cHccs+/- mice. Alternatively, a genetic approach using 
heterozygous Raptor KOs might serve this function as it would allow for inhibiting mTOR 
pathway activity earlier during heart development. cRaptor+/- mice are viable and survive until 
adulthood (see Chapter 6.4.1, Figure 16A). Moreover, their hearts are morphologically 
inconspicuous (see Chapter 6.4.2, Figure 16E). However, mTOR pathway activity in 10.5 dpc 
embryonic (see Chapter 6.4.3, Figure 16B-D+F) and neonatal cRaptor+/- hearts (data not 
shown) as well as HW/BW ratio in neonatal cRaptor+/- mice are reduced (data not shown). 
Thus, cRaptor+/- mice comprise an important potential to elucidate the role of the mTOR 
signaling cascade in the heart conditional Hccs KO model in more detail. Generation of 
double KO mice by crossing cRaptor+/- with cHccs+/- mice might help to elucidate open 
questions that cannot be addressed if the entire organism is affected.  
7.1.7 Cardiac-specific Raptor ablation revealed that the mTOR pathway is essential 
during early embryonic cardiac development 
To investigate the role of the mTOR signaling pathway during early cardiac development and 
specifically within the heart excluding secondary effects, we generated mice with cardiac-
specific Raptor ablation. The RAPTOR protein directly interacts with MTOR and is essential 
for mTORC1 assembly and function120,121. Genetic Raptor ablation causes disassembly of 
the mTORC1 complex, consequently impairing downstream signaling206.  
Cardiac-specific Raptor ablated mice died in utero between 10.5 dpc and 11.5 dpc (see 
Chapter 6.4.1, Figure 16A), suggesting that the mTOR pathway is essential during early 
heart development and thus for survival of the entire organism. Analyses of cardiac 
morphology revealed a fulminant phenotype at 10.5 dpc with severely reduced ventricular 
wall thickness, resulting in hypoplastic hearts (see Chapter 6.4.2, Figure 16E). Recent 
unpublished data from our lab demonstrated a significantly reduced proliferative potential of 
cardiomyocytes in 10.5 dpc cRaptor-/- hearts. Other mouse models with similar phenotypes 
and proliferation defects support our findings. For instance, mice lacking all three D-type 
cyclins (Ccnd1, Ccnd2, Ccnd3) die around 16.5 dpc due to heart abnormalities and impaired 
proliferation of myocardial cells267. Fetal cardiomyocyte-restricted inactivation of the yes-
associated protein 1 (Yap1) gene also causes decreased cardiomyocyte proliferation leading 
to myocardial hypoplasia and embryonic lethality after 16.5 dpc59. Moreover, we argued that 
in neonatal rapamycin treated hearts increased apoptosis is mediated by unrestricted 
autophagy (see Chapter 7.1.3). A similar scenario might contribute to hypoplasia in cRaptor-/- 
hearts. We assume that reduced proliferation and potentially increased apoptosis result in a 
reduced set of cardiac cells in 10.5 dpc cRaptor-/- hearts, causing the severe thinning of both 
the compact as well as the trabeculated myocardium. Hence, future attention should be paid 




specific Raptor KO model. The trabeculae, which develop between 8.5 dpc and 10.5 dpc, are 
especially important for proper and powerful contraction as well as for nutrient uptake from 
the ventricular blood flow by increasing the surface area, as a coronary artery system to 
supply the myocardium has not been developed at that stage (see Chapter 3.3.1). 
Consequently, a reduced set of contracting cardiac cells in combination with the almost 
absent trabeculae in cRaptor-/- hearts might result in insufficient nutritional supply of the 
growing myocardium and in the end cause death of the entire embryo.  
Interestingly, embryonic cMtor-KO mice die between 13.5 dpc and the end of gestation191. In 
these mice, cardiac-specific Mtor KO was achieved by using a myosin heavy chain-driven 
Cre recombinase191. However, only a subset of cardiomyocytes displays Mtor inactivation, 
because mosaic expression of Cre recombinase was observed191. Therefore, the embryonic 
day at which cMtor-KO mice die was shown to be dependent on the extent of cardiac Cre 
expression and hence Mtor inactivation191. Consequently, the reason for the longer survival 
of cMtor-KO embryos compared to our cRaptor-/- mice might be the cardiomyocyte mosaic 
for the KO of Mtor. Interestingly, cardiac proliferation rates in 10.5 dpc and 12.5 dpc cMtor-
KO embryos were found to be significantly reduced191; a finding that is consistent with our 
cRaptor-/- model. 
In line, prenatal rapamycin treatment from 11.5 dpc onwards causes fetal lethality (see 
Chapter 6.3.1 and Supplementary Figure 4), as demonstrated by a pilot experiment which 
was terminated after assessing the extensive consequences for the offspring. Importantly, 
mTORC1 inhibition by rapamycin during late gestation from 15.5 dpc does not result in 
prenatal lethality (see Chapter 6.3.2, Figure 10), even though neonatal rapamycin treated 
hearts are hypoplastic (see Chapter 6.3.3.1, Figure 11C-E). Analyses of neonatal cardiac 
proliferation rates revealed no significant differences between prenatal vehicle and 
rapamycin treatment (see Chapter 6.3.3.2, Figure 12C). However, proliferation was assessed 
using immunofluorescence staining for KI67, which labels proliferating cells in all active 
phases of the cell cycle217. Thus, a more specific proliferation marker, such as p-HH3, which 
is restricted to mitosis and the late G2 phase of the cell cycle218, might help to uncover subtle 
differences in proliferation rates in the neonatal stage. Importantly, differences in survival as 
well as in proliferation rates between the above discussed approaches are most likely due to 
the different phases of development during which the mTOR pathway was inhibited. 
Moreover, cell cycle activity in peri- and postnatal cardiomyocytes does not necessarily mean 
cell division69. It is conceivable to speculate that in controls, cardiomyocytes still actively 
divide, whereas they start to become binucleated in cHccs+/- neonates. In order to focus on 
potential differences regarding the moment when terminal differentiation occurs, cytokinesis 
markers, such as aurora B kinase (a chromosomal passenger protein that is involved in 
chromosome segregation, spindle-checkpoint, and cytokinesis)268 or determination of the 
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actual cell number might prove useful. Additionally, analyzing cardiomyocyte proliferation in 
fetal rapamycin treated hearts shortly before birth (e.g. between 17.5 dpc and 18.5 dpc) 
might help to reliably elucidate the impact of rapamycin treatment on cardiomyocyte 
proliferation rates. In this context, the IUGR phenotype of rapamycin treated neonatal hearts 
might not only be caused by reduced cardiomyocyte size and increased apoptosis rates, as 
discussed above, but also by reduced proliferation and thus reduced number of cardiac cells. 
This would again correlate with findings in classical IUGR rat models at birth: less 
cardiomyocytes23 as well as a suppressed replicative potential of cardiac cells upon 
intrauterine LPD24 and decreased cardiomyocyte number after placental insufficiency33. 
However, one can also speculate that the mTOR pathway plays different roles during 
different phases of cardiac development. In this context, our results suggest that during 
embryonic development, the mTOR signaling cascade regulates proliferation; while in later 
stages it might control cell size. Similar mechanisms have been proposed for cell cycle 
regulating genes. For instance certain cyclins were shown to be associated with proliferation 
in embryonic but with hypertrophy in adult cardiomyocytes76,77,231,269,270. Moreover, mTOR 
pathway hyperactivation is often associated with tumor growth, where it certainly promotes 
proliferation271-273. Hence, it appears that the same growth machinery (mTOR pathway) can 
induce proliferation in one cell type but increases cell size in the other. The latter seems to 
primarily affect terminally differentiated cardiomyocytes. Thus, for the heart, as long as 
cardiomyocytes are in principle able to divide, the mTOR pathway might induce proliferation, 
but as soon as cardiomyocytes withdraw from the cell cycle the mTOR signaling cascade 
might induce hypertrophy. This consideration would make the mTOR pathway especially 
interesting with regard to a potential role in the transition from hyperplastic to hypertrophic 
cardiac growth in the perinatal period, given that until now the molecular players initiating this 
switch are only insufficiently elucidated (see Chapter 3.3.2). 
Strikingly, homozygous cardiac-specific Raptor ablation completely abolishes 
phosphorylation of 4E-BP1 in 10.5 dpc embryonic hearts (see Chapter 6.4.3, Figure 16D+F). 
This is in line with cardiac-specific Mtor or Raptor ablation in adulthood as well as with 
12.5 dpc embryonic cMtor-KO mice182,183,191. In all three models significantly decreased 
cardiac 4E-BP1 phosphorylation was observed182,183,191. In contrast, mTORC1 inhibition by 
prenatal rapamycin treatment severely inhibited phosphorylation of S6K1 and S6 but not of 
4E-BP1 in neonatal hearts (see Chapter 6.3.1, Figure 9A). Differential effects of rapamycin 
on phosphorylation of various mTORC1 downstream targets have previously been reported 
in cell culture274. In this regard, it was demonstrated that rapamycin potently inhibits S6K1 
activity throughout the duration of treatment, while 4E-BP1 phosphorylation recovers within a 
few hours despite continued rapamycin exposure274. Phosphorylated 4E-BP1 dissociates 




dependent translation162. Thereby, EIF4E specifically enhances the translation of transcripts, 
which often encode proteins associated with a proliferative response, such as CYCLIN D1275. 
Moreover, recent studies revealed that the sequence composition of mTORC1 
phosphorylation sites is one of the key determinants of whether the site is a good or a poor 
mTORC1 substrate276. In this context, differences in substrate quality were shown to be most 
important to allow downstream effectors of mTORC1 to respond differentially to temporal and 
intensity changes in the levels of nutrients and growth factors or pharmaceutical inhibitors 
such as rapamycin276. Furthermore, cell culture experiments demonstrated that Eif4e 
overexpression is associated with significant acceleration of G1 phase progression from 
G0 phase to S phase, indicating cell cycle control277). Thus, it is tempting to speculate that 
the differences in 4E-BP1 phosphorylation are at least partially responsible (next to the 
developmental stage as well as differences in the proliferative potential of 10.5 dpc and P1 
cardiomyocytes) for the different effects of cardiac-specific Raptor ablation and rapamycin 
treatment, respectively, on cell proliferation. 
Taken together, all these findings indicate that regular cardiac mTOR pathway activity is 
essential during embryonic development, given that mTOR signaling appears to be required 
for normal cardiomyocyte proliferation and thus for the survival of the entire organism.  
7.1.8 Adult mice after prenatal mTORC1 inhibition by rapamycin treatment 
demonstrate postnatal catch-up growth but no signs of cardiac dysfunction 
The concept of developmental programming proposes that IUGR affects cardiac disease in 
adulthood. For instance, cardiac dysfunction27 and impaired recovery after ischemia-
reperfusion injury28-30 were observed in adult rat hearts upon intrauterine amino acid 
restriction. Besides, prenatal hypoxia was shown to result in pathological cardiac 
remodeling28 and LV diastolic dysfunction35 in adulthood.  
Analyses of BW and organ weights in adult mice after prenatal rapamycin treatment revealed 
postnatal catch-up growth, even though the weight parameters of rapamycin treated adult 
mice remained slightly below vehicle treated adults (see Chapter 6.3.4.1, Figure 14B+C and 
Supplementary Figure 5A+C+E). Interestingly, similar results were shown for classical IUGR 
models. BW and HW are reduced in LPD newborn rats, but normalize within the first few 
weeks of life if the diet is changed to SPD after birth, indicating postnatal compensatory 
growth25. In line, HW, which is reduced after placental insufficiency in pregnant rats, is also 
restored if postnatal nutrition is normalized33. In the context of developmental programming, 
accelerated postnatal growth is considered to additionally promote the manifestation of 
cardiovascular disease (CVD) in adulthood following IUGR and developmental 
programming14-17. For instance, in humans a relationship between glucose intolerance, low 
birth weight and obesity in adulthood was revealed9. Thereby, in low- and middle-income 
DISCUSSION 
112 
countries, the combination of poor nutrition in utero and overnutrition in later life contributes 
to the increasing incidence of diabetes20. As mentioned above, hearts of rapamycin treated 
animals also demonstrated increased postnatal catch-up growth. HW of 11 week old vehicle 
treated Hccs+/+ and cHccs+/- mice was 12-fold and 16-fold, respectively, higher compared to 
P1, while HW of 11 week old rapamycin treated Hccs+/+ and cHccs+/- mice was increased by 
the factor of 18 and 21, respectively, compared to their neonatal HW (see Chapter 6.3.3.1, 
Figure 11E and Chapter 6.3.4.1, Figure 14C). In contrast, in both vehicle as well as 
rapamycin groups, KW of 11 week old mice was approximately 12 times higher than in the 
neonatal stage (see Chapter 6.3.3.1, Supplementary Figure 3C and Chapter 6.3.4.1, 
Supplementary Figure 5C). These data indicate that the susceptibility of rapamycin treated 
hearts for pathological conditions and cardiac dysfunction in adulthood might be increased. 
However, cardiac function in adult mice after prenatal mTORC1 inhibition was found to be 
normal (see Chapter 6.3.4.2, Figure 15F+G) and no signs of pathological remodeling or 
cardiac stress (e.g. cardiac fibrosis or expression of heart failure genes) were observed (see 
Chapter 6.3.4.2, Figure 15C+D). In contrast, in 12 months old adult rats cardiac dysfunction 
was observed under baseline conditions upon prenatal hypoxia35 and intrauterine amino acid 
restriction27. Importantly, in our study 11 week old mice can be considered young adults. In 
the context of developmental programming, the increased risk for CVD in adulthood 
manifests if additional stress occurs. Given that we proposed that our approach represents a 
new IUGR model in mice, it would be interesting to investigate heart function and 
morphology of Hccs+/+ and cHccs+/- mice after prenatal rapamycin treatment at older age (for 
instance after 1 year) or if cardiac stress (such as TAC or chronic angiotensin infusion) is 
applied. Furthermore, analyses of older rapamycin treated adult mice might also reveal if 
organ size completely normalizes with ageing.  
Cardiomyocyte CSA in adult mice after prenatal rapamycin treatment was significantly 
increased compared to vehicle treated mice in both genotypes (see Chapter 6.3.4.2, Figure 
15B). However, the HW of rapamycin treated adults remained slightly below vehicle treated 
animals (see Chapter 6.3.4.1, Figure 14C). These findings suggest a reduced cardiomyocyte 
cell number in adult rapamycin treated hearts, resulting in compensatory increased 
cardiomyocyte size, which however cannot completely normalize HW by the age of 
11 weeks. Indeed, we observed increased apoptosis in neonatal rapamycin treated 
hearts (see Chapter 6.3.3.2, Figure 12D) and proposed a proliferation defect in the perinatal 
period (see discussion in Chapter 7.1.3) in both genotypes. It was previously shown that 
neonatal cHccs+/- hearts have a reduced number of cardiomyocytes and that cardiac 
hypertrophy in adulthood, as demonstrated in vehicle cHccs+/- hearts (see Chapter 6.3.4.2, 
Figure 15B), is a major hallmark of the cardiac-specific Hccs KO model to compensate for 




suggest additional reduction of the cardiomyocyte number in both genotypes. Thus, we 
propose that adult Hccs+/+ and cHccs+/- rapamycin hearts both respond with cardiomyocyte 
hypertrophy in addition to baseline compensatory cardiac hypertrophy of vehicle cHccs+/- 
hearts (see Chapter 6.3.4.2, Figure 15B). This might flatten the difference in cardiomyocyte 
CSA between adult Hccs+/+ and cHccs+/- hearts, which is observed under vehicle conditions 
but no longer obvious after prenatal rapamycin treatment (see Chapter 6.3.4.2, Figure 15B). 
7.2 Consequences of pre- and postnatal amino acid restriction 
Maternal LPD during pregnancy and lactation is a well-characterized rat model for IUGR, low 
birth weight and the subsequently increased risk for chronic diseases in the offspring. 
However, mice have been relatively neglected in this regard and represent a critical resource 
for investigating the underlying molecular mechanisms of developmental programming. 
Amino acids are key players in all life processes and apart from their role as building blocks 
for protein synthesis, they fulfill further central cellular functions and serve as intermediates in 
cell metabolism21. For instance, tyrosine and phenylalanine are precursors of low molecular 
weight hormones. Methionine, glycine and serine participate in maintenance of the methyl 
group pool in cells, which influences, amongst others, the establishment of epigenetic marks 
such as DNA methylation (reviewed by Kimball and Jefferson278). Gluthatione, an important 
cellular antioxidant, is synthesized de novo from glycine, cysteine and glutamic 
acid (reviewed by Wu et al.279). Furthermore, and most importantly, amino acid availability is 
an essential upstream stimulus to activate the mTOR pathway119. Consequently, given the 
importance of amino acids for cell growth and survival, it is not surprising that prenatal amino 
acid restriction affects the development of various organ systems including the heart, as 
discussed in the introduction (see Chapter 3.2.2). Moreover, our initial experiments revealed 
induction of genes involved in amino acid metabolism, biosynthesis and transport in neonatal 
cHccs+/- hearts (see Chapter 6.1, Table 18 and Supplementary Table S2-4), suggesting 
dependence of the developing cHccs+/- myocardium on intrauterine amino acid availability. 
Thus, the aim of the second major part of this PhD project was to understand the implications 
and involvement of the amino acid metabolism for pre- and postnatal cardiac growth in 
general and for embryonic cardiac regeneration and postnatal compensatory heart growth of 
cHccs+/- mice in particular. To address these questions, we fed pregnant dams either a SPD 
or a LPD during pregnancy and kept offspring on equal diets during lactation and after 
weaning. Consequences of LPD exposure were analyzed in 13.5 embryos and in neonates 
as well as in adult 11 week old mice. 
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7.2.1 Prenatal amino acid restriction does not induce IUGR in neonatal mice 
Maternal LPD in the rat is the most commonly used model to study IUGR. LPD newborn rats 
display significantly lower BW and HW compared to pups from SPD dams23. Surprisingly, we 
did not observe reduced BW or HW in our murine LPD model compared to SPD mice at 
birth (see Chapter 6.5.3.1, Figure 19B+C), indicating that IUGR was not induced. 
Consequently, we analyzed the food intake to investigate if the reduced protein content in the 
food is compensated by increased ingestion. However, we revealed that non-pregnant as 
well as pregnant mice on SPD and LPD take up the same amount of food (see Chapter 
6.5.1, Figure 17). While embryonic and postnatal effects of maternal LPD have been well 
characterized in rats280, less is known about how mice respond to in utero amino acid 
restriction. Importantly, we did not exactly determine the gestational age of our newborn LPD 
mice. We assume that most neonates at P1 were born at 20.5 dpc; however, offspring could 
also be born at 19.5 dpc or 21.5 dpc. Hence, the precise gestational age might play a role in 
our investigations. Furthermore, it is obscure whether pups had time to milk feed since this 
parameter was not monitored in our experiments. Though, this might also impact on neonatal 
BW. Interspecies differences could furthermore be explained by longer gestation times in 
rats. While pregnant mice give birth after 19 to 21 days of pregnancy, rats do so after 21 
to 23 days. Moreover, newborn rats have generally higher BW compared to newborn mice, 
such that slight weight differences in mice might be obscured. However, some recent studies 
suggested LPD-induced IUGR in mice. Mortensen et al. provided evidence that LPD results 
in BW reduction at birth by 40 % compared to murine SPD offspring281. Similar to our LPD 
composition with 8.8 % crude protein, they used 8 % crude protein containing LPD food281. 
LPD was fed to pregnant mice only after a vaginal plug was observed (gestational day 0)281. 
In contrast, we kept male as well as female mice on LPD at least 2 weeks prior to 
mating (see Chapter 5.1.5). The authors stated that mice gave birth at 19.5 dpc and newborn 
pups were analyzed immediately281. Importantly, Mortensen et al. used male as well as 
female pups to assess IUGR, without differentiating between the genders281. By comparison, 
we only analyzed females. Significant BW reduction in murine LPD offspring by 12 % was 
confirmed by Whitaker et al.282. They used isochaloric 8.5 % LPD during breeding, pregnancy 
and lactation but also did not start LPD treatment before breeding was initiated282. Again, the 
authors did not differentiate between male and female mice at the neonatal stage282. IUGR in 
neonatal mice was furthermore demonstrated by Bhasin et al.283. On detection of a vaginal 
plug, they placed females on 9 % LPD and analyzed newborn LPD mice at 19.5 dpc 
independent of their sex283. However, in all three studies the effect of prenatal LPD on 
neonatal BW but not HW and heart morphology was investigated. Due to the lack of 
knowledge regarding murine LPD models in general as well as due to the discrepancy 




absolutely essential. It might be indispensable to actually prove that the mice in our study are 
really subjected to amino acid restriction. Even though intake of SPD and LPD food does not 
differ, the mice might be able to adapt their metabolism in a way that they can extract 
relatively more protein out of the LPD food. Therefore, analyses of food utilization by 
measuring the protein amount that is excreted on the respective diet might prove useful. It 
might also be worth testing, if a further reduction of the dietary protein content causes IUGR 
in our neonatal mice.  
7.2.2 Consequences of prenatal amino acid restriction for neonatal cardiac organ 
size 
Interestingly, we found that the HW/BW ratio in LPD but not SPD cHccs+/- neonates was 
significantly reduced compared to their corresponding Hccs+/+ controls (see Chapter 6.5.3.1, 
Figure 19D). The SPD finding is in strong contradiction to the current understanding of the 
heart conditional Hccs KO model. We have previously shown that neonatal cHccs+/- mice 
have a reduced HW/BW ratio and hypoplastic hearts (unpublished data, see Chapter 3.4). 
The reduced HW/BW ratio in neonatal cHccs+/- mice was confirmed in the rapamycin 
approach both after prenatal vehicle and rapamycin treatment (see Chapter 6.3.3.1, Figure 
11F), but was not represented in the SPD group. As a result, a new project was initiated in 
the lab, which is currently under investigation. Recent data suggest that the difference in 
HW/BW ratio might be caused by different gestational ages on the day of birth. While 
neonatal mice in previous experiments as well as in the rapamycin study were born at 
19.5 dpc, pregnant dams in the LPD study mainly gave birth at 20.5 dpc (unpublished data). 
Thus, the intrauterine period seems to be a fundamental factor regarding embryonic cardiac 
regeneration and growth in cHccs+/- mice. We hypothesized that one additional day in utero 
might be able to normalize heart size in the latter, due to the growth permissive environment 
compared to postnatal conditions. The underlying cellular and molecular mechanisms are 
currently under investigation and results from this recently initiated project might help to 
elucidate consequences for preterm birth in humans. 
However, LPD cHccs+/- neonates, which similar to the SPD pups were also born at 20.5 dpc, 
revealed a reduced HW/BW ratio compared to LPD Hccs+/+ controls (see Chapter 6.5.3.1, 
Figure 19D). Strikingly, comparing HW/BW ratios between neonatal SPD and LPD Hccs+/+ 
mice or between SPD and LPD cHccs+/- neonates rather indicates a trend toward an 
increase in the Hccs+/+ group than toward a decrease in the cHccs+/- group upon intrauterine 
LPD exposure (see Chapter 6.5.3.1, Figure 19D). However, this is in slight contradiction to 
classical LPD models, which revealed rather unchanged HW/BW ratio in neonatal rats23. 
Though, elevated HW/BW ratio was found in LPD animals after 4 weeks due to reduced BW 
but unchanged HW25. Together, our data indeed provide substantial evidence that maternal 
dietary changes during development affect the regulation of cardiac organ size in cHccs+/- 
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neonates differentially than in Hccs+/+ controls, irrespective of the contradictory results 
regarding the SPD animals described above. This raises the question in which way amino 
acids sustain or promote growth of cHccs+/- hearts and how the reduced HW/BW ratio of 
cHccs+/- mice upon intrauterine LPD exposure can be explained. We considered changes in 
cardiomyocyte size or number (due to altered proliferation or apoptosis rates) as potential 
underlying mechanisms that might be affected by amino acid restriction and might explain 
the reduced HW/BW ratio in LPD cHccs+/- neonates compared to LPD Hccs+/+ controls. 
7.2.3 Cellular and functional consequences in the heart after pre- and postnatal 
amino acid restriction 
7.2.3.1 Consequences in neonatal hearts 
Amino acids play a fundamental role in protein synthesis and cell growth21. We analyzed 
cardiomyocyte size in neonatal hearts upon intrauterine SPD or LPD exposure. We found 
that the cardiomyocyte CSA was increased in both LPD groups compared to the 
corresponding vehicle groups, while the difference in CSA was only significant for cHccs+/- 
neonates (see Chapter 6.5.3.2, Figure 20D). Increased CSA but unchanged HW (see 
Chapter 6.5.3.1, Figure 19C) point toward cell size compensation for a reduced cell number. 
Evidence that cardiomyocyte CSA and cell number might be inversely correlated and that 
increased cardiomyocyte size in respect of normal HW can be considered an indirect 
measure for reduced cell number has recently been published82. The authors used a murine 
model for oxidative damage and revealed unchanged HW/BW ratio but increased 
cardiomyocyte size at P382. This was accompanied by severely reduced cardiomyocyte 
proliferation, indicating reduced cardiomyocyte number82. Even though cardiomyocyte CSA 
is increased especially in neonatal LPD cHccs+/- hearts (see Chapter 6.5.3.2, Figure 20D), 
the HW/BW ratio of this group is reduced (see Chapter 6.5.3.1, Figure 19D). This indicates 
that the increase in cell size might not be sufficient to compensate for the proposed reduction 
in cardiomyocyte number and that cardiomyocyte number in neonatal LPD cHccs+/- hearts 
might even be further reduced compared to neonatal LPD Hccs+/+ controls. Importantly, 
pathological cardiac hypertrophy is primarily achieved by an increase in width resulting in 
increased CSA, while physiologic cardiac growth is mediated by a combination of increased 
cardiomyocyte width and length284. Thus, the prediction of cardiomyocyte size from only 
measuring CSA is limited and it might therefore prove helpful to analyze isolated neonatal 
cardiomyocytes regarding their width, length, surface area and volume to get a precise 
estimate of their real size. It might be that cardiomyocytes in neonatal LPD hearts have 
increased CSA but are shorter in length. Hence, the overall cardiomyocyte volume might be 
unchanged, possibly explaining the unchanged HW.  
In the rat model, neonatal LPD hearts had significantly less cardiomyocytes than neonatal 




We also focused on cardiac proliferation rates in neonatal SPD and LPD hearts and found no 
significant differences (see Chapter 6.5.3.2, Figure 20C). These observations suggest that 
the proposed reduction in cell number might be established by a proliferation defect during 
prenatal development and that altered proliferation rates might no longer be detectable in 
neonatal hearts. This discrepancy to the rat LPD model might again be explained by 
interspecies differences between rats and mice as discussed above. Importantly, 
Aroutiounova et al.24 applied the more specific p-HH3 marker to assess neonatal proliferation 
rates, while we used KI67 staining, which labels proliferating cells in all active phases of the 
cell cycle217. Given the known issue of cell cycle activity versus cell division in the perinatal 
heart, as discussed in Chapter 7.1.7, a more specific cell cycle activity marker might help to 
elucidate this discrepancy. Moreover, precise determination of cardiomyocyte number in 
neonatal SPD and LPD hearts for instance by stereological approaches (as described by 
Corstius et al.23 and Lim et al.25) is certainly of major importance to exclusively address the 
question of altered cell number in our murine LPD model. 
7.2.3.2 Consequences in 13.5 dpc embryonic hearts 
We postulated that a possible reduction in cardiomyocyte number might be established by a 
proliferation defect during prenatal development when amino acids are restricted. Hence, we 
analyzed 13.5 dpc SPD and LPD hearts; but we neither revealed differences in 
apoptosis (see Chapter 6.5.4.2, Figure 22E) nor proliferation rates (see Chapter 6.5.4.2, 
Figure 22B). In detail, we found no significant differences between the diet groups regarding 
cardiac proliferation in general but also compensatory hyperproliferation of healthy cells in 
the cHccs+/- myocardium was not affected by prenatal LPD exposure (see Chapter 6.5.4.2, 
Figure 22B). These findings indicate that the demand for increased proliferation of healthy 
cells in cHccs+/- 13.5 dpc embryos does not depend on amino acid availability. Hence 
survival of cHccs+/- mice is ensured (see Chapter 6.5.2, Figure 18B) even if amino acids are 
restricted. Furthermore, morphology of 13.5 dpc embryonic LPD hearts was 
inconspicuous (see Chapter 6.5.4.1, Figure 21E), suggesting resistance of murine embryonic 
hearts against LPD exposure. However, it is conceivable that LPD might affect proliferation in 
the last trimester of prenatal development, the fetal phase, rather than in the embryonic 
phase. Previous studies (such as analyzing low oxygen conditions during pregnancy) 
revealed that IUGR can bring about changes in both embryonic and fetal development. For 
instance, increased apoptosis rates and premature terminal cardiomyocyte differentiation in 
fetal rat hearts34 and ventricular dilation and myocardial hypoplasia in mid-gestation mouse 
embryos36 were observed upon hypoxia. Moreover, Louey et al. previously showed that 
IUGR due to placental insufficiency causes decreased cell cycle activity in cardiomyocytes of 
fetal sheep hearts285. In the study on hand, the effects of prenatal LPD exposure on fetal 
cardiac development were not analyzed. Though, differential expression of cell cycle 
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regulating genes and accumulating evidence for reduced cell number in murine neonatal 
LPD hearts supports the general concept that LPD affects cardiomyocyte proliferative 
capacity. In conclusion, while effects of amino acid restriction in the rat become obvious in 
offspring at birth, we assume that in mice a reduced amino acid availability results in reduced 
cardiomyocyte proliferation capacity in fetal stages; a hypothesis that strongly urges for 
experiments focusing on proliferation rates in fetal hearts. 
7.2.3.3 Consequences in adult hearts 
In line with the developmental programming concept, studies in the classical LPD rat 
model (diet changed to SPD after birth) revealed that under baseline conditions prenatal 
amino acid restriction causes significant changes in heart morphology and function later in life, 
including interstitial fibrosis26, hypertrophy27 and increased stiffening28 of the LV in adulthood. 
In these models, the IUGR insult is released at birth and the rats display postnatal catch-up 
growth. To investigate if cardiac growth and function in adulthood is also affected if postnatal 
conditions resemble that of in utero, we analyzed 11 week old mice after pre- and postnatal 
amino acid restriction. It is conceivable that maintaining similar conditions during postnatal life 
prevents CVD caused by developmental programming. Interestingly, we did not observe 
significant changes regarding BW, HW and HW/BW ratio in adult mice after pre- and postnatal 
LPD exposure (see Chapter 6.5.5.1, Figure 23G-I). LPD rats also normalized HW until 
weaning; however they were on SPD after birth25. Strikingly, when a SPD was administered to 
the pups not immediately after birth but after 2 weeks postnatally, LPD rat offspring remained 
significantly smaller and demonstrated reduced HW, resulting in unchanged HW/BW ratio 
compared to SPD offspring at 18 weeks of life286. However, to the best of our knowledge, our 
study is the first approach that investigated long-term consequences of LPD treatment without 
changing the diet to SPD at any time; though that there are no studies we can directly 
compare our results with. 
Given that postnatal growth of the myocardium primarily occurs by cardiomyocyte hypertrophy 
and deposition of extracellular matrix (ECM)287, we focused on cardiomyocyte CSA and ECM 
deposition. According to previous findings in the cardiac-specific Hccs KO model (see Chapter 
3.4), cHccs+/- hearts compensate the hypoplastic neonatal phenotype by cardiomyocyte 
hypertrophy in adulthood (unpublished data, see Chapter 3.4). Strikingly, while compensatory 
hypertrophy is preserved in cHccs+/- females after pre- and postnatal LPD exposure (even 
though it misses statistical significance in the sample set used in this study), cardiomyocyte 
CSA in adult Hccs+/+ as well as cHccs+/- LPD hearts is significantly smaller than in adult SPD 
hearts (see Chapter 6.5.5.2, Figure 24C). These finding contradicts the adult HW, which was 
not reduced in LPD compared to SPD hearts in both genotypes (see Chapter 6.5.5.1, Figure 
23H). We speculate that other cardiac cell types (e.g. fibroblasts or smooth muscle cells) 




decreased cardiomyocyte CSA resulting in normal HW. Evidence comes from studies showing 
that upon pathological remodeling following injury dramatic shifts in the various cardiac cell 
populations and tissue composition occur, such that fibroblasts contribute to a larger extend to 
the heart tissue288. It will be important to investigate this potential mechanism by FACS 
quantification of non-cardiomyocytes within the LV myocardium of our LPD hearts. Besides, it 
is tempting to speculate that even though cardiomyocyte CSA is reduced, overall cell volume 
might be unchanged due to increase in length, as discussed for neonatal hearts above. 
Analyzing adult cardiomyocyte dimensions after fixation and dissociation of the LV 
myocardium might prove useful to investigate this alternative. Furthermore, ECM deposition, 
determined by measuring the percentage of fibrotic tissue, was not increased in adult LPD 
hearts (see Chapter 6.5.5.2, Figure 24D); excluding the possibility that aggregated ECM 
deposition is responsible for the normalization of the HW. This finding was also in line with 
normal expression of genes encoding for ECM components (see Chapter 6.5.5.2, Figure 24E). 
Moreover, prenatal LPD in the rat was shown to be associated with cardiac dysfunction in the 
first 2 weeks of life, as obvious by a severe depression in the EF, but recovery of cardiac 
function in the LPD offspring up to 40 weeks of age27. Investigation of heart function in our 
11 week old LPD mice revealed normal cardiac contractility (see Chapter 6.5.5.3, Figure 25D 
and Supplementary Table S7). However, we did not analyze cardiac function in murine LPD 
offspring during the lactation period. Furthermore, since 11 weeks old mice are rather young 
adults, investigating heart function and morphology of LPD Hccs+/+ and cHccs+/- mice at older 
age (e.g. after 1 year) or if cardiac stress (such as TAC or angiotensin) is applied, might reveal 
differences compared to adult SPD animals. Importantly, our data are in line with recent data 
from LPD rats, which revealed that maintaining a poor nutritional environment after birth might 
not increase the risk for CVD286. In this study, LPD rat offspring remained on LPD and were 
switched to SPD not until 2 weeks postnatally286. At 18 weeks of life, heart rate and FS of the 
cardiac muscle was not different between the treatment groups286. 
In conclusion, we did not find evidence that pre- and postnatal LPD alters postnatal cardiac 
growth and function in general or in the cHccs+/- myocardium in particular. This is in line with 
the developmental programming concept stating that postnatal cardiac catch-up growth, which 
does not occur in our approach, contributes to increased susceptibility for adulthood disease 
rather than being beneficial15,16. However, given that the IUGR insult is not released at birth, 
our postnatal LPD model might be limited when interpreting the results in regard of 
developmental programming. 
7.2.4 Consequences of pre- and postnatal amino acid restriction on mTOR pathway 
activity 
mTOR pathway activity was shown to be increased in neonatal cHccs+/- hearts (see Chapter 
6.2, Figure 8). Due to its dependency on amino acid availability119, it is assumed that amino 
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acid restriction downregulates the activity of the mTOR signaling cascade. However, to the 
best of our knowledge, so far none of the classical IUGR LPD models assessed the 
molecular consequences of amino acid restriction on mTOR pathway activity. One recent 
study revealed that maternal LPD, fed exclusively during the preimplantation period of mouse 
development (until 3.5 dcp), decreases the phosphorylation of S6 in 3.5 dpc murine 
blastocysts289. We also focused on the phosphorylation status of the mTORC1 downstream 
target S6 in 13.5 dpc embryonic hearts upon intrauterine LPD exposure (see Chapter 
6.5.4.1, Figure 21A+C) and in adult hearts after pre- and postnatal LPD treatment (see 
Chapter 6.5.5.1, Figure 23A+C+D). Interestingly, the phosphorylation status of S6 remained 
largely unchanged. In a previous study, LPD was successfully used to induce autophagy, 
which is normally inhibited by the mTOR signaling cascade, in skeletal muscle of adult 
collagen VI KO mice290. When we focused on the autophagy marker p62 in embryonic (see 
Chapter 6.5.4.1, Figure 21A+D) and adult LPD hearts (see Chapter 6.5.5.1, Figure 23A+E) 
we did not find evidence for induced autophagy. As discussed before, a solid proof of 
concept that our mice are indeed amino acid restricted is currently missing. It is possible that 
the 8 % protein content in the diet is still sufficient to allow normal amino acid levels within 
the cell, given that certain non-essential amino acids can be synthesized from other 
metabolic sources. Thereby, normal cardiac mTOR pathway activity might be maintained. 
However, the mTOR signaling pathway was shown to be specifically sensitive to the 
essential amino acid leucine291, which rather suggests a reduction of mTOR pathway activity 
due to decreased amino acid availability. Though, amino acids are not only essential building 
blocks for proteins but also serve as important energy source in cellular metabolism21. It 
might therefore be that mice change their metabolism from the very first day of prenatal 
development when amino acid restriction is applied. This might result in adaptation to amino 
acid restriction in postnatal development. This might furthermore explain why adult mice that 
receive LPD for the first time respond with increased autophagy after 4 weeks of LPD, 
indicating reduced mTOR pathway activity290. Moreover, detection of phosphorylation of S6 
might be not sensitive enough to determine subtle changes in mTOR pathway activity. 
Therefore, it is essential to optimize the detection of S6K1 phosphorylation (that did not work 
out in embryonic and adult heart tissue due to technical limitations), which is a more reliable 
indicator. As mentioned above, to date none of the well-established classical IUGR LPD 
models assessed the molecular consequences of amino acid restriction on mTOR pathway 
activity. However, we have preliminary data indicating that mTOR pathway activity is also 
unchanged in neonatal LPD rat hearts, which were gratefully provided by Mary Jane Black, 
Monash University, Australia. Hence, one has to consider that the mTOR signaling pathway 
might not mediate growth restriction in LPD animal models. Other mechanisms might 




different cellular effects than protein starvation. In this context, amino acids are known to 
modulate cell signaling not only via the mTOR signaling cascade but also through protein-
coupled receptors and gaseous molecules (e.g. NO)21. Moreover, certain non-essential 
amino acids (e.g. arginine, glutamine, glutamate, glycine and proline) play important roles in 
regulating gene expression292-294, micro-RNA levels295, blood flow296 and overall 
metabolism297-299. Hence it might not be the function of amino acids as protein building blocks 
that induces IUGR but their role as energy source or intermediate metabolite in other 
pathways. 
7.3 Conclusions and perspectives 
Given the multitude of maternal as well as environmental factors which negatively impact on 
prenatal heart development as well as the high incidence of preterm birth events in humans, 
better understanding of molecular and cellular mechanisms adapted by the postnatal heart to 
compensate for impaired cardiac intrauterine development seems imperative. Elucidation of 
key processes and factors crucial for the prenatal heart during times of molecular and cellular 
periods of vulnerability and IUGR might not only reveal important strategies for prevention of 
congenital and postnatal heart diseases but also identify key mechanisms for cardiac 
regeneration and cardiac developmental programming. Thus, in respect of developmental 
programming, we aimed at investigating the role of the mTOR pathway and the impact of 
amino acid metabolism for prenatal, perinatal and postnatal cardiac growth in general and for 
embryonic cardiac regeneration and postnatal compensatory heart growth of cHccs+/- mice in 
particular. 
We propose that mTORC1 inhibition by rapamycin represents a new model of IUGR in the 
mouse, which allows the investigation of developmental programming mechanisms 
particularly in the fetal and neonatal phase of development. We found that the mTOR 
pathway has an outstanding role in organ size control of the heart; given that prenatal 
mTORC1 inhibition more severely affects HW than the size of other organ systems in 
neonatal mice. In combination with cardiac-specific Raptor ablation, we revealed that the 
mTOR signaling cascade is important for the regulation of cardiomyocyte size in the 
postnatal heart, while it seems to play an essential role in cardiomyocyte proliferation during 
embryonic and fetal development. Given these differential regulation of proliferation and 
hypertrophy during different stages of heart development, the mTOR pathway might not only 
be a newly discovered target of developmental programming but also a potential factor 
mediating the transition from proliferative to hypertrophic cardiac growth in the perinatal 
period. Prenatal impairment of the mTOR signaling cascade does not cause increased risk 
for CVD in young adulthood under baseline conditions; however, consequences for the adult 
heart after additional stress is applied in the sense of developmental programming remain 
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conceivable. This would be in line with our observation that mice respond to IUGR due to 
prenatal rapamycin treatment with enhanced postnatal cardiac catch-up growth. With respect 
to our cHccs+/- mice, differential effects regarding apoptosis and cell size regulation were 
observed upon prenatal mTORC1 inhibition between Hccs+/- and cHccs+/- animals. More 
detailed investigation of the specific role of the mTOR pathway in the cHccs+/- 
myocardium might be obtained by adjusting the rapamycin injection protocol and by 
generating cHccs+/-/cRaptor+/- double KO mice.  
Amino acid restriction in the classical LPD rat model is associated with smaller hearts at birth 
due to a reduced cardiomyocyte number, which potentially might be caused by decreased 
proliferation rates. We analyzed for the first time cardiac proliferation under LPD conditions in 
embryonic mice and we were able to demonstrate that amino acid restriction does not affect 
proliferation in murine embryonic hearts, even if compensatory hyperproliferation is required. 
Hence, our data suggest that fetal development might depend in a larger extend on a 
sufficient amount of available protein and thus on an intact amino acid metabolism than 
embryonic development does. Besides, we did not reveal IUGR in neonatal mice upon 
intrauterine amino acid restriction. Given that we did not find altered mTOR pathway activity 
in embryonic or adult LPD animals, further investigations are required to analyze if the mTOR 
signaling cascade actually mediates growth restriction in LPD animal models. With respect to 
our cHccs+/- mice, amino acid availability neither seems to be essential for embryonic cardiac 
regeneration nor for postnatal compensatory hypertrophy. However, after conclusive proof 
that the mouse is a suitable model to study consequences of amino acid restriction on heart 
development, we still believe that our cHccs+/- mouse model represents a prime subject to 
evaluate organ-specific impaired growth and developmental programming at the molecular 
and cellular level in response to restricted amino acid availability. Moreover, we importantly 
revealed that amino acid restriction affects postnatal cardiomyocyte hypertrophic growth in 
general, given that we observed reduced cardiomyocyte CSA in 11 week old Hccs+/+ and 
cHccs+/- hearts after prenatal and long-term LPD treatment. Regarding developmental 
programming of adulthood CVD, pre- and postnatal amino acid restriction in the mouse does 
not cause an increased risk in young adulthood under baseline conditions. However, 
consequences for the health of older hearts and after additional stress is applied remain 
conceivable, a consideration that was not addressed in this study. Most importantly, our LPD 
results point toward the late fetal period as the vulnerable phase during development that is 
especially sensitive for maternal malnutrition. These findings might provide new insights for 
disease prevention in humans and further investigations, e.g. focusing on the mTOR 
pathway, might help to elucidate underlying mechanisms. 
In conclusion, the results anticipated from this study might have major implications for the 




therapeutic strategies to treat and prevent cardiac disease that have their origin in utero. 
Amino acid supplementation during pregnancy, especially during the last trimester of 
prenatal development, or determination of mTOR pathway activity as a diagnostic marker for 
IUGR might represent suitable approaches but require further investigations to evaluate their 










Gene name Gene symbol FC p-value 
1422651_at Adiponectin, C1Q and collagen domain containing Adipoq 20.80 7.56*10^-09 
1456225_x_at Tribbles homolog 3 Trib3 20.54 1.22*10^-08 
1450783_at Interferon-induced protein with tetratricopeptide repeats 1 Ifit1 13.43 1.19*10^-05 
1442026_at Zinc finger and BTB domain containing 16 Zbtb16 6.78 9.73*10^-08 
1417268_at CD14 antigen Cd14 6.07 8.62*10^-05 
1419665_a_at Nuclear protein transcription regulator 1 Nupr1 5.86 2.25*10^-05 
1417022_at 
Solute carrier family 7 (cationic amino acid transporter,  
y+ system), member 3 
Slc7a3 5.61 4.44*10^-06 
1426657_s_at 3-phosphoglycerate dehydrogenase Phdgh 5.53 3.13*10^-06 
1451006_at Xanthine dehydrogenase Xdh 5.47 1.22*10^-07 
1426175_a_at Tryptase alpha/beta 1 Tpsab1 5.16 1.92*10^-05 
1449434_at Carbonic anhydrase 3 Car3 5.01 3.73*10^-04 
1442033_at C1q and tumor necrosis factor related protein 9 C1qtnf9 4.83 4.68*10^-06 
1434202_a_at Family with sequence similarity 107, member A Fam107a 4.63 1.46*10^-04 
1419254_at 
Methylenetetrahydrofolate dehydrogenase (NAD+ 
dependent), methenyltetrahydrofolate cyclohydrolase 
Mthfd2 4.38 3.89*10^-08 
1427388_at Leucine rich repeat containing 2 Lrrc2 4.28 3.59*10^-06 
1457666_s_at Interferon activated gene 202B Ifi202b 4.26 1.55*10^-03 
1451382_at ChaC, cation transport regulator-like 1 Chac1 4.17 1.22*10^-03 
1449025_at Interferon-induced protein with tetratricopeptide repeats 3 Ifit3 3.95 2.02*10^-04 
1433966_x_at Asparagine synthetase Asns 3.79 1.45*10^-08 
1435477_s_at Fc receptor, IgG, low affinity IIb Fcgr2b 3.50 4.09*10^-04 
1428834_at Dual specificity phosphatase 4 Dusp4 3.47 2.07*10^-07 
1447927_at Guanylate binding protein 6 Gbp6 3.33 3.88*10^-06 
1454904_at X-linked myotubular myopathy gene 1 Mtm1 3.07 2.39*10^-03 
1427683_at Early growth response 2 Egr2 2.79 5.64*10^-04 
1422905_s_at Flavin containing monooxygenase 2 Fmo2 2.79 8.33*10^-04 
1457117_at Nuclear factor, erythroid derived 2, like 2 Nfe2l2 2.74 2.88*10^-05 
1451171_at RIKEN cDNA 2310008H04 gene 2310008H04Rik 2.69 1.76*10^-04 
1426937_at mesenteric estrogen dependent adipogenesis Medag 2.64 2.08*10^-06 
1436763_a_at Kruppel-like factor 9 Klf9 2.61 5.61*10^-05 
1436329_at Early growth response 3 Egr3 2.54 3.42*10^-04 
1423259_at Similar to Id4 LOC100045546 2.52 5.40*10^-05 
1419043_a_at Interferon inducible GTPase 1 Iigp1 2.52 7.52*10^-05 
1419456_at Dicarbonyl L-xylulose reductase Dcxr 2.51 5.18*10^-04 
1424638_at Cyclin-dependent kinase inhibitor 1A (P21) Cdkn1a 2.40 3.67*10^-05 
1423877_at Chromatin assembly factor 1, subunit B (p60) Chaf1b 2.37 3.48*10^-04 
1428838_a_at Deoxycytidine kinase Dck 2.35 1.30*10^-03 
1424948_x_at Histocompatibility 2, K region locus 1  H2-K1 2.33 1.47*10^-03 
1418203_at Phorbol-12-myristate-13-acetate-induced protein 1 Pmaip1 2.32 4.17*10^-03 
1424754_at Membrane-spanning 4-domains, subfamily A, member 7 Ms4a7 2.30 1.49*10^-04 
1419598_at Membrane-spanning 4-domains, subfamily A, member 6D Ms4a6d 2.28 3.02*10^-03 
1418901_at CCAAT/enhancer binding protein (C/EBP), beta Cebpb 2.28 7.81*10^-05 
1450886_at Germ cell-specific gene 2 Gsg2 2.25 3.43*10^-03 
1418326_at 
Solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 5 
Slc7a5 2.23 7.27*10^-05 
1425927_a_at Activating transcription factor 5 Atf5 2.17 7.07*10^-04 
1418248_at Galactosidase, alpha Gla 2.16 3.96*10^-03 
1453067_at Apoptosis-inducing, TAF9-like domain 1 Apitd1 2.13 5.01*10^-04 
1428942_at Metallothionein 2 Mt2 2.13 9.47*10^-05 
1424942_a_at Myelocytomatosis oncogene Myc 2.12 3.17*10^-04 
1456653_a_at 
Methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 1-like 
Mthfd1l 2.09 3.06*10^-04 
1423585_at Insulin-like growth factor binding protein 7 Igfbp7 2.09 2.44*10^-05 
1460302_at similar to thrombospondin 1 LOC640441 2.08 2.01*10^-03 
1448842_at Cysteine dioxygenase 1, cytosolic Cdo1 2.08 3.30*10^-05 
1460251_at Fas (TNF receptor superfamily member 6) Fas 2.05 1.54*10^-05 






Gene name Gene symbol FC p-value 
1452244_at Mesenteric estrogen dependent adipogenesis Medag 2.03 3.56*10^-03 
1423233_at CCAAT/enhancer binding protein (C/EBP), delta Cebpd 2.02 4.59*10^-04 
1417516_at DNA-damage inducible transcript 3 Ddit3 2.01 1.38*10^-04 
1453288_at Activating transcription factor 6 Atf6 2.01 2.47*10^-04 
1448749_at Pleckstrin Plek 2.01 8.54*10^-04 
1427126_at 
Heat shock protein 1A, heat shock protein 1B, 




1420715_a_at Peroxisome proliferator activated receptor gamma Pparg 2.01 2.76*10^-05 
1431166_at Chromodomain helicase DNA binding protein 1 Chd1 1.99 1.02*10^-03 
1429660_s_at Structural maintenance of chromosomes 2 Smc2 1.98 7.43*10^-03 
1418036_at DNA primase, p58 subunit Prim2 1.97 7.19*10^-04 
1455679_at Nucleic acid binding protein 1 Nabp1 1.97 1.41*10^-05 
1452115_a_at Polo-like kinase 4 Plk4 1.95 2.77*10^-04 
1435990_at 
A disintegrin-like and metallopeptidase (reprolysin type) 
with thrombospondin type1 motif, 2 
Adamts2 1.93 2.00*10^-03 
1441111_at Myosin light chain kinase family, member 4 Mylk4 1.93 1.08*10^-06 
1417185_at Lymphocyte antigen 6 complex, locus A Ly6a 1.93 1.01*10^-04 
1428660_s_at --- LOC100047963 1.92 1.14*10^-05 
1424265_at N-acetylneuraminate pyruvate lyase Npl 1.91 3.88*10^-04 
1452912_at Defective in sister chromatid cohesion 1 homolog Dscc1 1.89 4.92*10^-04 
1455899_x_at Suppressor of cytokine signaling 3 Socs3 1.89 5.00*10^-05 
1433479_at 
Ubiquitin protein ligase E3 component n-recognin 7 
(putative) 
Ubr7 1.86 1.39*10^-03 
1421009_at Radical S-adenosyl methionine domain containing 2 Rsad2 1.85 6.50*10^-07 
1415859_at Eukaryotic translation initiation factor 3, subunit C Eif3c 1.85 2.33*10^-03 
1437250_at Melanoregulin Mreg 1.84 1.76*10^-04 
1424556_at Pyrroline-5-carboxylate reductase 1 Pycr1 1.84 3.06*10^-05 
1425364_a_at 
Solute carrier family 3 (activators of dibasic and neutral 
amino acid transport), member 2 
Slc3a2 1.84 3.14*10^-05 
1417926_at Non-SMC condensin II complex, subunit G2 Ncapg2 1.84 1.11*10^-04 
1439071_at RIKEN cDNA 5430416N02 gene 5430416N02Rik 1.82 1.27*10^-03 
1423675_at Ubiquitin specific peptidase 1 Usp1 1.80 7.49*10^-04 
1432236_a_at Suppressor of variegation 3-9 homolog  Suv39h1 1.80 1.48*10^-03 
1429778_at Optineurin Optn 1.79 2.91*10^-04 
1449363_at Activating transcription factor 3 Atf3 1.79 4.18*10^-05 
1448620_at Fc receptor, IgG, low affinity III Fcgr3 1.79 1.23*10^-03 
1417143_at Lysophosphatidic acid receptor 1 Lpar1 1.77 1.23*10^-04 
1448899_s_at RAD51 associated protein 1 Rad51ap1 1.76 3.64*10^-04 
1429172_a_at Non-SMC condensin I complex, subunit G Ncapg 1.75 6.12*10^-03 
1430780_a_at Phosphomannomutase 1 Pmm1 1.75 1.11*10^-04 
1438427_at Family with sequence similarity 120, member B Fam120b 1.74 8.05*10^-04 
1438061_at RIKEN cDNA 4930523C07 gene 4930523C07Rik 1.74 1.98*10^-04 
1460353_at NDC1 transmembrane nucleoporin Ndc1 1.72 1.46*10^-04 
1422804_at 
Serine (or cysteine) peptidase inhibitor, clade B, 
member 6b 
Serpinb6b 1.72 1.57*10^-04 
1450350_a_at Jun dimerization protein 2 Jdp2 1.71 4.63*10^-04 
1421182_at C-type lectin domain family 1, member b Clec1b 1.71 9.71*10^-04 
1448272_at B-cell translocation gene 2, anti-proliferative Btg2 1.71 3.12*10^-04 
1417636_at 
Solute carrier family 6 
(neurotransmitter transporter, glycine), member 9 
Slc6a9 1.70 1.68*10^-03 
1437726_x_at 
Complement component 1, q subcomponent, 
beta polypeptide 
C1qb 1.70 6.15*10^-03 
1454011_a_at Replication protein A2 Rpa2 1.70 3.75*10^-05 
1418979_at Aldo-keto reductase family 1, member C14 Akr1c14 1.68 3.11*10^-03 
1448183_a_at Hypoxia inducible factor 1, alpha subunit Hif1a 1.67 1.20*10^-04 
1424211_at Solute carrier family 25, member 33 Slc25a33 1.67 6.73*10^-04 
1418825_at Immunity-related GTPase family M member 1 Irgm1 1.66 4.51*10^-03 
1438619_x_at Zinc finger, DHHC domain containing 14 Zdhhc14 1.66 1.27*10^-04 
1454942_at Family with sequence similarity 129, member A Fam129a 1.66 2.94*10^-04 
1438556_a_at Tropomodulin 3 Tmod3 1.65 1.65*10^-04 
1433508_at Kruppel-like factor 6 Klf6 1.65 4.64*10^-05 
1438385_s_at 
Glutamic pyruvate transaminase 
(alanine aminotransferase) 2 





Gene name Gene symbol FC p-value 
1429775_a_at Similar to Gpr137b protein LOC100044979 1.64 4.48*10^-06 
1423091_a_at Glycoprotein m6b Gpm6b 1.64 5.19*10^-03 
1447936_at RIKEN cDNA 2410006H16 gene 2410006H16Rik 1.64 2.81*10^-04 
1452358_at Retinoic acid induced 2 Rai2 1.64 4.41*10^-03 
1448390_a_at Dehydrogenase/reductase (SDR family) member 3 Dhrs3 1.64 5.48*10^-04 
1426519_at 
Procollagen-proline, 2-oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), alpha 1 polypeptide 
P4ha1 1.64 1.64*10^-04 
1448135_at Activating transcription factor 4 Atf4 1.63 1.25*10^-04 
1438161_s_at Replication factor C (activator 1) 4 Rfc4 1.62 8.95*10^-04 
1419693_at Collectin sub-family member 12 Colec12 1.61 5.62*10^-04 
1451064_a_at Phosphoserine aminotransferase 1 Psat1 1.61 3.22*10^-03 
1449708_s_at Checkpoint kinase 1 Chek1 1.61 3.66*10^-03 
1418649_at Egl-9 family hypoxia-inducible factor 3 Egln3 1.61 3.05*10^-04 
1439269_x_at Minichromosome maintenance deficient 7 Mcm7 1.61 8.97*10^-04 
1451924_a_at Endothelin 1 Edn1 1.60 1.27*10^-03 
1419029_at ERO1-like Ero1l 1.60 5.20*10^-05 
1418919_at Shugoshin-like 1 Sgol1 1.60 6.75*10^-04 
1424202_at SEH1-like Seh1l 1.59 9.13*10^-03 
1437187_at E2F transcription factor 7 E2f7 1.59 1.73*10^-04 
1448226_at Ribonucleotide reductase M2 Rrm2 1.58 3.29*10^-04 
1422535_at Cyclin E2 Ccne2 1.58 1.37*10^-04 
1453228_at Syntaxin 11 Stx11 1.58 1.27*10^-03 
1423918_at Rhomboid domain containing 1 Rhbdd1 1.57 2.90*10^-03 
1418290_a_at Enhancer of zeste homolog 1 Ezh1 1.57 1.65*10^-03 
1452792_at DAZ interacting protein 1 Dzip1 1.57 1.80*10^-03 
1452394_at Cysteinyl-tRNA synthetase Cars 1.57 1.40*10^-03 
1454968_at RIKEN cDNA 1110034A24 gene 1110034A24Rik 1.56 1.13*10^-03 
1423153_x_at Complement component factor h Cfh 1.56 2.07*10^-04 
1449155_at Polymerase (RNA) III (DNA directed) polypeptide G Polr3g 1.56 3.20*10^-03 
1449372_at DnaJ (Hsp40) homolog, subfamily C, member 3 Dnajc3a 1.55 4.29*10^-03 
1416041_at Serum/glucocorticoid regulated kinase 1 Sgk1 1.55 2.75*10^-04 
1448777_at Minichromosome maintenance deficient 2 mitotin Mcm2 1.55 1.15*10^-03 
1451310_a_at Cathepsin L Ctsl 1.55 6.85*10^-04 
1424648_at Intraflagellar transport 27 Ift27 1.54 5.35*10^-03 
1449061_a_at DNA primase, p49 subunit Prim1 1.54 9.49*10^-04 
1431005_at 
DNA segment, Chr 10, Wayne State University 102, 
expressed 
D10Wsu102e 1.54 3.48*10^-03 
1440866_at Eukaryotic translation initiation factor 2-alpha kinase 2 Eif2ak2 1.52 9.87*10^-05 
1422016_a_at Centromere protein H Cenph 1.52 3.46*10^-03 
1426995_a_at Growth factor, erv1-like (augmenter of liver regeneration) Gfer 1.52 8.05*10^-03 
1423620_at Centromere protein Q Cenpq 1.52 2.00*10^-04 
1416123_at Cyclin D2 Ccnd2 1.52 6.00*10^-03 
1425487_at SLU7 splicing factor homolog Slu7 1.52 1.08*10^-03 
1426622_a_at Glutaminyl-peptide cyclotransferase (glutaminyl cyclase) Qpct 1.52 2.91*10^-03 
1438852_x_at Minichromosome maintenance deficient 6 Mcm6 1.51 1.99*10^-03 
1426235_a_at Glutamate-ammonia ligase (glutamine synthetase) Glul 1.51 1.24*10^-03 
1419292_at HtrA serine peptidase 3 Htra3 1.51 6.42*10^-05 
1418753_at Glutamine fructose-6-phosphate transaminase 2 Gfpt2 1.50 6.24*10^-05 
1451111_at Nucleoporin 133 Nup133 1.50 1.66*10^-03 
1435981_at Neuron navigator 2 Nav2 -1.51 9.93*10^-03 
1436277_at Ring finger protein 207 Rnf207 -1.52 5.89*10^-03 
1435728_at tRNA-yW synthesizing protein 3 homolog Tyw3 -1.52 2.51*10^-04 
1426832_at DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 26B Ddx26b -1.57 5.67*10^-04 
1424919_at 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 
2, neuro/glioblastoma derived oncogene homolog 
Erbb2 -1.57 5.09*10^-04 
1427251_at ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 Atp2a2 -1.57 6.12*10^-04 
1426032_at 
Nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 2 
Nfatc2 -1.57 6.63*10^-03 
1436331_at Vacuolar protein sorting 13 D Vps13d -1.60 9.42*10^-03 
1440231_at Microtubule-associated protein 9 Mtap9 -1.62 9.89*10^-05 
1455849_at Neuron navigator 1 Nav1 -1.63 8.54*10^-03 






Gene name Gene symbol FC p-value 
1456347_at Leucyl/cystinyl aminopeptidase Lnpep -1.69 3.91*10^-03 
1457513_at Striatin interacting protein 1 Strip1 -1.70 4.29*10^-03 
1418723_at Lysophosphatidic acid receptor 3 Lpar3 -1.72 6.69*10^-05 
1445517_at Junction-mediating and regulatory protein Jmy -1.73 6.68*10^-03 
1447493_at 
Phosphoinositide-interacting regulator of transient 
receptor potential channels 
Pirt -1.73 6.55*10^-03 
1454532_at RIKEN cDNA C030043A13 gene C030043A13Rik -1.74 3.28*10^-03 
1460028_at Glutamate receptor interacting protein 2 Grip2 -1.74 6.72*10^-04 
1436936_s_at Inactive X specific transcripts Xist -1.77 4.69*10^-03 
1452661_at Transferrin receptor Tfr -1.78 1.55*10^-03 
1456632_at B-cell CLL/lymphoma 11A (zinc finger protein) Bcl11a -1.78 1.69*10^-03 
1451105_at Vasohibin 2 Vash2 -1.79 1.07*10^-06 
1417305_at SPEG complex locus Speg -1.79 2.68*10^-04 
1439848_at Blood vessel epicardial substance Bves -1.79 2.83*10^-03 
1449566_at NK2 homeobox 5 Nkx2-5 -1.85 4.15*10^-06 
1446965_at Rho guanine nucleotide exchange factor (GEF) 12 Arhgef12 -1.88 1.57*10^-04 
1460628_at Essential meiotic endonuclease 1 homolog 2 Eme2 -1.94 4.46*10^-03 
1446380_at cAMP responsive element binding protein 5 Creb5 -1.95 5.44*10^-04 
1429718_at SLIT and NTRK-like family, member 5 Slitrk5 -1.97 6.56*10^-04 
1440259_at Mannosidase, alpha, class 1A, member 2 Man1a2 -1.98 4.35*10^-04 
1426298_at Iroquois related homeobox 2 Irx2 -2.02 2.28*10^-04 
1443081_at GATA binding protein 6 Gata6 -2.02 1.43*10^-03 
1428117_x_at 
Dynein light chain Tctex-type 1, pseuodogene 1; Dynein 
light chain Tctex-type 1B; Dynein light chain Tctex-type 
1C; Dynein light chain Tctex-type 1D; Dynein light chain 







1441836_x_at Gametocyte specific factor 1 Gtsf1 -2.13 8.12*10^-04 
1446346_at 
A disintegrin-like and metallopeptidase (reprolysin type) 
with thrombospondin type 1 motif, 9  
Adamts9 -2.14 7.76*10^-03 
1441573_at Sex comb on midleg homolog 1 Scmh1 -2.16 6.06*10^-03 
1441140_at Arginine glutamic acid dipeptide (RE) repeats Rere -2.23 3.03*10^-03 
1435053_s_at 
Pleckstrin homology domain containing, family H 
(with MyTH4 domain) member 1 
Plekhh1 -2.32 7.42*10^-05 
1441193_at RIKEN cDNA 5730407M17 gene 5730407M17Rik -2.37 7.47*10^-03 
1439586_at --- LOC548102 -2.38 4.29*10^-04 
1442618_at Lactate dehydrogenase B Ldhb -2.45 6.11*10^-03 
1460499_at RIKEN cDNA 9230110I02 gene 9230110I02Rik -2.54 6.12*10^-04 
1441744_at 
Calcium channel, voltage-dependent, L type, alpha 1C 
subunit 
Cacna1c -2.58 7.10*10^-04 
1446014_at Mitogen-activated protein kinase 8 Mapk8 -2.60 6.79*10^-03 
1437431_at Cut-like homeobox 1 Cux1 -2.61 3.66*10^-04 
1443258_at Forkhead box P1 Foxp1 -2.69 3.01*10^-05 
1446954_at Pyruvate dehydrogenase E1 alpha 1 Pdha1 -2.74 7.85*10^-03 
1442632_at 
ArfGAP with GTPase domain, ankyrin repeat and PH 
domain 1 
Agap1 -2.83 1.76*10^-03 
1441441_at Proline rich Gla (G-carboxyglutamic acid) 1 Prrg1 -2.94 9.35*10^-04 
1442586_at Suppressor of cytokine signaling 2 Socs2 -2.95 7.96*10^-06 
1457642_at SKI/DACH domain containing 1 Skida1 -3.06 2.10*10^-04 
1454395_at RIKEN cDNA 4632404M16 gene 4632404M16Rik -3.09 1.03*10^-03 
1447043_at 
V-erb-a erythroblastic leukemia viral oncogene homolog 4 
(avian) 
Erbb4 -3.19 1.18*10^-04 
1443287_at Ankyrin repeat domain 63 Ankrd63 -3.20 3.59*10^-04 
1446258_at RIKEN cDNA 9530067D14 gene 9530067D14Rik -3.28 5.60*10^-07 
1457583_at 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-
N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 
St6galnac3 -3.43 5.12*10^-03 
1435984_at Zinc finger protein 40 Zfp40 -3.53 8.34*10^-03 
Listed are differentially regulated genes in neonatal (P1) cHccs
+/-
 hearts compared to Hccs
+/+
 controls as determined by 
Affymetrix microarray analysis. Only genes with a fold change (FC) higher than 1.5 or lower than -1.5 in combination with a 




Supplementary Table S2. Neonatal cHccs
+/-
 hearts display enrichment of genes involved in 
amino acid metabolism 
Functional group p-value 
Amino acid biosynthesis 1.3*10^-03 
Glutamine metabolic process 1.4*10^-03 
Glutamine family amino acid metabolic process 1.7*10^-03 
Cellular amino acid biosynthetic process 1.9*10^-03 
Alanine, aspartate and glutamate metabolism 8.4*10^-03 
Amine biosynthetic process 1.1*10^-02 
Detailed listing of significantly enriched functional groups involved in amino acid metabolism as determined by DAVID functional 







Supplementary Table S3. Neonatal cHccs
+/-
 hearts display enrichment of genes involved in 
amino acid transport 
Functional group p-value 
Amino acid transport 4.8*10^-03 
Amino acid transmembrane transporter activity 1.9*10^-02 
Amine transport 2.5*10^-02 
Carboxylic acid transport 3.1*10^-02 
Organic acid transport 3.2*10^-02 
Amine transmembrane transporter activity 3.4*10^-02 
Detailed listing of significantly enriched functional groups involved in amino acid transport as determined by DAVID functional 







Supplementary Table S4. Neonatal cHccs
+/-
 hearts display enrichment of genes involved in 
cellular metabolism 
Functional group p-value 
Hexose metabolic process 4.3*10^-03 
Glucose metabolic process 6.8*10^-03 
Monosaccharide metabolic process 8.2*10^-03 
Hexose biosynthetic process 3.6*10^-02 
Monosaccharide biosynthetic process 5.3*10^-02 
Detailed listing of significantly enriched functional groups involved in cellular metabolism as determined by DAVID functiona l 










Supplementary Table S5. Echocardiographic measurements in neonatal mice after prenatal 
mTORC1 inhibition 










































































































 mice after prenatal rapamycin treatment. Left ventricular (LV) 
wall thickness, diameter and contractility were determined in end-systole and end-diastole. Statistical significance among 
groups was assessed by one-way ANOVA followed by Bonferroni post-hoc test (§p<0.05 vs. vehicle Hccs
+/+
, §§p<0.01 vs. 
vehicle Hccs
+/+
, #p<0.05 vs. vehicle cHccs
+/-
). (dia: end-diastole, EF: ejection fraction, FS: fractional shortening, 
IVS: interventricular septum, LVID: left ventricular internal diameter, LVPW: left ventricular posterior wall, R: rapamycin, 
sys: end-systole, V: vehicle) 
Supplementary Table S6. Echocardiographic measurements in 11 week old adult mice after 
prenatal mTORC1 inhibition 




































































































 mice after prenatal rapamycin treatment. Left 
ventricular (LV) wall thickness, diameter and contractility were determined in end-systole and end-diastole. Note that no 
significant differences between the treatment groups and the genotypes were observed for any of the analyzed parameters. 
Statistical significance among groups was assessed by one-way ANOVA followed by Bonferroni post-hoc test. (dia: end-
diastole, EF: ejection fraction, FS: fractional shortening, IVS: interventricular septum, LVID: left ventricular internal diameter, 
LVPW: left ventricular posterior wall, R: rapamycin, sys: end-systole, V: vehicle) 
Supplementary Table S7. Echocardiographic measurements in 11 week old adult mice after 
pre- and postnatal amino acid restriction 




































































































 mice after pre- and postnatal SPD or LPD exposure. Left 
ventricular (LV) wall thickness, diameter and contractility were determined in end-systole and end-diastole. Note that no 
significant differences between the diet groups and the genotypes were observed for any of the analyzed parameters. Statistical 
significance among groups was assessed by one-way ANOVA followed by Bonferroni post-hoc test. (dia: end-diastole, 
EF: ejection fraction, FS: fractional shortening, IVS: interventricular septum, LPD: low protein diet, LVID: left ventricular internal 









A) Western blots of whole heart protein extracts from neonates illustrating total protein levels of MTOR, RAPTOR and RICTOR 
as well as the phosphorylation status of MTOR at serine 2448 and 2481. B) Quantification of MTOR phosphorylation normalized 
to total MTOR and C) of MTOR, RAPTOR and RICTOR total protein levels normalized to α-TUBULIN revealed no significant 




 hearts. Statistical significance among groups was assessed using unpaired 
2-tailed Student t-test (n=8 per group). (POI: protein of interest) 
 
 
Supplementary Figure 2. Phosphorylation status of mTORC1 downstream targets S6K1 and S6 is unchanged in 3 day 
and 3 week old cHccs
+/- 
hearts compared to hearts from Hccs
+/+
 littermate controls. 
A) Western blots of whole heart protein extracts from offspring at postnatal day 3 (P3) illustrating the phosphorylation status of 





 P3 hearts. C) Western blots of protein extracts from apical heart tissue of 3 week old 
animals illustrating the phosphorylation status of S6 at serine 235, 236, 240 and 244. B) Quantification of S6 phosphorylation 




 hearts. For B)+C): Statistical 





Supplementary Figure 3. Prenatal rapamycin treatment of pregnant mice results in mTORC1 inhibition in neonatal 
kidney and lung tissue as well as reduced neonatal kidney weight. 
A) Western blots of whole kidney protein extracts from neonates after prenatal vehicle or rapamycin treatment displaying the 
phosphorylation status of S6K1 at threonine 389 and of S6 at serine 235 and 236. In rapamycin treated mice, decreased 
phosphorylation was obvious at all sites analyzed, indicating mTORC1 inhibition in neonatal kidney tissue. B) Western blots of 
lung protein extracts from neonates after prenatal vehicle or rapamycin treatment displaying the phosphorylation status of S6 at 
serine 235 and 236. Phosphorylation of S6 was severely reduced in rapamycin treated mice, indicating mTORC1 inhibition in 
neonatal lung tissue. C) Significant reduction of kidney weight in rapamycin treated neonates compared to vehicle treated 
animals. D) Kidney weight to body weight (KW/BW) ratio in neonatal mice was unchanged between the genotypes and the 
treatment groups. For C)+D): Statistical significance among groups was assessed by one-way ANOVA followed by Bonferroni 
post-hoc test (§§p<0.01 vs. vehicle Hccs
+/+
, #p<0.05 vs. vehicle cHccs
+/-











Supplementary Figure 4. Prenatal mTORC1 inhibition from 11.5 dpc onwards results in preterm birth and fetal lethality. 
Hccs
+/+
 as well as cHccs
+/-
 embryos were subjected to lethal preterm birth at 16.5 dpc and demonstrated severe growth 





Supplementary Figure 5. Organ weights of liver, kidney and spleen in 11 week old adult mice upon intrauterine 
mTORC1 inhibition are not significantly different compared to those of vehicle treated animals. 
A) Liver weight (LW), B) LW to body weight (LW/BW) ratio, C) kidney weight (KW), D) KW to BW (KW/BW) ratio, E) spleen 
weight (SW) and F) SW to BW (SW/BW) ratio in adult mice displayed no significant differences between the treatment groups or 
the genotypes. Note that absolute LW, KW and SW in adult mice of both genotypes after prenatal mTORC1 inhibition were 
slightly lower than in vehicle treated animals, indicating only partial organ size normalization during postnatal life. Statistical 
significance among groups was assessed by one-way ANOVA followed by Bonferroni post-hoc test (n=7 for vehicle Hccs
+/+
, n=6 
for vehicle and rapamycin cHccs
+/-
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